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ABSTRACT  
Chordoma  is  a  rare  malignant  bone  tumour,  showing  notochordal 
differentiation, which occurs in the axial skeleton. Brachyury, a molecule 
involved  in  notochordal  development,  is  a  highly  specific  and  sensitive 
marker for chordoma. It is hypothesised that brachyury or genes involved 
in its activation are implicated in the pathogenesis of chordoma. As there is 
currently no effective drug therapy for chordoma the aim of this study was 
to identify genetic events involved in chordoma pathogenesis with a view to 
identifying potential therapeutic targets.  
One hundred chordomas (50 skull-based, 50 non-skull based) were 
studied.  Immunohistochemistry  showed  that  the  PI3K/AKT/TSC/mTOR 
pathway was activated in 65% of chordomas, thereby providing a rationale 
for  testing  mTOR  inhibitors  for  the  treatment  of  selected  cases.  DNA 
sequencing revealed no mutations in PI3KCA or RAS homologue enriched 
in brain (Rheb) in 23 tumours. Immunohistochemistry and Western blotting 
showed  activation  of  the  fibroblastic  growth  factor  receptor 
(FGFR)/RAS/RAF/MEK/ERK/ETS2/brachyury  pathway  in  more  than  90% 
of  cases,  but  no  mutations  were  found  in  the  genes  analysed  (FGFRs, 
KRAS,  BRAF  and  brachyury)  in  23  tumours.  Three  percent  of  cases 
revealed  brachyury  amplification  but  nearly  half  of  the  cases  showed 
chromosomal abnormalities involving the brachyury locus. Knockdown of 
brachyury was achieved in the U-CH1 chordoma cell line using shRNA and 
resulted  in  premature  cell  senescence.  These  findings  demonstrate  that 
brachyury plays an important role in chordoma pathology.    4 
FISH  analysis  showed  EGFR  copy  number  gain  in  45%  of 
chordomas,  including  6%  with  amplification  and  39%  with  high  level 
polysomy. The EGFR inhibitor, tyrphostin (AG1478) significantly inhibited 
growth of the chordoma cell line, and Western blotting showed this was 
associated with reduced phosphorylation  of EGFR in a dose  dependent 
manner.    This  study  provides  evidence  for  the  first  time  that  selected 
chordomas may be susceptible to treatment with EGFR inhibitors.     5 
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1. INTRODUCTION 
1.1 GENERAL INTRODUCTION 
Chordoma  is  a  rare  low  to  intermediate  grade  malignant  bone 
tumour that occurs along the axial skeleton and is thought to arise from 
cellular  remnants  of  notochord  (Bjornsson  et  al.,  1993;  Mirra  et  al., 
2002).  
1.1.1 History  
Chordoma  was  first  described  by  Luschka  (1856)  and  Virchow 
(1857)  who gave the name ecchondrosis physaliphora to this tumour 
believing it to be of cartilaginous origin. Müller (1858) was the first to 
suggest the tumour to be of notochordal origin based on the presence of 
notochordal remnants in the skull base and the coccyx and he changed 
the  name  to  ecchordosis  physaliphora.  Ribbert  (1894)  confirmed  this 
view and introduced the term chordoma. One year later, Ribbert (1895) 
showed experimental evidence by puncturing the intervertebral discs of 
rabbits that the escaped nucleus pulposus after a time showed evidence 
of mass formation with histological structure similar to that of chordoma. 
Congdon (1952) replicated this experiment using a similar model. 
The first report of a symptomatic chordoma was made by Klebs, 
(1864)  in the spheno-occipital region. The sacro-coccygeal  chordoma 
was  first  described  in  1900  by  Henning  while  the  first  intervertebral 
chordoma  was  described  by  Raul  and  Diss  in  1924.  Dedifferentiated   22 
chordoma  was  first  identified  in  the  literature  and  described  as 
malignant chordoma by Davison and Weil (1928). The chondroid variant 
of  chordoma  was  first  described  as  an  entity  by  Heffelfinger  et  al., 
(1973)  although  Virchow  (1857)  first  described  the  resemblance  of 
chordoma to cartilage. 
1.1.2 Incidence 
Chordomas  represent  1-4%  of  all  primary  malignant  bone 
tumours (Heffelfinger et al., 1973; Ishida and Dorfman, 1994; Mirra et 
al.,  2002)  and  are  the  fourth  most  common  malignant  bone  tumour 
(Gottschalk  et  al.,  2001;  Ishida  and  Dorfman,  1994).  The  general 
incidence  of  chordoma  in  the  population  is  approximately  0.08  per 
100,000 per year (Ishida and Dorfman, 1994; McMaster et al., 2001).  
Most  chordomas  arise  in  the  axial  skeleton  with  very  few 
chordomas arising in extra axial locations. Chordomas are nearly evenly 
distributed along the axial skeleton with 32% arising in the cranium, 33% 
in  the  whole  spine,  and  29%  in  the  sacrum  and  coccyx  (Ishida  and 
Dorfman,  1994;  McMaster  et  al.,  2001).  The  frequently  reported 
anatomical distribution of 50% sacral, 35% cranial and 15% vertebral 
was based on small studies while the more even distribution was found 
in a population based study (Heffelfinger et al., 1973; Eriksson et al., 
1981;  Dahlin  and  Unni,  1994;  McMaster  et  al.,  2001).  Generally,  no 
racial predilection has been reported. However, McMaster et al., found 
that  chordoma  is  four  times  more  common  in  white  than  in  black   23 
populations. There is a male predominance (2:1) for sacral presentation 
while  the  skull-based  chordomas  shows  no  difference  in  gender 
distribution (Weber et al., 1995; McMaster et al., 2001). 
Chordoma can present at any age from infancy to very late during 
the 8
th or 9
th decades, however, skull-based chordomas tend to present 
earlier, predominantly in the third and fourth decades. The median age 
for sacral chordoma is around 60 years (Perzin and Pushparaj, 1986).  
1.1.3 Risk factors 
There  are  no  reported  associations  with  irradiation  or  other 
environmental  factors.  However,  irradiation  may  be  a  predisposing 
factor for dedifferentiated chordoma, an aggressive variant of chordoma 
(Saito et al., 1998; Hanna et al., 2008b).  
A  small  percentage  of  chordomas  have  a  familial  pattern  of 
inheritance. Eight families have been reported to have more than two 
affected  members  (Foote  et  al.,  1958;  Enin,  1964;  Kerr  et  al.,  1975; 
Chetty et al., 1991; Stepanek et al., 1998; Dalpra et al., 1999; Miozzo et 
al., 2000; Kelley et al., 2001). Recently, abnormalities in brachyury, a 
gene involved in notochordal development, have been shown to confer 
a high susceptibility for familial chordomas (Yang et al., 2009b).  
Chordoma  has  no  association  with  any  of  the  inherited  tumour 
predisposition syndromes apart from six cases of chordomas occurring 
in  patients  with  tuberous  sclerosis  complex  (TSC)  syndrome  (Dutton   24 
and Singleton, 1975; Schroeder et al., 1987; Borgel et al., 2001; Lee-
Jones  et  al.,  2004;  Lountzis  et  al.,  2006).  A  case  of  chordoma  with 
Crohn’s disease has been reported and although Crohn's disease and 
chordoma share common chromosomal abnormalities in 1p, 3p, and 7q, 
there  is  no  obvious  genetic  relation  between  the  two  conditions  (De 
Jesus-Monge et al., 2004).  
1.1.4 Clinical presentation: 
Clinically, chordomas are slow-growing tumours resulting in local 
destruction  and  invasion.  Pain  and  neurological  symptoms  from  local 
compression  are  the  main  presenting  symptoms.  Sacral  chordomas 
manifest late, so the tumour is often huge at diagnosis. The symptoms 
include  low  back  pain,  anaesthesia,  paraesthesia  and  sometimes 
intestinal  obstruction.  Headache  and  diplopia  are  the  most  common 
symptoms related to skull-based chordoma (Rich et al., 1985; York et 
al., 1999). 
Local recurrence occurs in about 70% in cases where negative 
margins  are  not  achieved  after  surgical  resection  as  radical  surgical 
excision is rarely feasible because of the extensive local infiltration and 
the presence of vital structures in the vicinity of the tumour. In contrast, 
local recurrence affects only 10-20% of patients with tumours resected 
with  appropriate  negative  margins  (Chambers  and  Schwinn,  1979; 
Volpe  and  Mazabraud,  1983;  Kaiser  et  al.,  1984;  Sundaresan  et  al., 
1987; Boriani et al., 2006).    25 
Distant metastases occur in 20-48% of patients with chordomas 
of  the  spine  (Volpe  and  Mazabraud,  1983;  McPherson  et  al.,  2006; 
Vergara et al., 2008) and in less than 10% of patients with skull-based 
tumours  (Gay  et  al.,  1995).  The  most  common  sites  of  distant 
metastases are the lungs, liver, bones, lymph nodes and skin (Bergh et 
al., 2000). The metastases occur mostly from sacral chordomas due to 
late presentation compared to skull-based chordomas (Higinbotham et 
al., 1967; Chambers and Schwinn, 1979; Sundaresan, 1986; Vergara et 
al., 2008). Metastases usually occur within three years from the initial 
diagnosis; however, the range varies from 3 months to more than 10 
years (Bergh et al., 2000; Asano et al., 2003; Baratti et al., 2003). 
1.1.5 Radiological appearance 
Radiographically, chordoma appears as a destructive bony lesion 
geneally  with  a  large  soft  tissue  mass.  Intra-tumoural  amorphous 
calcification is seen in sacral chordomas in about 30-70% of cases as 
detected  by  X-ray  and  has  been  described  as  one  of  the  cardinal 
radiological signs of sacral chordoma (Hsieh and Hsieh, 1936; Bergh et 
al., 2000; Llauger et al., 2000).   
Computed tomography (CT) scanning is essential for evaluation 
of bone destruction, and calcification and/or bone fragments within the 
lesion. Chordomas appear on CT as homogeneous lytic lesions, with a 
density comparable  to that of muscle.  On contrast  enhancement,  the 
tumour  appears heterogeneous  and  frequently shows low  attenuation   26 
within  the  soft  tissue  component  reflecting  the  myxoid  nature  of  the 
stroma (Firooznia et al., 1986).  
Magnetic  resonance  imaging  (MRI)  is  the  best  means  of 
evaluating  the  extent  of  the  tumour  (Murphy  et  al.,  1998).  On  MRI, 
chordomas  are  lobulated  tumours,  with  low  to  intermediate  signal 
intensity  on  T1-weighted  images  and  heterogeneous  high  signal 
intensity on T2-weighted images (Sze et al., 1988; Leproux et al., 1993; 
Doucet et al., 1997; Murphy et al., 1998).  
1.1.6 Treatment of chordoma 
1.1.6.1 Surgery 
Surgery is the main line of treatment for chordomas. The radical 
resection  gives  better  local  control  and  survival.  However,  adequate 
excision has major sequelae with loss of urogenital and rectal function in 
case  of  bilateral  section  of  nerve  roots,  as  well  as  cranial  nerve 
impairments  after  resection  of  skull-based  chordomas.  Magrini  et  al., 
showed that radical resection is possible in average of 10-20% of cases 
arising  at  different  sites  (Magrini  et  al.,  1992).  Recent  advances  in 
imaging techniques improve the prognosis of chordoma by discovering 
small intra-osseous tumours which can be easily treated by en block 
resection (Smolders et al., 2003). Postoperative radiotherapy, both by 
linear accelerator, or proton therapy or combination can provide better 
control of the disease after surgery (Agrawal et al., 2006; Torres et al., 
2009).    27 
1.1.6.2 Radiotherapy 
Radiation  therapy  alone  is  the  second  choice  of  treatment  if 
surgery is not feasible although chordoma is a relatively radio-resistant 
tumour. In 1952, Dahlin and MacCarty, first reported the beneficial role 
of  radiotherapy  in  treatment  of  skull-based  chordomas.  The  dose  of 
conventional  photon  radiotherapy  required  for  the  best  response  is 
relatively high (60-70 Gy) being restricted by the low radiation tolerance 
of the adjacent vital structures and so other types or modalities may be 
better  tolerated  (Dahlin  and  MacCarty,  1952;  Park  et  al.,  2006; 
Takahashi et al., 2009).  
Proton beam radiotherapy can be used to maximize the dose of 
radiation to the tumour, while sparing adjacent critical structures. Proton 
radiotherapy is mainly used for skull based-chordomas, and results in 
the best long-term control and is associated with fewer complications 
(Munzenrider and Liebsch, 1999; Amichetti et al., 2009; Takahashi et 
al.,  2009).  Hug  (2001)  reported  treatment  of  33  patients  with  proton 
beam radiotherapy and found increased survival rate in comparison to 
other types of radiotherapy (Hug et al., 1999; Munzenrider and Liebsch, 
1999;  Hug,  2001).  Carbon-ion  radiotherapy  characterised  by  high 
biologic  effectiveness  can  be  also  used  to  treat  chordomas  with 
promising results of phase II clinical trials as measured by good local 
tumour  control  and  an  associated  mild  reaction  in  the  normal  tissue 
(Schulz-Ertner et al., 2003b; Imai et al., 2009; Mizoe et al., 2009).    28 
New modalities of delivering focal photon radiotherapy, including 
fractionated stereotactic radiation therapy (FSRT), intensity modulated 
radiation  therapy  (IMRT)  and  stereotactic  radiosurgery  (SRS)  allow 
delivery  of  higher  and  more  conformal  doses  to  the  tumour  while 
protecting  the  surrounding  normal  tissue  (Foweraker  et  al.,  2007; 
Gabriele et al., 2003; Henderson et al., 2009; Munzenrider and Liebsch, 
1999; Debus et al., 2000; Mizoe et al., 2009; Chang et al., 2001).  
1.1.6.3 Chemotherapy 
Chordomas are generally considered to be resistant to standard 
cytotoxic chemotherapy. Dedifferentiated chordoma, a high grade form 
of chordoma with rapidly dividing cells has shown a limited response to 
chemotherapeutic drugs such as doxorubicin, ifosfamide, cisplatin and 
etoposide which are active in sarcomas (Fleming et al., 1993; Scimeca 
et al., 1996). 
1.1.6.4 Targeted Drug therapy  
1.1.6.4.1 Kinase inhibitors 
The  tyrosine  kinase  inhibitor,  imatinib  mesylate  has  shown  a 
partial anti-tumour clinical and radiological response in a limited number 
of  patients  with  chordoma,  most  probably  through  inactivation  of 
platelet-derived  growth  factor  receptor-β  (PDGFR  β)  (Casali  et  al., 
2004). Adding cisplatin has been shown to have synergistic activity and 
can  re-establish  a  tumour  response  in  advanced  chordoma  patients   29 
progressing on imatinib mesylate alone (Casali et al., 2007; Stacchiotti 
et al., 2009). 
Three  cases  of  advanced  chordomas  have  been  reported  to 
respond  to  inhibitors  of  epidermal  growth  factor  receptor  (EGFR), 
suggesting that inhibition of this molecule may be useful therapeutically 
for the treatments of chordomas (Hof et al., 2006; Singhal et al., 2009; 
Linden  et  al.,  2009).  Recent  reports  suggested  c-Met  oncoprotein 
inhibitors  (Ostroumov  and  Hunter,  2008),  and  signal  transducers  and 
activators of transcription 3 (STAT3) inhibitors as potential drug targeted 
therapy for chordoma  (Yang et al., 2009a) Although these targets are 
interesting, detailed preclinical in vitro and in vivo studies are required 
before using these drugs in the clinical management of the disease. 
1.1.6.4.2 PI3K/AKT/TSC/mTOR pathway inhibitors 
The  activation  of  the  PI3K/AKT/TSC/mTOR  pathway  has  also 
been demonstrated in a small number of tumour samples (Han et al., 
2009). In line with these data, Stacchiotti et al., (2009) reported a partial 
tumour  response  in  7  out  of  9  advanced  chordoma  patients  with  the 
combined use of sirolimus, an mTOR inhibitor, and imatinib myselate a 
receptor tyrosine kinase inhhibitor. The PI3K/mTOR pathway inhibitor, 
PI-103 has also been shown to exhibit in vitro effects on a chordoma 
cell line U-CH1 in the form of reduction of proliferation and induction of 
apoptosis (Schwab et al., 2009a; Stacchiotti et al., 2009).   30 
1.1.7 Prognosis 
1.1.7.1 Survival rate 
Median survival for patients with chordoma has been reported as 
6 to 7 years, and the overall survival rates 70% at 5 years, and 40% at 
10 years (Naka et al., 2003; McMaster et al., 2001; Stacchiotti et al., 
2010). In general, patients with sacral chordomas have a better survival 
rate  than  those  with  skull-based  chordomas.  Complete  surgical 
resection  offers  the  best  chance  for  long-term  survival  (Gay  et  al., 
1995). Post-operative radiation therapy  can increase the local control 
and  prolong  survival.  The  best  results  are  reported  with  aggressive 
surgical treatment and proton-beam postoperative radiotherapy with a 
disease-free survival rate up to 77% at 5 years and 69% at 10 years 
(Rosenberg et al., 1999; Crockard et al., 2001).  
Local recurrence markedly decreases the chances of achieving a 
cure and is considered as the most important predictor of mortality in 
chordoma patients (Bergh et al., 2000; Colli and Al-Mefty, 2001). Five-
year survival of 35% is reported with incomplete resection even when 
followed by conventional photon radiation therapy (Zorlu et al., 2000). 
Detection of metastases markedly decreases the median survival time 
to less than a year (Bergh et al., 2000; Asano et al., 2003; McPherson et 
al., 2006).   31 
1.1.7.2 Prognostic factors: 
1.1.7.2.1 Clinical factors 
The prognosis of chordoma is affected by many clinical factors, 
and  poorer  outcome  has  been  associated  with  skull-based  location, 
larger tumour size, invasion of the surrounding muscle, female gender, 
and  age  over  40  years  (Forsyth  et  al.,  1993;  O'Connell  et  al.,  1994; 
Thieblemont et al., 1995; Chen et al., 2010). The resectability and the 
quality  of  surgical  margins  represent  the  main  prognostic  factors 
(Forsyth et al., 1993; Bergh et al., 2000; Boriani et al., 2006; Osaka et 
al., 2008; Chen et al., 2010). 
1.1.7.2.2 Histopathologic and genetic factors 
The important histopathological factors which have been found to 
be  associated  with  reduced  survival  include  nuclear  pleomorphism 
(Chambers and Schwinn, 1979; Naka et al., 2003), proliferation index of 
more  than  5%  as  assessed  by  MIB-1  expression,  increased  mitotic 
activity and microscopic tumour necrosis (Matsuno et al., 1997; Matsuno 
and  Nagashima,  2000;  Naka  et  al.,  2003).  The  presence  of  a 
dedifferentiated  component  is  associated  with  a  markedly  poor 
prognosis compared to the conventional variant (Hanna et al., 2008a; 
Saito et al., 1998).   
Low expression of E-cadherin and over-expression of TP53 are 
considered to be predictors of poor prognosis (Mori et al., 2002; Naka et 
al.,  2005;  Saad  and  Collins,  2005).  Expression  of  matrix   32 
metalloproteinases  is  also  associated  with  unfavourable  prognosis 
(Naka et al., 2004).  Among the genetic markers, isochromosome 1q 
has  been  suggested  as  a  marker  of  aggressiveness  in  skull-based 
chordomas (Sawyer et al., 2001) and loss of heterozygosity (LOH) at 
the  Rb1  gene  locus  13q14  has  been  shown  to  be  associated  with 
aggressive chordomas (Eisenberg et al., 1997).  
Although numerous studies have tried to use histological features 
as  predictors  for  prognosis  and  biologic  behaviour,  none  has  been 
proved satisfactory and therefore are not used in clinical or diagnostic 
settings and the relationship between histological features and biological 
behaviour remains controversial (Kaiser et al., 1984; Bjornsson et al., 
1993; Naka et al., 1996). Most of these studies were based only on a 
small number of specimens resulting in divergent results (Matsuno et 
al., 1997; Holton et al., 2000). Owing to low incidence and slow growth 
rate  of  chordomas,  the  reports  were  based  on  patient  cohorts  being 
treated over a long time span:  different markers were used in attempt to 
predict  outcome  and  different  therapeutic  modalities  were  also 
employed. These various issues have resulted in failure to develop a 
reliable prognostic marker for chordomas (Kaiser et al., 1984; Rich et 
al., 1985; York et al., 1999).    33 
1.2 PATHOLOGY OF CHORDOMA 
Chordoma is classified according to the histological appearance 
into  three  different  variants.  These  are  conventional,  chondroid  and 
dedifferentiated.  A  component  of  the  conventional  type  is  virtually 
always present in the chondroid variant and small chondroid areas are 
commonly found in the conventional variant. By definition a conventional 
or chondroid component must be present in a dedifferentiated chordoma 
(Gottschalk et al., 2001; Rosenberg et al., 1994). 
Macroscopically,  conventional  chordoma  is  a  soft,  tan-grey 
lobulated mass with a gelatinous cut section. Foci of haemorrhage and 
necrosis are common especially in the large tumours. The  chondroid 
chordoma  is  less  gelatinous  and  is  more  firm  giving  the  lesion  a 
chondral appearance. The dedifferentiated component of a chordoma is 
fleshy  and  does  not  show  the  gelatinous  or  chondral  appearance 
described above (Batsakis et al., 1980; Mirra et al., 2002). 
1.2.1 Conventional chordoma 
Microscopically, conventional chordoma is formed of nests, cords, 
lobules  or  clusters  of  cells  separated  by  homogeneous  amorphous 
myxoid  stroma.  The  cells  show  great  variability  in  size  from  small 
polyhedral  or  stellate  cells  to  intermediate  cells  and  larger  cells  with 
abundant cytoplasm and numerous intra-cytoplasmic vacuoles giving a 
‘bubbly’ appearance and described as physaliphorous cells by Virchow 
(1857). The physaliphorous cells are characteristic of chordoma but are   34 
not  pathognomonic  as  they  may  be  found  in  other  tumour  types 
including  carcinoma,  chondrosarcoma,  epithelioid  hemangio-
endothelioma and liposarcoma. The nuclei of the neoplastic cells are of 
moderate size, dark staining and may contain small nucleoli or pseudo-
inclusions.  Additional  morphologic  features  include  significant  nuclear 
pleomorphism,  spindling  of  the  tumour  cells  and  physaliphorous  cells 
with  a  single  large  cytoplasmic  vacuole.  Foci  of  necrosis  and 
haemorrhage  are  common,  especially  in  larger  tumours  (Naka  et  al., 
2003). 
Based  on  the  degree  of  cellularity,  conventional  chordoma  has 
been divided into two histological subtypes; the non-solid type which is 
composed of cord-like structures and the solid type composed of diffuse 
sheets of tumour cells (Naka et al., 2003). A representative histological 
section  of  conventional  chordoma  is  shown  in  Figure  1.1A,  while  the 
characteristic physaliphorous cells containing multiple clear cytoplasmic 
vacuoles can be seen in Figure 1.1B. 
Histochemistry is rarely, if ever used, for diagnosing chordomas 
as it is of limited value since the advent of immunohistochemistry. The 
cytoplasm  of  chordoma  cells  contains  periodic  acid-Schiff  diastase-
sensitive  glycogen  granules,  although  the  cytoplasmic  vacuoles  are 
glycogen  free.  The  myxoid  stroma  is  rich  in  acidic  and  sulphated 
mucopolysaccharides and stains faintly with mucicarmine, and strongly 
with alcian blue which is not significantly reduced by prior digestion with   35 
hyaluronidase.The  stroma  does  not  stain  with  phosphotungstic  acid 
haematoxylin  and  reticulin  stains  whereas  cartilaginous  ground 
substance is strongly impregnated by these reagents (Crawford, 1958). 
The  immunoreactivity  of  conventional  chordomas  shows  high 
expression of the nuclear transcription factor brachyury: this is highly 
sensitive and specific for chordoma and is absent in a wide range of 
other  various  epithelial  and  mesenchymal  tumours  apart  from 
hemangioblastoma, known to derive embryologically from the posterior 
mesoderm (Glasker et al., 2006; Vujovic et al., 2006). 
Chordomas also express epithelial markers including cytokeratins 
(especially cytokeratins 8, 18 and 19), and epithelial membrane antigen 
(EMA)  (Salisbury  and  Isaacson,  1985;  Vujovic  et  al.,  2006).  The 
combination  of  brachyury  nuclear  immunoreactivity  and 
immunoreactivity for cytokeratin 19 (CK19) is diagnostic for chordoma 
and  used  to  differentiate  chordomas  from  other  histologically  similar 
tumours  including  chondrosarcomas  (Tirabosco  et  al.,  2008).  An 
example  of  brachyury  and  CK19  immunoreactivity  in  chordomas  is 
shown in Figure 1.1 C and D.  
Immunoreactivity for S100 protein is variable from 30-90% in the 
literature (O'Donnell et al., 2007; Rosenberg et al., 1994; Walker et al., 
1991). Vimentin is expressed in most cases while immunoreactivity to 
carcinoembryonic antigen (CEA) and glial fibrillary acidic protein (GFAP) 
is variable (Harrowe and Taylor, 1981; Bouropoulou et al., 1989). The   36 
matrix  of  chordoma  contains  predominantly  type  I  collagen  and  to  a 
lesser extent type II collagen. Basement membrane proteins such as 
collagen type IV and laminin are present on the surface of cellular cords 
(Gottschalk et al., 2001; Taniguchi et al., 1984; Ueda et al., 1992).  
Ultrastructurally,  the  neoplastic  cells  have  epithelial  features 
including villous-like projections, intra-cytoplasmic lumina, tonofilament-
like bundles of intermediate filaments and well developed desmosomes 
(Murad  and  Murthy,  1970).  The  cells  show  abundant  cytoplasmic 
glycogen,  mitochondria-rough  endoplasmic  reticulum  complexes  and 
attenuated  mitochondriae.  The  vacuoles  in  the  physaliphorous  cells 
represent  either  dilated  rough  endoplasmic  reticulum,  cytoplasmic 
inclusions of the extracellular space or intracellular lumina (Spjut and 
Luse, 1964; Erlandson et al., 1968).   
1.2.3 Chondroid chordoma  
Chondroid  chordoma  was  originally  defined  in  1973  by 
Heffelfinger  et  al.,  as  a  tumour  that  contains  areas  of  conventional 
chordoma  as  well  as  chondroid  areas  resembling  low-grade  hyaline-
type chondrosarcoma (Heffelfinger et al., 1973).  
Chondroid chordoma has a predilection for the skull base but can 
occur in the spinal and sacro-coccygeal regions. It represents 5%-15% 
of  all  chordomas  and  up  to  one  third  of  the  skull-based  chordomas 
(Chugh et al., 2007).    37 
It  was  originally  thought  that  chondroid  chordoma  were 
associated  with  a  better  survival  than  conventional  chordoma 
(Heffelfinger et al., 1973; Raffel et al., 1985; Rich et al., 1985). However 
subsequent  studies  showed  that  there  is  no  difference  in  the  overall 
survival  (Forsyth  et  al.,  1993;  Mitchell  et  al.,  1993;  O'Connell  et  al., 
1994;  Rosenberg  et  al.,  1994;  Almefty  et  al.,  2007).  The  marked 
discrepancies  in  the  results  can  be  attributed  to  inclusion  of  some 
chondrosarcomas into the chondroid chordoma group due the absence 
of  immunohistochemistry  in  the  earlier  studies  (Almefty  et  al.,  2007; 
O'Connell et al., 1994).  
The  controversy  following  the  initial  description  of  chondroid 
chordoma  regarding  its  existence  as  a  variant  of  chordoma  was  first 
raised by Brooks et al., (1987) and was based on failure to demonstrate 
epithelial marker immunoreactivity as seen in conventional chordoma. 
However Mitchell et al., (1993) showed epithelial immunoreactivity in a 
subset of chondroid chordoma and argued that the tumours that were 
negative for epithelial markers are in fact low-grade chondrosarcoma. 
This issue is now resolved as the chondroid areas have been shown to 
express brachyury and CK19 (Vujovic et al., 2006) and therefore should 
be classified as chordomas.  
Microscopically, the chondroid regions in chordomas merge with 
or  abruptly  appose  the  surrounding  conventional  component.  The 
chondroid areas are composed of neoplastic cells distributed individually   38 
in lacunar-like spaces surrounded by solid appearing hyalinised matrix 
similar to hyaline cartilage. The quantity of the chondroid component in 
any individual tumour is variable and a tumour is now only classified as 
a chondroid chordoma when at least 60% of the tumour has a chondroid 
appearance. However, in some cases; it is so abundant that it may be 
difficult to distinguish the tumour from chondrosarcoma (Heffelfinger et 
al., 1973; Rosenberg et al., 1994). A histological section of chondroid 
chordoma is shown in Figure 1.1 E.   
The tumour cells in the chondroid areas of chordoma exhibit the 
same epithelial characteristics as those in conventional foci and exhibit 
the  same  immunohistochemical  and  ultra-structural  features.  This 
supports  the  view  that  the  chondroid  appearance  in  these  tumours 
represents a morphologic difference in the extra-cellular matrix rather 
than  the  presence  of  hyaline  cartilage  in  a  chordoma  which  only 
contains Type II collagen (Ishida and Dorfman, 1994; Rosenberg et al., 
1994).  
1.2.4 Dedifferentiated chordoma  
Dedifferentiated chordoma was defined by Meis et al., (1987) as a 
tumour characterised by a sharp demarcation between a conventional 
chordoma and a high-grade sarcomatous component. Dedifferentiated 
chordoma comprises less than 5% of all chordomas and most frequently 
complicates  sacro-coccygeal  tumours  (Hanna  et  al.,  2008b).  The 
dedifferentiation is suspected to occur as a result of ongoing cumulative   39 
mutations  in  conventional  chordoma  cells  and  may  arise  within  a 
primary tumour as opposed to arising in a recurrence or secondary to 
radiotherapy (Ikeda et al., 1997; Saito et al., 1998).  
Grossly the dedifferentiated component of chordoma is fish flesh-
like  in  appearance,  and  morphologically  it  is  usually  distinct  from  the 
areas  of  conventional  chordoma.  The  light  microscopic  features, 
immunohistochemical  phenotype  and  ultrastructural  characteristics  of 
the  dedifferentiated  component  usually  are  those  of  a  pleomorphic 
sarcoma or ﬁbrosarcoma, although rarely there is osteosarcomatous or 
rhabdomyosarcomatous  differentiation  present  (Meis  et  al.,  1987; 
Morimitsu et al., 2000; Bisceglia et al., 2007).  
The importance of identifying a dedifferentiated chordoma is that 
it  behaves  aggressively.  It  has  the  worst  prognosis  of  all  chordoma 
types  and  is  usually  rapidly  fatal  with  systemic  spread  occurring  in 
approximately  90%  of  cases.    The  size  of  the  dedifferentiated 
component is a significant predictor of survival (Hanna et al., 2008b). A 
representative histological image of dedifferentiated chordoma is shown 
in Figure 1.1 F.  
1.2.5 Extra-axial chordoma: 
A small number of chordomas arising outside the axial skeleton in 
bone and soft tissue has been reported. These reports were based on 
the identical morphological features as those seen in conventional axial 
chordoma (McMaster et al., 2001; DiFrancesco et al., 2006; van Akkooi   40 
et  al.,  2006;  Tirabosco  et  al.,  2008).    Tirabosco  et  al.,  (2008)  have 
recently shown immunoreactivity for brachyury and CK19 in eight extra-
axial skeletal and two soft tissue cases, providing a strong evidence for 
the first time, that these were similar tumours. These extra-axial tumours 
were  first  described  by  Laskowski  (1955)  as  chordoma  periphericum 
and  by  Dabska  in  1977  who  labelled  them  as  parachordoma 
(Laskowski, 1955; Dabska, 1977; Scolyer et al., 2004; Tirabosco et al., 
2008). Soft tissue tumours with a morphological phenotype of chordoma 
which do not express brachyury are now considered to represent mixed 
tumour/myoepithelioma/parachordoma (Tirabosco et al., 2008).   41 
 
Figure 1.1 Histology of chordoma. H&E section of a conventional chordoma (A), 
with the characteristic physaliphorous cells (B). Immunohistochemistry for brachyury 
(C) and CK19 (D).  H&E section of a chondroid chordoma (E) and a dedifferentiated 
chordoma (F).    42 
1.3 ORIGIN OF CHORDOMA 
1.3.1 Origin of axial chordoma 
Chordoma shows evidence of notochordal differentiation and the 
most  accepted  theory  is  that  chordoma  arises  from  notochordal 
remnants  in  the  vertebral  bodies  as  evidenced  by  the  histological, 
immunohistochemical  and  ultrastructural  similarities  to  the  notochord. 
The  sites  of  notochordal  vestiges  correspond  closely  with  the 
distribution of chordomas as evidenced by the complex irregularities and 
forking  at  both  ends  in  the  three  dimensional  reconstruction  of  the 
notochord (Persson et al., 1991; Salisbury, 1993; Salisbury et al., 1993; 
Yamaguchi et al., 2004b).  
Cappell  (1928)  has  pointed  out  that  the  great  variation  in 
histological appearance of chordoma is consistent with the histological 
appearances of the notochord in its various stages of development. A 
relatively recent theory has suggested that chordoma develops from a 
benign notochordal  tumour. As supporting evidence for this theory, a 
few chordomas associated with a benign notochordal cell tumour have 
been reported (Yamaguchi et al., 2002; Deshpande et al., 2007).  
 Historically  trauma  to  notochordal  rests  was  suggested  for  the 
development  of  a  chordoma.  This  theory  was  based  on  Ribbert’s 
experiments in 1895 when he pierced the nucleus pulposus of rabbits 
and reported the development of tumours similar to chordoma. In line   43 
with  this  theory,  there  is  a  report  of  a  thoracic  vertebral  chordoma 
associated with a preceeding history of injury (Husain, 1960). 
1.3.2 Origin of extra-axial chordoma 
It has been suggested that the extra-axial chordomas arise from 
heterotopic notochordal remnants left during embryogenesis and then 
undergo neoplastic transformation (Fisher and Miettinen, 1997; Fisher, 
2000;  DiFrancesco  et  al.,  2006;  O'Donnell  et  al.,  2007).  However, 
developmentally  this  is  very  unlikely  as  there  are  no  notochordal 
remnants  found  in  extra-axial  sites.  Therefore,  it  may  be  that 
notochordal  differentiation  has  occurred  at  the  site  of  the  extra-axial 
chordomas,  although  the  molecular  signals  or  mutations  that  would 
induce such differentiation are not known. 
1.3.3 Notochord 
The notochord in humans is a transient embryonic rod-like midline 
structure arising from the ectoderm at the rostral end of the primitive 
streak  and  first  appears  around  the  second  gestational  week  and 
extends along much of the embryo's length (Stemple, 2005).  
The  functions  of  the  notochord  include  acting  as  an  early 
structural support and induction of the surrounding cells to construct the 
vertebral  column  (Fleming  et  al.,  2001).  During  embryologic 
development,  most  of  the  notochordal  cells  disappear  and  become 
replaced with bone of the vertebral bodies and by the nucleus pulposus 
in the intervertebral discs. There is a great risk of incomplete involution   44 
at the caudal and rostral ends due to a high rate of complicated folding 
(Salisbury et al., 1993).  
The  most  classic  form  of  notochordal  vestiges  is  known  as 
ecchordosis physaliphora, a collection of notochordal cells found at the 
skull base in 2% of autopsies.  Microscopic intra-osseous notochordal 
vestiges  persisting  in  adults  within  the  vertebral  bodies  have  been 
identified and these remnants were found mostly in the clival and sacro-
coccygeal areas with a few found in the cervical and lumbar vertebrae 
(Ulich and Mirra, 1982; Yamaguchi et al., 2004b; Wang et al., 2008). 
1.3.4 Brachyury 
The brachyury gene is the prototypic member of the T-box family 
of  related  genes  encoding  transcriptional  factors.    Brachyury  plays  a 
crucial role in notochordal development and the early specification of the 
posterior mesoderm (Smith et al., 1991; Wilkinson et al., 1990; Muller 
and Herrmann, 1997). Brachyury has also been shown to be involved in 
the  differentiation  of  mesenchymal  stem  cells  into  the  chondrogenic 
lineage (Hoffmann et al., 2002) while the related TBX3, a member of the 
T-box family of transcription factors, induces osteogenic differentiation in 
human adipose tissue stromal cells (Lee et al., 2007).  
Brachyury  expression  is  induced  by  fibroblastic  growth  factor 
(FGF) and activin and the activation of these pathways is required for its 
expression (Herrmann and Kispert, 1994). The Wnt signalling pathway 
may also play a role in brachyury regulation (Arnold et al., 2000).   45 
 Loss of function of brachyury was reported more than 80 years 
ago  when  mice  with  heterozygous  deletion  exhibited  a  short  tail 
phenotype.  The  homozygous  deletion  was  lethal:  an  abnormal 
notochord,  absent  somites,  and  reduced  allantois  were  reported 
(Gruneberg,  1958).  In  humans,  genetic  variations  in  brachyury  have 
been  shown  to  be  associated  with  many  neural  tube  defects  (spina 
bifida and anencephaly) and sacral agenesis (Meisler, 1997; Jensen et 
al., 2004). One report has implicated missense mutation in brachyury in 
the  development  of  congenital  vertebral  malformations  including 
hemivertebra,  vertebral  bars,  supernumerary  vertebrae,  butterfly  and 
wedge-shaped vertebrae (Ghebranious et al., 2008).    
1.3.5 Benign notochordal cell tumour 
Benign  notochordal  cell  tumour  (BNCT),  previously  known  as 
giant  notochordal  rest  or  hamartoma  is  a  distinctive  notochordal 
collection of cells that has an indolent course (Yamaguchi et al., 2008). 
The vast majority are asymptomatic incidental findings detected during 
careful dissection at autopsy or in clinical imaging studies of the axial 
skeleton.  At  autopsy,  approximately  11.5%  have  been  found  in  the 
clivus, 5% in the cervical vertebrae, 12% in the sacro-coccygeal region 
and 2% in the lumbar vertebra (Yamaguchi et al., 2004a).   
Morphologically, BNCT consists of sheets of large polyhedral cells 
with  abundant  clear  to  pale  pink  cytoplasm  and  mildly  pleomporphic 
round nuclei containing fine or homogeneously dense chromatin with no   46 
mitoses.  Some  cells  contain  periodic  acid-Schiff  positive,  diastase-
resistant variable sized hyaline globules, which may be encountered in 
small  extracellular  cystic  spaces.  The  lack  of  typical  physaliphorous 
cells and myxoid stroma can differentiate histologically between BNCT 
and chordomas. Immunohistochemical profile of BNCT includes positive 
immunoreactivity  for  epithelial  membrane  antigen,  pancytokeratin, 
cytokeratin 18 and S100 protein. The expression of brachyury has not 
been  studied  in  the  published  cases  (Yamaguchi  et  al.,  2005, 
Yamaguchi et al., 2008).  
1.4 GENETICS OF CHORDOMA 
Genetic  studies  performed  on  chordomas  include  chromosome 
analysis, metaphase comparative genomic hybridisation (mCGH), array 
comparative  hybridisation  (aCGH),  assessment  of  telomere  reduction 
and  telomere  activity,  fluorescent  in  situ  hybridisation  (FISH),  DNA 
micro-satellite  analysis,  loss  of  heterozygosity  (LOH),  and  clonality 
studies (Butler et al., 1995; Klingler et al., 2000; Scheil et al., 2001; Riva 
et al., 2003; Chugh et al., 2007; Hallor et al., 2008). 
1.4.1  Cytogenetics,  fluorescent  in  situ  hybridisation  (FISH)  and 
comparative genomic hybridisation (CGH) 
Chordoma  is  a  genetically  heterogeneous  multiclonal  tumour 
lacking  consistent  structural  chromosomal  aberrations  as  detected  by 
the  use  of  cytogenetic  G-banding,  metaphase  and  array  comparative   47 
genomic hybridisation and fluorescent in situ hybridisation (Hallor et al., 
2008; Klingler et al., 2006). 
Most cytogenetically investigated chordomas have a near diploid 
or  moderately  hypodiploid  karyotype  with  several  numerical  and 
structural  rearrangements.  However,  Scheil  et  al.,  (2001)  found  that 
33%  of  tumours  were  hyperdiploid  by  using  CGH  technique.  They 
suggested that failure to detect this hyperdiploid pattern by karyotyping 
was caused by the method used to prepare the cells for karyotyping by 
gowing  them  in  tissue  cultures,  where  the  hypo-  or  near  diploid  cell 
populations dominate as they have in vitro growth advantages (Scheil et 
al., 2001). DNA flow cytometry studies suggested that hypoploidy is not 
a feature of chordoma (Hruban et al., 1990). 
The identified recurrent chromosomal aberrations include loss or 
rearrangement  of  1p  and  9p  and  gain  of  chromosome  7,  loss  of 
chromosomes 3, 4, 10 and 13. The commonest reported losses are 3p 
and 1p (Mertens et al., 1994; Scheil et al., 2001; Brandal et al., 2004). 
Isochromosome  1q  has  been  found  to  be  a  recurrent  chromosome 
aberration and a marker of aggressiveness (Sawyer et al., 2001). Two 
chordomas have been shown by cytogenetics to have a translocation 
involving  21q22  where  the  transcription  factors  ERG  and  ETS2  are 
located (Gibas et al., 1992). All chordomas analysed using aCGH were 
found  to  harbour  chromosomal  imbalances  in  contrast  to  the  studies 
performed using karyotyping which reported that some chordomas had   48 
normal karyotype which can be explained by in vitro growth advantage 
of the normal cell population (Scheil et al., 2001; Hallor et al., 2008). 
The aCGH study of chordomas showed that chromosomal losses 
are more common than chromosomal gains and that there are no high 
level amplifications. The most common deletion found in this study was 
at 9p21 where CDKN2A and CDKN2B are located. More than 70% of 
the  chordomas  examined  (16/21)  showed  deletion  of  the  region 
covering  CDKN2A  icluding  13  cases  with  heterozygous  deletion  and 
cases  of  homozygous  deletion.  Loss  of  CDKN2A  expression  in 
chordomas has been also reported using immunohistochemistry (Hallor 
et al., 2008; Naka et al., 2005).  
Loss or rearrangement at 1p36 is a common finding in sporadic 
chordomas and has been linked to hereditary chordoma suggesting the 
existence of a tumour suppressor gene (Riva et al., 2003). A minimally 
deleted region in 1p36.31-p36.11 where the transcription factor RUNX3 
is located was found in 57% of chordomas. The chromosomal region 
containing  TP53  gene  was  lost  in  48%  of  chordomas  using  aCGH 
(Hallor et al., 2008).  
The most common gains included chromosome 5, 7, 12 and 20. 
Frequently  gained  regions  included  7p15.1  which  contains  the  genes 
CREB5, CPVL and CHN2 none of which could be related to chordoma 
or notochordal development. There is also a consensus gained region 
on chromosome 7 at 7q36 which includes homeobox-containing gene   49 
HLXB9 and sonic hedgehog gene (SHH), both of which are expressed 
during notochordal development (Ross et al., 1998; Scheil et al., 2001). 
Kelley  et al., (2001) performed  a linkage analysis study in  the family 
reported  by  Stepnak  et  al,  and  mapped  minimal  disease  lesion  to  a 
locus  7q33.  However,  no  loss  of  heterozygosity  was  found  at  any 
markers residing in this 7q critical region suggesting the presence of an  
oncogene (Kelley et al., 2001).  
The locus of TGFB1 at 5q31.1-q31.2 was gained in five of the 
cases and there is some evidence that this gene product is involved in 
cartilage development. The chromosomal region harbouring FGFR4 on 
chromosome 5 (5q35.1-q35.3) also showed gain in 33% (7/21) of cases. 
The chromosomal region 6q27 containing brachyury gene showed gain 
in 29 % (6/21) of chordomas (Hallor et al., 2008).  
Recently,  another  aCGH  study  on  familial  chordomas  identified 
brachyury copy number variation in four out of seven analysed families 
suggesting its major role in susceptibility for familial chordoma (Yang et 
al., 2009b). 
1.4.2 Loss of heterozygosity  (LOH), microsatellite instability  (MSI) and 
clonality studies in chordoma 
The  first  LOH  study  on  chordomas  examined  the  Rb1  locus 
(13q14) where LOH was detected in 2 out of 7 cases (Eisenberg et al., 
1997).  This  finding  is  consistent  with  the  frequently  reported  loss  of 
chromosome 13 as detected by cytogenetics and CGH studies. Another   50 
LOH study showed loss of 17p and 9p where known tumour suppressor 
genes (TP53, CDKN2A) are present (Klingler et al., 2000). 
Based  on  the  identification  of  LOH  at  the  chromosomal  region 
1p36.13 in one family with familial chordoma and the frequent loss of 1p 
in  chordomas,  a  targeted  LOH  study  was  performed  by  Riva  et  al., 
(2003). It showed that 85% (25/27) of chordomas had LOH at 1p36.13. 
Putative tumour suppressor genes at this locus include CASP9, EPHA2, 
PAX7, DAN and DVL1. Expression studies of these genes showed that 
out of 8 chordomas, EPHA2, DVL1, and CASP9 were absent in 1, 4, 
and 5 tumours respectively (Dalpra et al., 1999; Riva et al., 2003). The 
limitations of this study are the high gene density in this region and its 
common loss in many solid tumours suggesting a possible non specific 
role in chordomas (Larizza et al., 2005).  
In  a  single  study,  MSI  and  LOH  were  performed  on  12 
chordomas. MSI was detected in 50% of the chordomas at one or more 
loci and LOH was identified in two chordomas, one of which had MSI 
(Klingler et al., 2000).  
A limited study has revealed telomere lengthening in 4 out of 4 
chordomas  in  contrast  to  telomere  length  reduction  that  has  been 
reported  in  most  cancers  and  during  in  vitro  senescence  of  human 
fibroblasts (Butler et al., 1996). The activity of telomerase, the enzyme 
responsible for telomere length maintenance has been demonstrated in 
about half of the chordomas studied (Butler et al., 1995).   51 
A clonality study has been performed on seven sacral chordomas 
using an X chromosome inactivation protocol and a polymorphic human 
androgen  receptor  gene  (AR)  located  on  the  X  chromosome  as  a 
marker and demonstrated that chordoma is polyclonal in origin. Like in 
other  solid  tumours,  this  polyclonality  may  be  caused  by  imbalanced 
chromosomal  alterations  and  added  more  difficulties  to  the  use  of 
molecular targeted therapy in comparison to monoclonal tumours like 
haematopoietic malignancies (Klingler et al., 2006).  
1.5 GENE EXPRESSION IN CHORDOMAS 
1.5.1 Gene expression microarrays 
The  chordoma  gene  expression  pattern  was  found  by  gene 
expression microarrays to cluster closely with cartilaginous neoplasms 
including  chondrosarcomas,  chondroblastomas  and  chondromyxoid 
fibromas (Henderson et al., 2005; Schwab et al., 2009b). Among various 
types of sarcomas, chordoma and chondrosarcoma grouped together in 
a  genomic  cluster  distinct  from  that  of  other  types  of  sarcoma.  Both 
tumours showed higher levels of expression of genes characteristic of 
extracellular matrix and hyaline cartilage such as collagen II, aggrecan, 
cartilage  linking  protein,  cartilage  oligomeric  matix  protein,  the 
chondrogenic transcription factor SOX9, fibronectin, MMP9 and MMP19 
than other connective tissue tumours (Henderson et al., 2005; Schwab 
et al., 2009b).   52 
The  genes  expressed  in  chordomas  and  not  in  cartilagenous 
neoplasms  include  brachyury,  CD24,  cytokeratins  8,  15,  18,  19, 
discoidin  domain  receptor  1  (DDR1)  and  periplakin  (Schwab  et  al., 
2009b; Vujovic et al., 2006). Over-expression of EGFR and its ligand, 
EGF was found in chordomas relative to the nucleus pulposus (Schwab 
et  al.,  2009b).  Chordomas  were  not  found  to  express  high  levels  of 
collagen X implicated in cartilage calcification,  platelet-derived growth 
factor alpha, a mitogen for connective tissue cells or reticulocalbin 3, a 
putative endoplasmic reticulum protein (Vujovic et al., 2006). 
1.5.2 Protein expression studies 
Many expression studies have been performed to investigate the 
possible roles of various molecules in chordoma biology. Expression of 
tyrosine kinases has been investigated using immunohistochemical and 
reverse  transcription  polymerase  chain  reaction  techniques  and 
demonstrated that platelet-derived growth factor receptor beta (PDGFR 
β)   was  expressed in virtually all chordomas (Tamborini et  al., 2006; 
Fasig et al., 2008). This provided a basis for the phase II clinical trial of 
imatinib  mesylate  in  chordomas  (Casali  et  al.,  2007;  Ferraresi  et  al., 
2010).  
In  a  study  of  21  chordomas,  EGFR  has  been  reported  to  be 
expressed in 67% (14/21). KIT and c-MET were detected in 33% and 
66% of examined specimens while HER2 was not detected in any of the 
cases. The active phosphorylated forms of the transduction molecules;   53 
ERK,  AKT  and  STAT3,  indicative  of  tyrosine  kinase  activity,  were 
detected in 86%, 76% and 67% of cases (Fasig et al., 2008). In another 
study of 12 chordomas, Weinberger et al., (2005) reported expression of 
EGFR and c-MET in all of the 12 chordomas while HER2 expression 
was  detected  in  only  7  chordomas.  The  expression  of  nerve  growth 
factor receptor (TrkA) and nerve growth factor (NGF) was significantly 
higher in chordomas than in notochordal cells (Park et al., 2007).  
Cyclo-oxygenase-2 (COX2) has been detected in 90% (19/21) of 
chordomas, oestrogen receptor beta (ERβ) in all the 21 tested cases 
and the androgen receptor has been detected in 90% of cases (19/21) 
while  oestrogen  receptor  alpha  (Erα)  or  progesterone  receptors  have 
not  been  detected  (Fasig  et  al.,  2007).  Expression  of  high  molecular 
weight  melanoma-associated  antigen  (HMW-MAA),  also  known  as 
chondroitin  sulphate  proteoglycan  4  (CSPG4),  a  possible  target  of 
immune therapy has been detected in 62% of 21 chordomas (Schwab et 
al., 2009b).  
Expression of the adhesion molecules E-cadherin, α-catenin, β-
catenin,  γ-catenin  and  neural  cell  adhesion  molecule  (NCAM)  in 
chordoma  has  been  detected  in  chordomas  and  are  thought  to  be 
associated  with  the  formation  and  maintenance  of  chordoma  tissue 
architecture but these are not related to the microscopic characteristics 
or prognosis (Naka et al., 2001). Horiguchi et al., suggested that nuclear 
expression on E-cadherin is a characteristic feature of chordoma while   54 
Mori et al., suggested E-cadherin is a diagnostic marker for chordomas 
(Mori et al., 2002; Horiguchi et al., 2004). 
1.6 AIMS   
The overall aim of this work was to understand the pathogenic 
mechanisms underlying the development of chordomas and to attempt 
to link the findings to possible therapeutic applications.  
The  first  aim  of  this  work  was  to  investigate  the  role  of  the 
PI3K/AKT/TSC/mTOR  pathway  in  chordomas  and  the  potential  of  its 
molecules to be used as targeted therapy.  
The  second  aim  was  to  analyse  the  status  of  the  FGFR-
RAS/RAF/MEK/ERK-ETS2-brachyury  pathway  in  chordomas  and  to 
investigate the role of brachyury in chordoma pathogenesis by targeting 
its expression in a chordoma cell line U-CH1 by shRNA.  
The  final  aim  was  to  investigate  the  expression  pattern  and 
genetic alterations of EGFR and to test the effect of one of the EGFR 
inhibitors on the U-CH1 chordoma cell line in an attempt to find a basis 
for using EGFR inhibitors for treating chordomas.    55 
2. MATERIALS AND METHODS 
2.1 Clinical samples 
The  tissues  and  clinical  data  used  in  this  study  were  retrieved 
from  the  archives  of  The  Royal  National  Orthopaedic  Hospital, 
Stanmore, UK and from the Institute of Neurology, University College 
London  (UCL),  London,  UK.  The  selection  was  restricted  to  paraffin-
embedded tissues and snap-frozen tissues available within the last 10 
years.  The  study  complied  with  standards  laid  down  by  the  Central 
Office for Research Ethics Committees (COREC) and approved by the 
relevant ethics committees under the study number 07/Q0506/8. 
2.2 Tissue microarrays (TMAs) 
Two tissue microarrays of 50 non skull-based chordomas and 50 
skull-based chordomas were constructed using a manual tissue arrayer 
(Beecher Instruments Inc, Sun Prairie, WI, USA).  H&E sections were 
examined and two different representative areas from each case were 
marked on the paraffin blocks. Two 0.6 mm cores were taken for the 
array from all cases.  Paraffin blocks from salivary gland, kidney, tonsil, 
lymph node, placenta, thyroid, renal cell carcinoma, breast carcinoma 
and thyroid carcinoma were also marked for representative areas and 
cores were taken as controls and orientation markers.     56 
2.3 Immunohistochemical analyses 
 Sections  of  3  µm  thickness  were  cut  from  paraffin-embedded 
tissue,  de-paraffinized  in  xylene  for  5  min,  rehydrated  in  ethanol  and 
treated  with  the  appropriate  antigen  retrieval  method  as  described  in 
Table  2.1.  The  iVIEW  DAB  detection  kit  and  Ventana  NexES 
Autostainer  (Ventana  Medical  Systems,  Inc.  Tucson,  AR,  USA)  were 
used according to the manufacturer’s instructions.  
The  detailed  conditions  and  the  antibodies  used  are  listed  in 
Table  2.1.  Immunohistochemistry  was  also  performed  manually  for 
some antibodies using the iVIEW DAB kit (Ventana Medical Systems, 
Inc.)  with  overnight  incubation  at  4° C  in  a  humidif ied  chamber. 
Diaminobenzidine  (DAB)  was  used  as  a  chromogen  in  all  reactions. 
Incubation  without  a  primary  antibody,  as  well  as  incubation  with  the 
matching  IgG  isotype,  under  the  same  conditions  for  each  antibody 
served as the negative controls.  
Each  antibody  was  scored  with  reference  to  cores  of  positive 
control  tissue  included  in  the  TMA  design.  For  each  antibody,  the 
labelling intensity and extent were scored. The intensity scores included; 
negative  in  the  absence  of  immunoreactivity,  ‘low’  when  the 
immunoreactivity  was  unequivocal  but  less  strong  than  the  positive 
control and ‘high’ when the immunoreactivity was at least as strong as 
the positive control. The extent of staining was assessed as +, ++ and 
+++ indicating that less than 5%, between 6 and 49%, and at least 50%,   57 
respectively,  of  the  lesional  cells  were  immunoreactive  (Fasig  et  al., 
2008).  The  presence  of  non-neoplastic  cells  (macrophages, 
lymphocytes,  fibroblasts,  endothelial  cells)  in  the  cores  of  neoplastic 
tissue was also used as internal negative control.   58 
Table 2.1 Details of antibodies used for immunohistochemistry 
 
 
*PC = pressure cooker: min= minute 
**O/N = over night 
***Ventana NexES = Ventana NexES Autostainer 
  Antibody/clone  Source  Antigen retrieval  Diluti
on 
Incubation time 
and temperature  Method 
1  CK19 clone  b170  Novocastra Laboratories Ltd, Newcastle 
upon Tyne, UK   Protease 20 min  1:100  30 min at 37° C  ***Ventana NexES  
2  Brachyury (H-210): sc-20109  Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA  *PC 2 min  1:50  30 min at 37° C  Ventana NexES  
3  PTEN clone 28H6  Abcam, Cambridge, UK  PC 2 min  1:100  30 min at 37° C  Ventana NexES  
4  p16
 INK4a CINtec
® clone E6H4TM 
MTM laboratories AG,  Heidelberg, 
Germany  PC 2 min  1:100  20 min at 37° C  Manual staining 
5  p-AKT (ser 473) clone 736E11  Cell Signaling Technology,  Danvers, 
MA, USA  PC 6 min  1:50  **O/N at 4° C  Manual staining 
6  Harmatin/TSC1  Cell Signaling Technology  PC 2 min  1:25  30 min at 37° C  Ventana NexES  
7  Tuberin/TSC2  Santa Cruz Biotechnology  PC 2 min  1:100  30 min at 37° C  Ventana NexES  
8  p-tuberin/TSC2 (Thr
1462)   Abcam  PC 4 min  1:25  O/N at 4° C  Manual staining 
9  p-mTOR (ser 
2448) clone 49F9  Cell Signaling Technology  PC 3 min  1:100  30 min at 37° C  Ventana NexES  
10  Total mTOR  Cell Signaling Technology  PC 4 min  1:50  O/N at 4° C   Manual staining 
11  p-p70 S6K1 (Thr 
389)  Cell Signaling Technology  PC 4 min  1:50  O/N at 4° C   Manual staining 
12  S6K  Abcam  PC 6 min  1:100  O/N at 4° C   Manual staining 
13  p-S6RP 
(ser
235/236) clone 91B2  Cell Signaling Technology  PC 3 min  1:50  30 min at 37° C  Ventana NexES  
14  Total S6RP  Cell Signaling Technology  PC 2 min  1:100  30 min at 37° C  Ventana NexES  
15  p-4E-BP1 (Thr
70)  Cell Signaling Technology  PC 2 min  1:50  O/N at 4° C   Manual staining 
16  eIF4E  Cell Signaling Technology  PC 2 min  1:50  O/N at 4° C   Manual staining 
17  FGFR1/Flg (C-15): sc-121  Santa Cruz Biotechnology  Protease 14 min  1:150  30 min at 37° C  Ventana NexES  
18  FGFR2/Bek (C-17): sc-122  Santa Cruz Biotechnology  Protease 14  min  1:100  30 min at 37° C  Ventana NexES  
19  FGFR-3 (C-15): sc-123  Santa Cruz Biotechnology  Protease 14 min  1:100  O/N at 4° C  Manual staining 
20  FGFR-4 (C-16): sc-124  Santa Cruz Biotechnology  Protease 14 min  1:50  30 min at 37° C  Ventana NexES  
21  EGFR   Dako UK Ltd., Ely, Cambridgeshire, UK  Protease 14 min  1:25  30 min at 37° C  Ventana NexES  
22  p-EGFR (Tyr
1173)   Cell Signaling Technology  PC 3 min  1:100  O/N at 4° C   Manual staining   59 
2.4 Fluorescent in situ hybridisation (FISH) analysis  
FISH  was  performed  on  TMAs  using  probes  from  the  bacterial 
artificial  chromosomes  (BACs)  from  the  RP-BACs  library  (BAC/PAC 
resources centre, Oakland, CA, USA). The details of the BACs used are 
shown in Table 2.2. Chromosome enumeration probes (CEP) were used 
as  references  and  obtained  from  three  different  resources;  ready-
labelled  for  chromosomes  9  and  16  from  Vysis  (Vysis,  Abbott 
Laboratories  Inc,  Des  Plaines,  IL,  USA),  alpha  satellite  DNA  for 
chromosomes 1, 6 and 7 (Resources for Molecular Cytogenetics, Bari, 
Italy) labelled in green with Vysis reagents and telomeric BAC clones 
(BAC/PAC  resources  centre)  for  chromosomes  5  and  21  labelled  in 
green with Vysis reagents. Details of chromosome enumeration markers 
are listed in Table 2.3.  
TMA  sections  were  cut  at  4  µm  thickness,  de-paraffinized  in 
xylene and rehydrated in ethanol. Sections were pre-treated using the 
Paraffin  Pretreatment  Reagent  Kit  II  (Vysis).  Briefly,  the  slides  were 
placed in the pre-treatment solution at 80° C for 50 -70 min, and in pepsin 
solution 0.05% at 37° C 20 to 25 min. The probes wer e applied to the 
slides and co-denatured for 5 min at 73° C and hybri dized for at least 16 
h at 37° C in a Thermo-Brite hybridizer (Iris, Westwood, MA, USA). The 
slides  were  washed  in  formamide-free  solutions:  2XSCC/0.3%  Igepal 
CA-630 (Sigma-Aldrich Company Ltd, Gillingham, Dorset, UK) at room 
temperature for 5 min, at 73° C for 2 min and at roo m temperature for 1   60 
min,  and  then  counter-stained  with  4',6’-diamidino-2-phenylindole 
(DAPI)  and  analysed  under  a  fluorescent  microscope  (Olympus, 
Watford,  Hertfordshire,  UK)  using  AnalySIS  software  (Olympus).  The 
chromosome localisation of all BAC clones  was confirmed  on normal 
metaphase spread slides (Vysis).  
Fifty  non-overlapping  nuclei  that  contained  unequivocal  signals 
were  counted  for  each  case.  For  all  of  the  probes  used  apart  from 
EGFR probes, amplification was defined by a ratio of more than 2 for 
the  gene-specific  probe  compared  to  the  chromosome-specific 
reference probe, and hemizygous deletion was defined as more than 
20%  of  non-overlapping  tumour  nuclei  containing  one  gene-specific 
probe signal (red) and two chromosome-specific probe signals (green).  
FISH  analysis  for  EGFR  comprises  two  groups;  FISH  positive 
(EGFR  genomic  gain)  and  FISH  negative  (no  or  low  EGFR  genomic 
gain) according to the Colardo criteria developed or non small cell lung 
carcinoma, The former included high level polysomy (≥ 4 copies/cell in ≥ 
40% of cells) and amplification (defined by the presence of tight gene 
clusters, or ratio EGFR gene signals/CEP7 signals ≥ 2, or ≥ 15 copies of 
the gene per cell in ≥ 10% of analysed cells). The latter included two 
subgroups; low level polysomy (> 2 copies/cell in ≤ 40% of cells or 3 
copies/cell in ≥ 40% of cells) and diosomy (≤ 2 copies in > 90% of the 
cells) (Cappuzzo et al., 2005; Martin et al., 2009; Varella-Garcia et al., 
2009).   61 
 
Table 2.2 Details of BACs used to generate FISH probes  
  BAC reference  Gene covered 
Chromosome 
location 
Type of aberration 
looked for 
Labelling colour 
1  RP11-235F13  Brachyury  6q27  Amplification  Orange 
2  RP11-830D9  ETS2  21q22.2  Amplification  Orange 
3  RP11-8N7   ETS2  21q22.2  Break-apart  Orange 
4  RP11-42C22    ETS2  21q22.2  Break-apart  Orange 
5  RP11-381G5  EGFR    7p11.2    Amplification  Orange 
 6  RP11-1008G19   FGFR4  5q35.2  Amplification  Orange 
 7  RP11- 81C14  TSC1  9q34.13    Deletion  Orange 
 8  RP11-846C9  TSC2  16p13.3   Deletion  Orange 
9  RP11-1107P2  mTOR (FRAP1)  1p36.22    Deletion  Orange 
10  RP11-624N8  S6RP  9p22.1  Deletion  Orange 
 
Table 2.3 Details of probes used as chromosome enumeration markers  
  Location  Company   Labelling colour 
Chromosome  enumeration 
probe  9 (CEP9)  
Chromosome  9  Vysis, Abbott Laboratories 
Inc, Des Plaines, IL, USA 
Green 
Chromosome  enumeration 
probe 16 (CEP16)  
Chromosome16  Vysis  Green 
D1Z5 (CEP1)  Chromosome 1  Resources for Molecular 
Cytogenetics, Bari, Italy 
Green 
Chromosome  6  alpha 
satellite DNA (CEP6) 
Chromosome 6  Resources for Molecular 
Cytogenetics 
Green 
Chromosome  7  alpha 
satellite DNA  (CEP7) 
Chromosome 7  Resources for Molecular 
Cytogenetics 
Green 
RP1-240G13  Chromosome 5  BAC/PAC  resources centre, 
Oakland, CA, USA 
Green 
RP11-159E6  Chromosome 21  BAC/PAC resources centre   Green 
 
2.5  DNA  isolation  and  mutational  analysis  by  denaturing  high 
performance chromatography (dHPLC) and direct sequencing 
Genomic  DNA  was  extracted  using  proteinase  K  (Qiagen, 
Crawley,  West  Sussex,  UK)  from  23  frozen  chordoma  samples 
according  to  the  manufacturer’s  protocol.  Briefly,  the  samples  were   62 
dissolved in 180 µl of lysis buffer ATL, and 20 µl of proteinase K was 
added and the sample was incubated at 56° C for 3 h,  after which, 200 µl 
of buffer AL was added and the sample was incubated at 70° C for 10 
min. After a brief centrifugation, 200 µl of 100% ethanol was added and 
each sample was applied to a QIAamp spin column and centrifuged at 
8000 rpm for 1 min. The column was washed in Buffers AW1 and AW2 
and centrifuged at 14000 rpm for 3 min; the DNA was eluted in 100 µl of 
buffer AE and kept at -20° C.  
The  tissue  samples  comprised  at  least  80%  tumour.  The  PCR 
primers  were  designed  to  include  the  intron/exon  boundaries  to  be 
analysed in addition to the coding sequence (Table 2.4). 
2.5.1  Denaturing  high  performance  liquid  chromatography  (dHPLC) 
analysis of KRAS and BRAF for the common mutations 
Fifty  nanograms  of  genomic  DNA  was  amplified  using  the 
following touchdown PCR protocol which involved initial heating at 95° C 
for 15 min. The annealing temperature was reduced by 1°C per cycle, 
from 65° C to 56° C, followed by 35 further cycles at  56° C. Each cycle 
was performed as follows: denaturation at 95° C for  45 s, annealing at 
65° C down to 56° C for 45 s, extension at 72° C for 9 0 s, followed by a 
final  extension  step  at  72° C  for  10 min.  The  PCR  re action  was 
performed in a total  volume of 25   L  containing 2.5  L of  10X PCR 
buffer II, 0.2  M of dNTP, 10pmol of each primer, 0.1 mM MgCl2, 1.25 U 
of  optimase  enzymes  (Transgenomic,  Crewe,  Cheshire,  UK).  Prior  to   63 
dHPLC  analysis,  the  PCR  products  were  run  on  an  agarose  gel  to 
ensure  that  only  the  specific  product  was  amplified  and  that  no 
contaminating bands were present. 
A Transgenomic Wave DNA Fragment Analysis System was used 
to perform dHPLC analysis (Transgenomic Inc, Omaha, NE, USA). Prior 
to  dHPLC  analysis,  the  un-purified  PCR  products  were  denatured  at 
95° C for 5 min and cooled to 25° C using a temperatu re ramp of 1° C 
/min to produce heteroduplexes, and 6  L of the PCR products were 
loaded  onto  a  preheated  DNASep
®  HT  Cartridge  column 
(Transgenomic Inc). DNA was eluted at a flow rate of 0.9 ml/min using a 
linear  acetonitrile  gradient  that  consisted  of  buffer  A  (0.1  M 
triethylammonium  acetate;  TEAA)  and  buffer  B  (0.1  M  TEAA,  25% 
acetonitrile).  The  dHPLC  melt  software,  available  from 
http://insertion.stanford.edu/melt.html  was  used  to  select  the  optimal 
temperature to separate heteroduplexes.  
2.5.2  Direct sequencing  
Fifty nanograms of genomic DNA was amplified by the following 
touchdown PCR protocol which involved initial heating at 95° C for 15 
min. The annealing temperature being reduced by 1
oC per cycle, from 
65° C
 to 56
oC, followed by 35 further cycles at 56° C as describ ed above. 
The PCR reaction was performed in a total volume of 50  L containing 
5  L of 10X Hotstart buffer I, 0.2  M dNTP, 10 pM of each primer, 1 U of 
Hotstart DNA polymerase (CLP, San Diego, CA, USA). PCR products   64 
were purified using Qiagen PCR Purification kit (Qiagen) and sent for 
DNA  sequencing  at  the  Scientific  Support  Services  at  UCL  Cancer 
Institute/Wolfson Institute for Biomedical Research (WIBR). Sequencing 
reactions  were  run  using  GenomeLab™  DTCS  Quick  Start  chemistry 
(Beckman  Coulter  UK  Ltd,  High  Wycombe,  Bucks,  UK)  and  were 
analysed  on  a  CEQ™  8000  Genetic  Analysis  System  (Beckman 
Coulter). 
Table  2.4  Primer  sequences  used  for  mutation  analysis  of  the  FGFRs, 
Brachyury, KRAS, BRAF, RHEB, PI3KCA, and EGFR 
FGFRs primers 
Gene (exon)  Primer sequence  Length bp 
F  5’- AGATGTGGAGCCTTGTCACC -3’  FGFR1 (exon 3) 
R  5’- CCTGTTGACCACATCACCTG -3’ 
226 
 
F  5’- TGCCTGTCTCTCTTGGCTTT -3’  FGFR1 (exon 6 
R  5’- CCTCCCCTGTTCCCATTACT -3’ 
314 
F  5’- TGGGAAGCCCTGACTAAGAA -3’  FGFR1 (exon 11) 
R  5’- AAGCAAGGAATGCCTTCAAA -3’ 
355 
F  5’- GTGGGGTTTCTTTGAGGTGA 3’  FGFR1 (exon 12) 
R  5’- CACCGGCTGGAAGACTAGGG -3’ 
302 
F  5’- CTCCCCTGTGCTGCTTTC -3’  FGFR1 (exon 14) 
R  5’- CATCTGGAGCAGAGGGAATG -3’ 
368 
F  5’- TTTACTCATGGAGGGGAAGC -3’  FGFR2 (exon 5) 
R  5’- CGAGACTCCATCGCAAAAA -3’ 
314 
F  5’- GCGTTTTCCTTGCAGCGGCTGG - 3’  FGFR2 (exon 7) 
R  5’ - GTAAGTCACAGGATTCCCGTC - 3’ 
321 
 
F  5’ - CTTTAGTAAGCCGCTGAAAGA -3’  FGFR2 (exon 11) 
R  5’- TTCACATGCCACAAAGGAA - 3’ 
 
302 
F  5’- CGGGAAACACAAAAACATCA - 3’  FGFR2 (exon 12) 
R  5’- CTGAAGCCTCTCCACCTCTC -3’ 
408 
F  5’- AGGCTTCCACTGCTGTGTCT -3’  FGFR3 (exon 2) 
R  5’- GCACTCGGCTCCTTTCTGTA - 3’ 
389 
 
F  5’- AGGAAGTGCTGCCCAAATG - 3’  FGFR3 (exon 3) 
R  5’- TTAGTCCCTCAGCTGCCTGT - 3’ 
258 
 
F  5’- GAAGGGGGTTGTTCAGAGG -3’  FGFR3 (exons 4,5) 
R  5’- CTGTGGGGGCAGATGACGCTCA -3’ 
538 
F  5’- GCGTCGTGGAGAACAAGTTT -3’  FGFR3 (exon 6) 
R  5’- GAAGCTCCAACCCCTAGACC -3’ 
449 
F  5’- GCCTATCGCTCTGCTCTCTC -3’  FGFR3 (exon 7) 
R  5’- GGCCGTAAGTCACAGGATTC -3’ 
275 
F  5’- GCTCCTTCTCTCCAGGGTCT -3’  FGFR3 (exon 8) 
R  5’- TTCCACCAGCATTGAATGAA -3’ 
340 
F  5’- TTCATTCAATGCTGGTGGAA -3’  FGFR3 (exon 9) 
R  5’- CCTCTGACTGGTGGCTGTTT -3’ 
430 
F  5’- CTGCAGAGCTCAGGCTTCA -3’  FGFR3 (exon 15) 
R  5’- CGCCTTATTCGGGAACAG -3’ 
453   65 
F  5’- CCCAGAGTGCTGAGGTGTG -3’  FGFR3 (exon 17) 
R  5’- ACCCAGGGTACCTCTGCAC -3’ 
476 
F  5’- GCAGGGTAAGCAGGAGACAG -3’  FGFR4 (exon 7) 
R  5’- GACATGCTCTGGGGTCACA -3’ 
447 
F  5’- GAGCTGGGAGGGACTGAGTT -3’  FGFR4 (exon 9) 
R  5’- ATGGAGAAAGTCCAGCCTCA -3’ 
601 
F  5’- CTGTGGTGGGTCATGTCTGT -3’  FGFR4 (exon 16) 
R  5’- GGAGGAGGACGAGGAGTTCT -3’ 
349 
Brachyury primers 
Gene (exon)  Primer sequence   Length bp 
F  5’- GCGCAAGACTCCTCTGAACT -3’  Brachyury (promoter) 
R  5’- CTCTCACCATCTGGAAAAGGAA -3’ 
609 
F  5’- AGGGAAGGTGGATCTCAGGT -3’  Brachyury (exon 2) 
R  5’- CCTCCTCCAGGAGAAAAAGG -3’ 
380 
F  5’- CTCTGTGCCCCGAAATAACT -3’  Brachyury (exon 3) 
R  5’- GAGAAGGCTGTGGCAGTTTC -3’ 
502 
F  5’- TTCCCTCAACAGCAGAGACA  3’  Brachyury (exon 4) 
R  5’- CTTCCTCTCAGTGCGGGTTA -3’ 
368 
Brachyury (exons 5 and 6)  F  5’- ATTTAAAAGTGGTACTGGCATTT -3’ 
  R  5’- CTCCACTTCCCAGCTCTCAG -3’ 
428 
Brachyury (exon 7)  F  5’- GAGGGAGCACTAATGCAGGT -3’ 
  R  5’- AGTGGCGGAGACATAAAT -3’ 
398 
Brachyury (exon 8)  F  5’- GCAATAAATCTTGCCCCTGA - 3’ 
  R  5’ - CCTATGGGAATGGAAACAGC - 3’ 
390 
Brachyury (exon 9)  F  5’ - TTGGAGAAAATGACCTGTTTGA -3’ 
  R  5’- TGAGGCTGCATTTCCTTCTT - 3’ 
534 
KRAS and BRAF primers 
Gene (exon)  Primer sequence   Length bp 
KRAS (exon 2)  F  5’GATACACGTCTGCAGTCAACTG--3’ 
  R  5’-GGTCCTGCACAGTAATATGC-3’ 
270 
KRAS (exon 3)  F 
R 
5’-TGCACTGTAATAATCCAGACTGTG-3’ 
5’-CTCCTTAATGTCAGCTTATTATATTCA-3’ 
240 
BRAF  (exon 11)  F  5’- TCCCTCTCAGGCATAAGGTAA -3’ 
  R  5’- CGAACAGTGAATATTTCCTTTGAT -3’ 
350 
BRAF (exon 15) 
 
F 
R 
5’- TCATAATGCTTGCTCTGATAGGA -3’ 
5’-CTGATTTTTGTGAATACTGGGAAC TC-3’ 
220 
RHEB primers 
Gene (exon)  Primer sequence   Length bp 
F  5’-TTTGTTGAAGGCCAATTTGTG-3’  RHEB (exon 2) 
R  5’-TGGAGTATGTCTGAGGAAAGATAGAA-3’ 
180 
F  5’-GGCCAATTTGTGGACTCCTA -3’  RHEB (exon 4) 
R  5’-TCCCCACCATATCCAACAAT-3’ 
220 
PI3KCA primers 
Gene (exon)  Primer sequence   Length bp 
F  5’-CGCCCCCTTAATCTCTTACA- 3’  PI3KCA (exon 4) 
R  5’-TGGATGTTCTCCTAACCATCTG- 3’ 
 
386 
F  5’-GGCAGCAACTAATTTTGGTGA -3’  PI3KCA (exon 5) 
R  5’-ACTTTTTGTAGAAATGGGGTCT- 3’ 
 
392 
F  5’-TTTCCAATCAATCTCTTTCCTG- 3’  PI3KCA (exon 6) 
R  5’-TCCCAAGGTATTCTTCCATGAT-3’ 
 
396 
F  5’-GCTTTTTCTGTAAATCATCTGTG -3’  PI3KCA (exon 9) 
R  5’-CATGCTGAGATCAGCCAAATTC- 3’ 
 
286 
F  5’-GTCTACGAAAGCCTCTCTAATTT- 3’  PI3KCA (exon 20) 
R  5’-TAATGCTGTTCATGGATTGTGC- 3’ 
 
483 
EGFR primers 
Gene (exon)  Primer sequence   Length bp 
EGFR (exon 18)  F  5’-TTCCAAATGAGCTGGCAAGT- 3’  405   66 
R  5’-CTGAGTGTTTGGGAAACTCCA- 3’ 
F  5’-CCCCAGCAATATCAGCCTTA- 3’  EGFR (exon 19) 
R  5’-TCTCCCATGCTGGTATCCAC- 3’ 
455 
F  5’-CTTTTGCAGGCACAGCTTTT- 3’  EGFR (exon 20) 
R  5’-GAGTTTGCCATGGGGATATG- 3’ 
431 
F  5’-ACTAACGTTCGCCAGCCATA- 3’  EGFR (exon 21) 
R  5’-ACATTCTGGGTGAGCTCG- 3’ 
412 
2.6 DNA Methylation studies 
2.6.1 DNA extraction and bisulphite treatment of the DNA 
Genomic  DNA  was  extracted  using  proteinase  K  (Qiagen).  In 
total, 500 µg DNA (concentration 100 ng/µl) was treated using EZ DNA 
Methylation-Gold
TM Kit (Zymo Research, Orange, CA, USA) according 
to the manufacturer's protocol. Briefly, 130  l of CT Conversion Reagent 
was added to 20  l of DNA sample and mixed, then heated to 98° C for 
10 min and then 64°C for 2.5 h and kept at 4° C.  M- Binding Buffer was 
added (600  l) to a Zymo-Spin IC Column, then the sample was added 
and the column was centrifuged at full speed (>10,000 rpm) for 30 s. 
The  flow-through  was  discarded  and  100   l  of  M-Wash  Buffer  was 
added to the column. The column was centrifuged for 30 s and 200  l of 
M-Desulphonation buffer was added to the column and left for 15-20 
min at room temperature. The column was then centrifuged at full speed 
for 30 s. A wash step was then performed by addition of 200 µl of M-
Wash Buffer to the column after which the column was centrifuged for 
30 s. This wash step was repeated twice. M-Elution buffer (10  l) was 
added directly to the column matrix and the bisulfite-treated DNA was 
collected in 1.5 ml micro-tubes and stored at -20°C .    67 
2.6.2 PCR and pyrosequencing 
The  primers  described  in  Table  2.6  were  designed  using  the 
PyroQ  assay  design  software  (Biotage,  Uppsala,  Sweden).  All 
pyrosequencing  assays  for  repetitive  elements  included  at  least  one 
primer in a unique sequence outside of the repeat and followed by a 
unique  nested  primer  pair  for  some  amplicons  to  ensure  specific 
amplification. A common tag was placed on either the forward or the 
reverse  primer  (depending  on  the  strand  to  be  sequenced),  and  a 
common  universal  biotinylated  primer  was  used  for  all  reactions  as 
described previously (Tost and Gut, 2007). Two rounds of bisulphite- 
PCR  cycling  conditions  included  denaturation  at  95°C  for  4  min, 
followed  by  10  cycles  of  94° C  for  15  s,  touchdown  f rom  60–50° C 
(reducing 1° C per cycle) for 15 s and 72°C for 20 s  followed by a further 
30 cycles at a 50°C annealing temperature. The seco nd PCR used 2 µl 
of a 1:10 dilution of the first PCR as  template  and the same cycling 
conditions. All products were confirmed to be single bands by agarose 
gel electrophoresis. Methylation values were calculated as an average 
of all CpG sites within each assay as determined by the Pyro Q-CpG 
Software (Biotage). 
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Table  2.5  Sequence  of  primers  used  for  methylation-specific  PCR  and 
pyrosequencing 
FRAP1 (mTOR gene) primers 
FRAP1_F1 
FRAP1_R1 
GAGGGGTGGGAGTTAAGGTT 
TTTTTCAATCCATCTTCTCCCTA 
FRAP1_F2 
FRAP1_R2 
[BIOTEG]-TTGGTYGTGGGTTTGGATATTA 
TCAAAACTAAAAACCCTCCTTC 
FRAP1_S1 
FRAP1_S2 
FRAP1_S3 
AAACCCTCCTTCCCT 
ATAAAACAAAAAACCTAAA 
CRACAACTAAAACCTT 
First  round  PCR  (F1-R1) 
– 339 bp 
 
Second  round  PCR  (F2-
R2) – 192 bp 
RPS6 primers 
RPS6_F1 
RPS6_R1 
GTATTTTAGGATTTTGGTTTTAGG 
CCTTTCATATTACCTCCACACA 
RPS6_F2 
RPS6_R2 
TGGAGAAGGGTTTTAAGTAGGA 
[BIOTEG]-ACCTACCRCAAACTAAACAACA 
RPS6_S1  GGTATGGAGTTTTTTGGT 
First Round PCR (F1-R1) 
- 403 bp 
 
Second  Round  PCR 
(F2-R2)- 170 bp 
2.7 Tandem duplication study of BRAF 
For  detection  of  tandem  duplication  at  BRAF  locus,  a  reverse 
transcription polymerase chain reaction was performed using previously 
published  primers  (Jones  et  al.,  2008).  cDNA  was  prepared  as 
previously described in section 2.6, from 23 chordoma tumours and 2 µl 
of a 1:5 dilution of the reverse transcribed cDNAs were used in the PCR 
assays. The PCR was performed in 25 µl containing 2 µl of cDNA, 1X 
PCR buffer, 0.5 U GoTaq Flexi DNA Polymerase (Promega), 200 nmol 
of each dNTP, 5 pmol of each primer. cDNA from a positive control was 
kindly provided by Dr David Jones, Cambridge University, Cambridge, 
UK.   69 
Table 2.6 Primers used for tandem duplication study of BRAF  
Gene (exon)  Sequence  
KIAA1549 (ex15 F)    5’-CGGAAACACCAGGTCAACGG-3’ 
KIAA1549 (ex16 F)    5’-AAACAGCACCCCTTCCCAGG-3’ 
BRAF (ex9 R)    5’-CTCCATCACCACGAAATCCTTG-3’ 
BRAF (ex11 R)    5’-GTTCCAAATGATCCAGATCCAATTC-3’ 
BRAF (ex7 R)    5’-AAGGGGATGATCCAGATGTTAGG-3’ 
BRAF (ex6 F)   5’-TTGTGACTTTTGTCGAAAGCTGC-3’ 
Primer combinations for breakpoint detection:  
KIAA1549:BRAF (16_9):    KIAA1549 (ex16 F) / BRAF (ex9 R), 124bp 
KIAA1549:BRAF (16_11):   KIAA1549 (ex16 F) / BRAF (ex11 R), 182bp 
KIAA1549:BRAF (15_9):   KIAA1549 (ex15 F) / BRAF (ex9 R), 159bp 
 
 
2.8 Protein isolation and Western blot analysis 
Ten  10  mm  sections  were  cut  from  snap-frozen  tumours  and 
placed  into  micro-tubes.  A  tumour  lysate  was  produced  with  Radio- 
Immunoprecipitation  Assay  (RIPA)  lysis  buffer  (150  mM  NaCl,  1% 
Igepal  CA-630,  0.5%  sodium
  deoxycholate,  0.1%  sodium  dodecyl 
sulfate, 50 mM Tris
 [pH 8.0]) containing both phosphatase and protease 
inhibitor cocktails (Sigma-Aldrich). Lysates were incubated on ice for 15 
min and then centrifuged at 13,000 rpm and 4° C for  10 min to remove 
debris.  Proteins  were  quantified  with  BCA  protein  assay  kit  (Fisher 
Scientific UK Ltd, Loughborough, Leicestershire, UK). Thirty micrograms 
of  protein  lysate  were  resolved  by  SDS-8%  polyacrylamide  gel 
electrophoresis
  (SDS-8%  PAGE)  and  transferred  to
  a  polyvinylidene 
fluoride (PVDF) Immobilion-P transfer membrane (Millipore Corporation, 
Bedford,  MA,  USA)  by  standard  semi-dry
  electro-transfer  methods 
(Kurien  and Scofield  2003). The membrane was blocked with
 PBS,   70 
0.1% Tween 20, 5% BSA for
 a minimum of 30 min and probed with the 
appropriate primary antibody overnight at 4° C. Blot s were washed three
 
times  (10  min  each)  in  1X  PBS  with  0.1%  Tween  20  (PBS-T)  and 
incubated for 1 h at room temperature with the appropriate secondary 
horseradish
 peroxidise (HRP)-conjugated antibody, followed by further 
washing
 and enhanced using chemiluminescence (ECL) detection (GE 
Healthcare  Ltd,  Amersham,  Buckinghamshire,  UK).  The  details  of 
antibodies used for Western blotting are shown in Table 2.7 
Table 2.7 Details of antibodies used in Western blot analysis 
Protein  lysates  from  HeLa  cells  (a  cervical  carcinoma  cell  line, 
SKOV3  cells  (an  ovarian  carcinoma  cell  line)  and  A431  cells  (an 
epidermoid carcinoma cell line) were used as a positive control when 
  Antibody/clone  Source  Dilution  Incubation time and 
temperature 
1  p-AKT (ser 
473)  Cell Signaling Technology  1:250   O/N incubation at 4° C 
2  Total AKT   Cell Signaling Technology  1:1000  O/N incubation at 4° C  
3  p-p70S6K (Thr 
389)    Cell Signaling Technology  1:1000  O/N incubation at 4° C  
4  Total  p70S6K 
(isoforms 1 and 2) 
kindly  provided  by  Prof. 
Ivan Gout (UCL, UK) 
1:1000  O/N incubation at 4° C 
5  p-4E-BP1 (Thr 
70)  Cell Signaling Technology  1:1000  O/N incubation at 4° C 
6  p-RPS6 (ser
235/236)  Cell Signaling Technology  1:1000  O/N incubation at 4° C 
7  Total  RPS6  (clone 
54D2) 
Cell Signaling Technology  1:1000  O/N incubation at 4° C 
8  p-mTOR (Ser 
2448)  Cell Signaling Technology  1:1000  O/N incubation at 4° C 
9  mTOR (clone 7C10)  Cell Signaling Technology  1:1000  O/N incubation at 4° C 
10  p-FRS2a (Tyr
196)  Cell Signaling Technology  1:1000  O/N incubation at 4° C 
11  p-ERK1/2  Cell Signaling Technology  1:1000  O/N incubation at 4° C 
12  total ERK1/2  Millipore Ltd, Watford, 
Hertfordshire, UK 
1:1000  O/N incubation at 4° C 
13  Brachyury  (H-210): 
sc-20109 
Santa Cruz, CA, USA  1:10.000  O/N incubation at 4° C 
14  GAPDH (Mab 6C5)  Advanced Immunochemical 
Inc, Long beach, CA, USA 
1:5000  60  min  at  room 
temperature    71 
assessing activation of PI3K/AKT/TSC1/TSC2/mTOR molecules, FGFR 
pathway  molecules  and  EGFR  phosphorylation  respectively 
(Shahbazian et al, 2006; Doukas et al, 1999; Meuillet et al, 2000). 
2.9 Proteomic profiling of receptor tyrosine kinase activity 
The  activity  of  receptor  tyrosine  kinases  was  assessed  using 
Human  Phospho-Receptor  Tyrosine  Kinase  (phospho-RTK)  array 
membranes  (R&D  Systems,  Minneapolis,  MN,  USA)  using  the 
manufacturer’s  instructions.  These  are  nitrocellulose  membranes  with 
42 receptor tyrosine kinase antibodies spotted in duplicates with control 
antibodies spotted at the corners.The protein lysates were added to the 
membranes  and  the  levels  of  RTK  phosphorylation  were  assessed 
using  HRP-conjugated  pan  phospho-tyrosine  antibody  followed  by 
chemiluminescence detection. Briefly, the membrane was blocked for 1 
h in array buffer 1 and the protein lysate, extracted as described above 
in section 2.9, was diluted in array buffer 1 to a concentration of 100 
µg/ml  and  incubated  with  the  membrane  overnight  at  4° C.  The 
membrane  was  then  washed  in  wash  buffer  1,  and  anti-
phosphotyrosine-HRP  detection  antibody  was  added  for  2  h  at  room 
temperature and subsequently washed in wash buffer. The reaction was 
detected by adding chemiluminescence (ECL) detection reagents (GE 
Healthcare Ltd) and exposed to X-ray film (GE Healthcare Ltd.) for 1-10 
min.  Scion  image  soft  ware  available  from  the  following  link   72 
http://www.scioncorp.com/pages/download_now.asp was used to analyse the 
data. 
2.10  Analysis  of  EGFR  tyrosine  phosphorylation  using  Human 
EGFR Phosphorylation Antibody Array membranes 
The  phosphorylation  of  various  sites  of  EGFR  was  assessed 
using  Human  EGFR  Phosphorylation  Antibody  Array  1  detecting  the 
relative  levels  of  phosphorylation  of  EGFR  family  at  17  different 
phosphorylation sites (RayBiotech, Inc, Norcross, GA, USA) according to 
the manufacturer’s instructions.  
Briefly, the membrane was blocked for 1 hour in blocking buffer 
and the protein lysate, extracted as described above in section 2.9, was 
diluted  in  the  blocking  buffer  to  a  concentration  of  100  µg/ml  and 
incubated with the membrane overnight at 4° C. The m embrane was then 
washed in wash buffer 1 and wash buffer 2 three times for 5 min each, 
and  a  diluted  cocktail  of  biotin-conjugated  anti-EGFR  was  added  and 
incubated  at  4° C  overnight  followed  by  washing  as  d escribed  above. 
HRP-conjugated  streptavidin  was  then  added  to  the  membrane  and 
incubated at room temperature for 2 h followed by washes. To detect the 
reaction,  equal  volumes  of  detection  buffer  C  and  detection  buffer  D 
were mixed together and applied to the membrane for 2 min followed by 
exposure to X-ray film (GE Healthcare Ltd.) for 1-10 min.   73 
2.11 Mammalian cell culture 
2.11.1 The U-CH1 chordoma cell line 
The  U-CH1  chordoma  cell  line  was  generously  provided  by  Dr 
David  Alcorta  (Duke  University,  Durham,  NC,  USA)  through  the 
Chordoma Foundation. The cell line was established from a recurrent 
sacral  chordoma  by  Dr  Silke  Bruederlein  at  the  University  of  Ulm, 
Germany (Scheil et al., 2001). U-CH1 cells have abundant vacuolated 
cytoplasm  with  physaliphorous  appearance.  The  cells  show  positive 
immunoreactivity for CK19, brachyury and S100. The CGH analysis of 
U-CH1  cells  showed  nearly  identical  pattern  to  that  of  the  parental 
tumour tissue (Scheil et al., 2001).   
 
Cells were maintained as monolayers in 75 cm
2 flasks (Corning 
Glass  works,  Corning,  NY,  USA)  coated  with  0.1%  gelatine  (Sigma-
Aldrich). The U-CH1 culture medium was formed from a four to one ratio 
(4:1)  of  Iscove's  Modified  Dulbecco's  Medium  (IMDM)/Roswell  Park 
Memorial  Institute  medium  1640  (RPMI-1640).  The  medium  was 
supplemented with 10% fetal bovine serum (FBS) (Invitogen), 100 U/ml 
penicillin G, and 100 µg/ml streptomycin (Invitrogen) and incubated at 
37°C  in  5%  CO2  incubator.  When  cultures  had  attained  80-90% 
confluence,  the  cells  were  split  1:3  using  0.05  mM  trypsin/EDTA 
(Invitrogen).    74 
2.11.2 Cell count calculations 
Cells  were counted  using a Neubauer haemocytometer (Weber 
Scientific  International  Ltd.,  Middlesex,  UK).  Trypan  blue  solution 
(Sigma-Aldrich) was added to the cell suspension to identify dead cells. 
2.11.3 HeLa human cervix carcinoma cells and HEK293T (Human 
Embryonic Kidney 293T) cells  
HeLa and HEK293T cells and were obtained from the American 
Type Culture Collection (ATCC, Middlesex, UK). Cells were maintained 
in  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM)  (Invitrogen) 
supplemented  with  fetal  bovine  serum  (FBS)  (Invitrogen),  100  U/ml 
pencillin and 100 µg/ml stereptomycin (Invitrogen).  
2.12 Knockdown of brachyury gene using shRNA 
Two green fluorescent protein (GFP)-labelled brachyury shRNA 
clones  were selected from the GIPZ Lentiviral  shRNAmir library from 
Open  Biosystems  (Huntsville,  AL,  USA).  The  referenced  names  are 
V2LHS_153725 and V2LHS_153729. A non-silencing sequence in the 
same vector was chosen as the non-silencing control to determine off-
target effects.  Detailed sequence information for each shRNA used is 
shown in Table 2.8 and a diagrammatic structure of the vector is shown 
in figure 2.1   75
     Table 2.8 Sequences of shRNA  
  Sense sequence  Loop sequence  Antisense sequence 
V2LHS_153725   CCGAGGAGATCACAGCTCTTAA  TAGTGAAGCCACAGATGTA  TTAAGAGCTGTGATCTCCTCGT 
V2LHS_153729,  CGCTAATCTCTTGTGTTGTTAA  TAGTGAAGCCACAGATGTA  TTAACAACACAAGAGATTAGCT 
Non Silencing (NS)    TCTCGCTTGGGCGAGAGTAAG   
Empty vector  ATTACTCCGTCTCGTGTCTTGTTGCATATGTCTGCTGGTTTGTTTGATGTTGTTTGCGGGC 
 
 
 
 
   
 
 
Figure 2.1 Schematic diagram of pGIPZ lentivirus structure.  
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2.12.1 Propagation of bacteria containing pGIPZ hairpin constructs 
and preparation of plasmid DNA  
Bacteria containing pGIPZ hairpin constructs were streaked on to 
solid agar stab cultures containing 100 µg/ml ampicillin and the cultures 
were grown overnight at 37° C. On the following day,  the bacteria were 
streaked on LB agar plates and kept overnight at 37° C. Single colonies 
were picked and grown in 5 ml LB broth containing 100 µg/ml ampicillin 
for 1 h at 37° C with vigorous shaking and then dilu ted in 500 ml of LB 
broth  and  incubated  overnight  under  shaking.  The  cell  pellets  were 
formed and DNA was extracted using Qiagen Plasmid Purification kit 
(Qiagen) following the manufacturer’s instructions.  
The pellet was re-suspended in 10 ml of buffer P1 and 10 ml of 
buffer  P2  was  added  and  incubated  for  5  min  at  room  temperature. 
Then, 10 ml of P3 buffer was added and incubated on ice for 20 min. 
The  sample  was  then  centrifuged  at  15.000  rpm  at  4°C  and  the 
supernatant containing the plasmid was removed and re-centrifuged for 
15 min at 4° C. The columns were prepared by adding  10 ml of buffer 
QBT and allowed to empty by gravity. The supernatant was applied and 
allowed to enter the resin by gravity and then washed twice in 30 ml 
buffer QC. The DNA was eluted in 15 ml buffer QF and precipitated by 
adding 10.5 ml isopropanol with centrifugation at 13,000 rpm for 30 min 
at  4° C.  The  pellet  was  washed  in  5  ml  of  70%  ethano l  at  room 
temperature,  air-dried  for  10  min  and  re-suspended  in  500  µl  of  TE   77 
buffer  pH  8.  The  quality  of  DNA  extracted  was  assessed  using  a 
nanodrop  (Thermo  Scientific,  NanoDrop  products,  Wilmington,  DE, 
USA). The sequence of DNA was confirmed by direct sequencing at the 
Scientific Support Services at UCL Cancer Institute/WIBR. Sequencing 
reactions  were  run  using  GenomeLab™  DTCS  Quick  Start  chemistry 
(Beckman  Coulter  UK  Ltd.)  and  were  analysed  on  a  CEQ™  8000 
Genetic Analysis System (Beckman Coulter). 
2.12.2 Lentivirus production 
HEK293T cells were maintained in DMEM media supplemented 
with 10% FBS and 1% penicillin and streptomycin. They were split 3 
times a week at a ratio of 4:1 using 0.05 mM trypsin/EDTA. HEK293T 
cells  were  seeded  one  day  before  the  transfection  by  splitting  a 
confluent  plate  1/4  in  10  cm2  plates  with  8  ml  complete  media  and 
incubated at 37° C, 5% CO 2. On the day of transfection, the following 
mixture  was  prepared  in  1.5  ml  micro-tube;  1µg  p8.91  (gag-pol 
expressor), 1 µg pMDG.2 (VSV-G expressor), 1.5 µg pGIPZ DNA (for 
each construct) and sterile TE for 15 µl final volume. In a second micro-
tube, 10 µl Fugene (Roche Diagnostics Ltd., Burgess Hill, West Sussex, 
UK)  was  added  to  200  µl  Optimem  (Invitrogen)  for  each  of  the 
transfection mixtures. The DNA mix was added to the Optimem-Fugene 
mix and left at room temperature for 15 min. The medium was changed 
with  fresh  complete  medium  and  the  Optimem/DNA/Fugene  mix  was 
added  to  the  cells  and  incubated  overnight  at  37°C,   5%  CO2.    The   78 
medium was changed to fresh complete medium after 24 h. At 48 h, the 
lentivirus-containing  supernatant  was  collected  in  a  10  ml  syringe 
(Fisher) and filtered through a 0.45  m filter (VWR International Ltd., 
Lutterworth, Leicestershire, UK) into a 50 ml tube. The supernatant was 
aliquoted and stored at -80°C.  
2.12.3 Lentivirus titration and infection of the U-CH1 cells 
The day before titration, 293T cells were seeded at 0.5x10
5 cells per 
well in 6 well plates in 2 ml of complete medium and incubated overnight at 
37C, 5% CO2. Different concentrations of the virus stock to be titrated were 
added together with 8ug/ml polybrene (Sigma-Aldrich) to different wells and 
incubated  for  two  days.  The  cells  were  detached  with  trypsin/EDTA 
(Invitrogen) and analysed by fluorescence activated cell sorting (FACS) for the 
ratio of the GFP expressing cells. The concentrations of viral stock that gave 
ratios  of  less  than  20%  were  selected  and  used  to  transfect  U-CH1  cells. 
Stable transfected U-CH1 cells were selected in 5  g/ml puromycin (Sigma-
Aldrich)  after  performing  a  puromycin-kill  curve  to  determine  the  optimal 
concentration needed for selection. After 5 days, all non-infected cells were 
killed, and the remaining cells had GFP expression.  
2.12.4  Semi-quantitative  real  time  RT-PCR  for  brachyury 
expression 
2.12.4.1 RNA extraction from cultured cells 
Total  RNA  was  extracted  from  the  cultured  cells  using  QIAzol 
lysis reagent (Qiagen). Briefly, the cells were washed with PBS and 700 
µl of QIAzol was added and cells were scraped with a cell scraper and   79 
kept  in  a  micro-tube  for  5  min  at  room  temperature.  Then  200  µl  of 
chloroform were added and left for 3 min at room temperature followed 
by  centrifugation  at  13,000  rpm  for  15  min  at  4° C.  The  top  clear 
supernatant was transferred to a new tube and 350 µl of isopropanol 
were added and left for 10 min at room temperature. The sample was 
then centrifuged at 10,000 rpm at 4° C for 10 min an d 400 µl of 100% 
ethanol was added and centrifuged at 10,000 rpm for 5 min at 4° C. The 
supernatant was removed and the pellet allowed to dry for 10 min and 
then  re-suspended  in  100  µl  of  nuclease  free  water.  The  RNA  was 
purified using the RNeasy Mini Kit (Qiagen) following the manufacturer’s 
protocol.  
2.12.4.2 Synthesis of cDNA using gene-specific primers 
Two hundred nanograms of total RNA were used to synthesise 
cDNA  using  Superscript  III  First-Strand  Synthesis  kit  (Invitrogen)  and 
gene  specific  primers.  All  primers  used  for  reverse  transcription  and 
reverse  transcription  PCR  are  shown  in  Table  2.10.  Briefly,  1  µl  of 
primer mix and 1 µl of dNTP mix, were added to 200 ng total RNA, and 
the volume was made to 10 µl with RNase free water (Invitrogen). The 
mixture was incubated for 5 min at 65°C and briefly  chilled on ice before 
the addition of 2 µl of 10X first strand buffer (Invitrogen), 2µl of 0.1M 
DTT, 4 µl of 25 mM MgCl2, 1 µl of RNaseOUT, and 1 µl (200 U/µl) of 
SuperScript III. The resulting mix was incubated at 50° C for 50 min. The 
reaction was terminated at 85°C for 15 min and then  chilled on ice. For   80 
each reaction, 1 µl (2 U) of RNase H was added and incubated at 37°C 
for 20 min.  
2.12.4.3 Real time semi-quantitative RT-PCR 
The real time PCR reaction was performed in 25 µl and included 
1µl of cDNA, 5 pmol of each primer, and 12.5 µl of SYBR® Green PCR 
Master  Mix  (Applied  Biosystems,  Birchwood,  Warrington,  UK).  The 
cycles included initial heating at 95° C for 3 min f ollowed by 50 cycles of 
heating to 95° C for 15 s and 60° C for 1 min.  GAPDH was used as a 
control  house  keeping  gene.  The  comparative  threshold  cycle  (Ct) 
method with the calculation of 2
-[delta][delta]Ct
 was used to assess the 
relative level of expression of brachyury. 
      Table 2.9 Sequences of the primers used for real time RT-PCR  
  Primer sequence  Product length 
5’-GTGGCTTCTTCCTGGAACC-3’  Brachyury 
5’-ACAATGCCAGCCCACCTAC-3’ 
67 bp 
5’-GGAGTCAACGGATTTGGTCGTA-3’  GAPDH 
5’-GGCAACAATATCCACTTTACCAGAGT-3’ 
78 bp 
2.13 Senescence-associated beta-Galactosidase staining (SA-β Gal) 
For  detection  of  cell  senescence,  beta-Galactosidase  staining 
was  performed.  The  U-CH1  cells  with  brachyury  knockdown  and 
controls  were  plated  in  6-well  plates  in  triplicates  for  3  d  and  then 
washed twice with PBS. The cells were then fixed in 4% formaldehyde 
for 5 min and then washed with PBS supplemented with 1 mM MgCl2. 
The staining solution (X-Gal solution) formed of 1 mg/ml of X-Gal, 0.12 
mM K3Fe[CN]6, 0.12 mM K4Fe[CN]6 and 1 mM MgCl2 in PBS at pH   81 
6.0 was added and the cells were incubated overnight at 37°C. Cells 
were examined  under phase-contrast microscope and 100  cells  were 
counted at different field. The result of the staining was expressed as 
stained cells/100 cells. 
 2.14  Treatment  of  U-CH1  cells  with  EGFR  inhibitor  tyrphostin 
(AG1478) 
2.14.1 Morphologic changes 
For morphologic analysis of the effect of EGFR inhibition on U-
CH1 cells, the EGFR inhibitor tyrophostin (AG1478) from Cell Signalling 
Technology was applied to the cells. The cells were seeded in 6 well 
plates at a density of 1x10
5 per well and incubated in complete U-CH1 
media  for  2  d  after  which  the  medium  was  replaced  with  complete 
medium containing different concentrations of the drug at 0, 5, 10, 20, 
50, 100, 200 nmol/L with DMSO 0.05% as a vehicle. The cells were 
grown  for  two  days  after  which  the  medium  was  replaced  with  fresh 
medium containing the drug and grown for another two days. In parallel 
a subset of cells for which the medium containing the drug was removed 
after 4 d and replaced with complete medium for another 4 d was grown 
to assess the reversibility.  
To test for the effect of tyrphostin (AG1478) on phosphorylation of 
EGFR, the cells were starved for 24 h in a serum-free medium.The drug 
was diluted in a serum-free medium and added to the cells for 48 h and 
before harvesting the cells for protein extraction, EGF (50 ng/ml) was   82 
added for 15 min to stimulate the cells. The cells were harvested using 
0.05  mM  trypsin/EDTA  and  protein  was  extracted  as  previously 
described  in  section  2.9.  The  experiments  were  performed  at  three 
separate times and in triplicates each time.  
2.14.2 MTS assay 
The U-CH1 cells were cultured in a density of 2500 cells/well in 
96 well plates in 100 µl of complete U-CH1 medium and maintained in a 
37° C in an incubator with 5% CO2 for 48 h after whi ch tyrphostin was 
added in different concentrations (0, 5, 10, 20, 50, 100, 200 nmol/L) with 
0.05% DMSO as a vehicle. Cell proliferation was assessed at days 0, 3, 
4,  5  and  7  after  addition  of  the  drug  using  the  MTS  [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt) assay (CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay, Promega). Briefly, 20  l of MTS and phenazine 
methosulfate (MTS-PMS) solution was added to each well. Plates were 
incubated at 37°C for 2 h, after which the absorban ce at 490 nm was 
measured using a microplate-reader (Thermo Scientific Varioskan Flash 
microplate-reader). For assessment of cell recovery after withdrawal of 
the tyrphostin (AG1478), the cells were plated as described above in 96-
well  plates  and  treated  with  the  drug  for  4  d  after  which,  the  drug-
containing medium was removed and replaced with full medium, and 
cells were allowed to grow for another 4 d. The cells were examined by 
the MTS assay as described above.    83 
 
2.15 Statistical Analysis 
All experiments were performed in independent replicates. Error 
bars  correspond  to  the  standard  deviation  from  the  calculated  mean. 
SPSS (Version 18.0, Chicago, IL) was used for all statistical analyses. 
Mean  value and standard deviation  were calculated using descriptive 
statistics. Comparison of means was performed by one-way analysis of 
variance. Chi-square tests, Student T test or Fisher exact  tests  were 
used,  where  applicable,  to  analyze  differences  between  independent 
variants.  Differences were considered significant if p<0.05.     84 
3. ANALYSIS of PI3K/AKT/TSC/mTOR PATHWAY IN CHORDOMA 
3.1 INTRODUCTION 
The majority of chordomas occur as a sporadic disease, however 
a few families have been reported to have multiple affected members 
denoting  that  inherited  genetic  changes  can  predispose  to  these 
tumours (Larizza et al., 2005). There is no reported association between 
chordomas and any of the inherited tumour predisposition syndromes 
apart  from  six  reported  cases  of  tuberous  sclerosis  complex  with 
chordomas (Dutton and Singleton, 1975; Schroeder et al., 1987; Borgel 
et al., 2001; Lee-Jones et al., 2004; Lountzis et al., 2006). One of these 
reports identified somatic inactivation of tuberous sclerosis genes within 
the chordoma tumours suggesting the possible aetiological role of these 
genes  in  chordoma  (Lee-Jones  et  al.,  2004).  Somatic  mutations  of 
TSC1 and TSC2 were also identified in other tumours such as sporadic 
lymphangioleiomyomatosis (Sato et al., 2002). 
Tuberous  sclerosis  complex  syndrome  (TSC)  is  a  rare  tumour 
suppressor  gene-related  syndrome  characterised  by  abnormal  tissue 
growth  known  as  hamartoma  affecting  many  organs  including  brain, 
kidney, heart, eyes, lung and skin.  It is caused by inactivating mutations 
in TSC1 and TSC2 tumour suppressor genes encoding TSC1 (hamartin) 
and TSC2 (tuberin) respectively (van Slegtenhorst et al., 1997). 
Hamartin and tuberin form a complex heterodimer and function by 
linking the PI3K/AKT signalling pathway to mTOR (mammalian target of   85 
rapamycin)  where  they  function  to  inhibit  mTOR  activation  and 
subsequent  transcription  and  cell  proliferation  (Hengstschlager  et  al., 
2001). 
The PI3K/AKT/TSC/mTOR  pathway is found to be activated in a 
variety  of  solid  cancers  and  haematological  malignancies,  including 
malignant gliomas, ovarian, endometrial, breast, renal, prostate, colon 
and  lung  carcinomas,  mantle  cell  lymphoma,  and  in  post-transplant 
lymphoproliferative disorders (Vivanco and Sawyers, 2002; Vignot et al., 
2005;  Vega  et  al.,  2006;  El-Salem  et  al.,  2007).    The  mTOR  protein 
kinase, is an essential regulator of protein synthesis, and controls entry 
into G1 phase of the cell cycle through phosphorylation of the substrates 
p70S6K and 4E-BP1, molecules that cooperate in translational initiation 
and ribosomal biogenesis. It is for these reasons that mTOR inhibitors 
are  considered  potential  therapeutic  agents  in  tumours  where  mTOR 
signalling  is  activated.  Therefore,  screening  of  tumour  specimens  for 
activated  molecules  in  this  pathway  may  provide  a  rational  basis  for 
identification of the patients who might benefit from therapy with mTOR 
inhibitors  (Vega  et  al.,  2006).  Based  on  the  previous  reports  of 
chordoma occurrence in the context of TSC syndrome, looking for this 
pathway activation is considered reasonable. 
3.1.1 PI3K/AKT/TSC/mTOR pathway 
The  PI3K/AKT/TSC/mTOR  pathway  regulates  several  normal 
cellular  functions  including  cellular  proliferation,  growth,  survival  and   86 
mobility. Components of this pathway are frequently abnormal in various 
types  of  tumors  (Vivanco  and  Sawyers,  2002).  The 
PI3K/AKT/TSC/mTOR  signalling  pathway  can  be  activated  via  over-
expressed or mutated receptor tyrosine kinases (Bose et al., 2006). The 
pathway components are schematically represented in Figure 3.1.  
3.1.1.1 Phosphoinositide 3 kinase (PI3K) 
Phosphoinositide 3 kinase (PI3 kinase or PI3K) is a heterodimer 
lipid kinase consisting of p85 and p110 catalytic subunits. It becomes 
activated by signals transmitted through many receptor tyrosine kinases 
resulting  in  phosphorylation  of  phosphatidylinositol-4,5-bis  phosphate 
(PIP2)  to  phosphatidylinositol-3,4,5-tris  phosphate  (PIP3)  at  the  cell 
membrane (Franke et al., 1997). 
3.1.1.2 Protein Kinase B (PKB or AKT) 
Protein  Kinase  B  (PKB  or  AKT)  is  a  cytosolic  protein  kinase  
recruited  by  PIP3  and  in  the    presence  of  the  activated  membrane 
threonine kinase called phosphoinositide-dependent kinase 1 (PDK-1), 
AKT becomes phosphorylated at threonine
308 (Thr
308). The full activation 
of AKT requires phosphorylation at serine
473 (Ser
473) caused by reaction 
with  phosphoinositide-dependent  kinase  2  (PDK-2)  proved  to  be  the 
mammalian  target  of  rapamycine  complex  2  (mTORC2)  (Toker  and 
Newton  2000;  Sarbassov  et  al.,  2004).  Phosphorylated  AKT  in  turn 
phosphorylates  many  highly  significant  substrates  involved  in  cell 
growth, proliferation and apoptosis (Bose et al., 2006; Stephens et al.,   87 
1998).  AKT  phosphorylation  of  TSC2  leads  to  inhibition  of  the 
TSC1/TSC2 complex function thereby releasing its inhibitory effect on 
Rheb, which in turn leads to activation of mTOR (Inoki et al., 2002). 
3.1.1.3  Tuberous  sclerosis  complex  1/  Tuberous  sclerosis  complex  2 
(TSC1/TSC2) 
Directly  upstream  of  mTOR  is  a  protein  complex  composed  of 
TSC1 and TSC2, and the presence of both proteins is required for the 
function  of  the  heterodimer.  TSC2  is  the  main  reactive  protein  while 
TSC1 serves to stabilize the complex. The main function of TSC2 is to 
increase  the  intrinsic  rate  of  GTP  hydrolysis  on  RAS  homologue 
enriched in brain (Rheb) resulting in its inactivation. TSC1/2 complex 
can be inactivated by mutation of either TSC1 or TSC2 genes as occurs 
in TSC syndrome (Inoki et al., 2005). TSC2 can be also inactivated by 
being phosphorylated at its GAP (guanosine triphosphatase activating 
protein) domain by activated AKT in response to activated membrane 
receptors  (Manning  et  al,  2002;  Han  et  al,  2004).  Phosphorylation  of 
TSC2  is  thought  to  accelerate  its  degradation  through  ubiquitin-
mediated mechanism (Plas and Thompson, 2003). 
3.1.1.4 Phosphatase and tensin homologue deleted on chromosome 10 
(PTEN) 
Phosphatase and tensin homologue deleted on chromosome 10 
(PTEN)  is  a  phosphatase  enzyme.  It  dephosphorylates  PIP3  to  PIP2   88 
and  so  considered  to  be  a  tumour  suppressor  gene  by  negatively 
regulating the PI3K/AKT pathway (Radu et al., 2003). 
3.1.1.5  RAS homologue enriched in brain (Rheb) 
RAS  homologue  enriched  in  brain  (Rheb)  is  a  member  of  Ras 
family of oncogenes and is considered a potent mTOR activator.  It is 
negatively regulated by TSC1/2 complex that converts Rheb guanosine 
triphosphate  (GTP)  to  Rheb  guanosine  diphosphate  (GDP),  so 
inactivates  the  Rheb  and  accordingly  inhibits  mTOR  (Brendan  et  al, 
2003). 
3.1.1.6 Mammalian target of rapamycin  
Mammalian  target  of  rapamycin  (mTOR)  is  a  289-kDa 
seine/threonine  kinase  originally  identified  in  1994  shortly  after  its 
orthologues  TOR1  and  TOR2  were  identified  in  yeast  as  the  target 
protein for the drug rapamycin. It represents an integration point linking 
numerous upstream signals to the translation system (Heitman et al., 
1991; Sabatini et al., 1994). It exists in  two distinct complexes, each 
consists  of  mTOR,  G  protein  β  subunit-like  (GβL,  also  known  as 
mLST8)  and  either  regulatory-associated  protein  of  mTOR  (raptor)  in 
mTOR  complex  1  (mTORC1)  or  rapamycin-insensitive  companion  of 
mTOR  (rictor)  in  mTOR  complex  2  (mTORC2).  The  mTORC1  is 
rapamycin sensitive and its activation regulates protein synthesis, cell 
growth,  and  proliferation  through  its  downstream  targets,  eukaryotic 
initiation  factor  4E  (elF-4E),  binding  protein  1  (4E-BP1)  and  p70S6   89 
kinase (p70S6K). mTORC2 is rapamycin resistant and its main function 
is to phosphorylate AKT at the Ser
473 position, leading to full activation 
of  AKT  and  organization  of  the  cytoskeletal  structure.  It  acts  as  a 
positive feedback loop (Sarbassov et al., 2004; Sarbassov et al., 2005). 
3.1.1.7 p70S6 Kinase  
p70S6 Kinase (S6K) is a serine/threonine kinase, the activity of 
which leads to an increase in protein synthesis and cell proliferation via 
phosphorylation  of  S6  ribosomal  protein  (RPS6)  leading  to  increased 
translation of mRNAs (Nojima et al., 2003). There are two similar S6K 
proteins (S6K1 and S6K2) encoded by two different genes, with S6K1 
showing rapamycine sensitivity. The S6Ks are activated at different sites 
of which Thr
389 is the most important one (Lee-Fruman et al., 1999). 
3.1.1.8 Ribosomal protein S6 (RPS6) 
S6 protein of the 40S ribosomal subunit becomes phosphorylated 
by  the  active  S6K  at  several  sites,  including  Ser
235,236,  leading  to 
initiation of protein synthesis (Dufner et al., 1999). 
3.1.1.9 Euokaryotic Initiation factor 4E -Binding Protein 1 (4E-BP1) 
Euokaryotic  Initiation  factor  4E-Binding  Protein  1  (4E-BP1)  is  a 
cytoplasmic protein that binds to and inhibits the function of the cap-
dependent euokaryotic initiation factor 4E (eIF-4E). Phosphorylation of 
4E-BP1 releases its inhibitory effect on resulting in increased translation 
of mRNAs (Rojo et al., 2007).   90 
3.1.1.10  Euokaryotic initiation factor 4E (eIF-4E) 
Euokaryotic Initiation factor 4E (eIF-4E) is a translation initiation 
factor  involved  in  cap-dependent  translation  of  mRNAs  and  is 
considered as the rate-limiting component of the eukaryotic translation 
apparatus (Mamane et al., 2004). 
 
 
Figure 3.1 A schematic diagram of PI3K/AKT/mTOR pathway   91 
3.1.2 Aim 
The aim of this part of the project was to investigate the activation 
status  of  PI3K/AKT/TSC/mTOR  signalling  pathway  in  a  cohort  of  50 
sacro-coccygeal  chordomas,  50  skull-based  chordomas  and  a 
chordoma-derived cell line, U-CH1. 
3.1.3 Objectives  
￿  Analysis  of  PI3K/AKT/TSC/mTOR  pathway  activation  in  sacro-
coccygeal chordomas as follow 
￿  Study  the  expression  of  active  phosphorylated  molecules  using 
immunohistochemistry on TMAs and confirm the results by Western 
blot analysis of selected cases. 
￿  Study the genetic status of molecules in the PI3K/AKT/TSC/mTOR 
pathway  through  mutational  analysis  of  genes  in  the  pathway  with 
previously reported activating mutations including PI3KCA and Rheb 
and analysis of the copy number changes in some of the pathway 
genes using interphase fluorescent in situ hybridisation (FISH). 
￿  Analysis of PI3K/AKT/TSC/mTOR pathway activation in skull-based 
chordomas  and  the  U-CH1  chordoma-derived  cell  line  using 
immunohistochemistry.   92 
3.2 RESULTS 
3.2.1 Immunohistochemistry 
Immunohistochemistry  was  performed  on  TMA  slides  from  50 
sacro-ccocygeal  chordomas  using  phospho-specifc  antibodies.  More 
than 90% were immunoreactive for p-AKT (Ser
473), p-TSC2 (Thr
1462), p-
4E-BP1 (Thr
70) and eIF-4E (Figure 3.2, Table 3.1). The labelling pattern 
of these antibodies was largely similar and consisted of diffuse granular 
cytoplasmic immunoreactivity, although nuclear positivity for p-AKT and 
p-4E-BP1  was  noted  in  less  than  10%  of  cases  (Figure  3.2).    The 
immunoreactivity  for  p-mTOR  (Ser
2448),  p-S6K  (Thr
389),  p-RPS6 
(Ser
235/236) was found in 13 of 48 (27%), 29 of 46 (62%) and 11 of 49 
(22%) cases respectively (Table 3.1, Figure 3.2). Immunohistochemistry 
results  for  the  total  proteins  mTOR,  S6K,  RPS6  showed  positive 
labelling  for  33  of  44  (75%),  50  of  50  (100%)  and  22  of  45  (49%) 
respectively.  
As shown in table 3.2, immunohistochemistry results for the skull-
based chordoma TMA containing 50 tumours showed immunoreactivity 
for p-AKT (62.5%), p-TSC2 (68.7%), p-mTOR (54%), p-p70S6K (52%), 
p-4E-BP1 (95.8%), p-RPS6 (62.5%), eIF-4E (91.6%).  
Immunoreactivity  for  PTEN  was  absent  in  16%  (7/43)  of  sacro-
coccygeal  and  skull-based  (8/50)  chordomas  (Figure  3.2,  Table  3.1, 
Table 3.2).    93 
A  summary  of  the  immunohistochemistry  results  in  skull-based 
chordoma versus sacro-coccygeal chordoma is shown in Table 3.3.  
Formalin  fixed  U-CH1  chordoma-derived  cell  line  showed 
immunoreactivity for p-AKT, p-TSC2, p-mTOR, p-RPS6, p-S6K, p-4E-
BP1,  eIF-4E  with  no  immunoreactivity  for  PTEN  (Figure  3.3).  94 
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Figure 3.2 Immunohistochemistry results of PI3K/mTOR pathway active molecules in sacro-coccygeal 
chordomas; the photomicrographs on the left hand panel represent cores of positive control tissues (breast carcinoma Ai-
Gi and colon, Hi) that are immunoreactive for the indicated antibodies. The middle panel shows representative chordomas 
which were scored as ‘strong’ for expression of the indicated antibodies indicating that the immunoreactivity is as strong 
as that in the positive control (Aii-Hii). The right hand panel includes representative chordomas that were not 
immunoreactive for the relevant antibodies (Aiii-Hiii).  TMA slides incubated with the isotype IgG for each antibody served 
as negative controls.   97 
 
Figure  3.3  Immunohistochemistry  of  formalin-fixed,  paraffin-embedded  U-CH1  cell  line  for  active  molecules  in  the 
PI3K/AKT/TSC/mTOR  pathway.    Formalin-fixed,  paraffin-embedded  HeLa  cells  served  as  the  positive  control  for  various 
antibodies  while  slides  incubated  with  IgG  isotype  served  as  negative  controls  for  each  of  the  antibodies  used.  98 
Table 3.1 Immunohistochemistry for AKT/TSC/mTOR pathway molecules in sacro-coccygeal chordoma 
  p-AKT 
(Ser
473)  TSC1  TSC2  p-TSC2 
(Thr
1462) 
p-mTOR 
(Ser
2448)  mTOR  p-p70S6K 
(Thr
389)  S6K  p-RPS6 
(Ser
235/236)  RPS6 
p-4E-
BP1 
(Thr
70) 
eIF-4E  PTEN  CDKN2A 
No 
immunoreactivity  4  26  0  2  35  11  18  0  41  23  2  1  7  46 
Low 
immunoreactivity  31  14  40  47  5  33  11  50  8  21  25  35  28  2 
High 
immunoreactivity  14  8  9  0  8  0  18  0  3  1  21  12  9  0 
Positive  cases/total 
cases (%) 
45/49 
(92) 
22/48 
(46) 
49/49 
(100) 
47/49 
(96) 
13/48 
(27) 
33/44 
(75) 
29/47  
(62) 
50/50 
(100) 
11/49 
 (22) 
22/45 
(49) 
46/48 
(96) 
47/48 
(98) 
37/43 
(86) 
2/48 
(4) 
 
Table 3.2 Immunohistochemistry for AKT/TSC/mTOR pathway molecules in skull-based chordoma 
  p-AKT 
(Ser
473) 
p-TSC2 
(Thr
1462) 
p-mTOR 
(Ser
2448)  p-p70S6K (Thr
389)  p-RPS6 
(Ser
235/236 
p-4E-BP1 
(Thr
70)  eIF-4E  PTEN 
No immunoreactivity  18  15  20  23  18  2  4  8 
Low immunoreactivity  21  24  9  24  13  25  19  42 
High immunoreactivity  9  9  17  1  17  21  25  0 
Positive cases/total cases (%)  30/48 (62.5)  33/48 (68.7)  26/48 (54)  25/48 (52)  30/48 (62.5)  46/48 (95.8)  44/48 (91.6)  42/50 (84) 
Table 3.3 Percentage of sacro-coccygeal versus skull-based chordomas showing immunoreactivity for active molecules in 
PI3K/AKT/TSC/mTOR pathway   
  Sacro-coccygeal chordoma TMA          Skull-based chordoma TMA 
p-AKT  92%  62.5% 
p-TSC2  96%  68.7% 
p-mTOR  27%  54% 
p-S6K  62%  52% 
p-RPS6  22%  62.5% 
p-4E-BP1  96%  95.8% 
eIF-4E  98%  91.6% 
PTEN  86%  84% 
 
 
Although  the  TMAs  were  composed  of  50  non  skull-based  and  50  skull-based  chordomas,  the  total  numbers  in  the  tables  represent  the  number  which  could  be 
interpreted. The scoring system employed was as follows: negative in the absence of immunoreactivity, ‘low’ when the immunoreactivity was unequivocal but less strong 
than the positive control, and ‘high’ when the immunoreactivity was at least as strong as the positive control. In all of the positive cases, the staining was diffuse and in 
more than 95% of the neoplastic cells 99 
3.2.2 Western blot analysis           
Western blot analysis of p-AKT, p-4E-BP1 and p-p70S6K on six 
selected  chordomas  was  largely  in  agreement  with  the  results  of 
immunohistochemistry (Figure 3.4). In addition, the Western blot result 
for total p70S6K showed positive reactivity for the rapamycin-sensitive 
p70S6K isoform 1 in the six examined cases (Figure 3.4). Specifically, 
Western  blot  analysis  of  p-mTOR  confirmed  the  results  of 
immunohistochemistry  in  four  out  of  six  studied  cases  by  showing 
positive reactivity in one case and absence of activated protein in the 
other three cases. In two cases, Western blot analysis failed to detect 
the p-mTOR showed by immunohistochemistry. This can be explained 
by the technical difficulties to detect the phosphorylated high molecular 
weight  proteins  like  mTOR  (289  kDa)  by  Western  blot  analysis.  The 
Western blot results for p-RPS6 confirmed the immunohistochemistry 
data in five out of six cases with one discrepant case showing p-RPS6 
by  immunohistochemistry  but  not  by  Western  blotting.  On  the  other 
hand,  Western  blot  analysis  detected  total  RPS6  protein  in  all  the  6 
cases although two of these were negative by immunohistochemistry. 
These two cases revealed loss of one allele of RPS6 gene by FISH 
analysis (see below) and both were negative for p-RPS6 by Western 
blot  analysis  suggesting  that  the  positive  result  for  total  RPS6  by 
Western blot may be explained by non-neoplastic contaminating stromal 
cells.  100 
 
 
Figure 3.4 Western blot analysis of 6 selected chordomas (Chdm) for active molecules in the PI3K/AKT/TSC/mTOR pathway correlated 
with immunohistochemistry results. All cases showed a strong band for p-AKT at Ser
473 (all 6 cases positive by immunohistochemistry). For 
p-mTOR, Western blotting confirmed the immunohistochemistry data in 4 of 6 cases showing the presence of the activated protein in one case 101 
and the absence in 3 cases. Two cases were negative by Western blotting inspite p-mTOR can be detected by immunohistochemistry.  Total 
mTOR protein was detected in all cases. Five cases showed a band for p-p70S6K expression and showed immunohistochemical reactivity while 
the last case showed no band with Western blotting was also negative by immunohistochemistry. Antibodies against isoform 1 and 2 of total 
p70S6K protein showed that p70S6K1 isoform was expressed in the 6 analysed chordomas. Western blot identified p-RPS6 expression in one 
case and this reflected the immunohistochemistry findings. All cases showed a band corresponding to total RPS6 expression despite the fact 
that two cases did not express total RPS6 by immunohistochemistry. Expression of p-4E-BP1 (Thr
70) was shown in five chordomas by both 
methods, however, Western blot failed to reveal a band for one case which was scored as equivocal on immunohistochemistry. The membranes 
were probed with the first antibody (p-AKT) and then with anti-GAPDH antibody as a loading control and then stripped with addition of each of 
the  various  antibodies  used.  The  GAPDH  images  showed  here  represent  GAPDH  expression  before  stripping  of  the  membranes.102 
3.2.3 FISH results for mTOR (FRAP1), RPS6, TSC1 and TSC2  
FISH  analysis  for  mTOR  (FRAP1)  locus  on  chromosome  1 
showed loss of one allele in 11 of 33 (33.3 %) and for RPS6 showed 
loss of one allele in 21 of 45 (46.6%) cases (Figure 3.5). FISH for TSC1 
(28 of 28 cases) and TSC2 (24 of 24 cases) showed two alleles. 
 
Figure 3.5 FISH analysis of mTOR (FRAP1) and RPS6. Chordoma with no allelic 
loss for mTOR (FRAP1) (A), chordoma with allelic loss for mTOR (FRAP1) (B), 
chordoma with no allelic loss for RPS6 (C) and chordoma with allelic loss for RPS6 
(D).  The red signals identify mTOR (FRAP1) and RPS6 respectively. The green 
signals represent chromosome enumeration probe 1 (CEP1) for mTOR and (CEP9) 
for RPS6. Fifty non-overlapping nuclei were counted for each case. Hemizygous 
deletion was defined by the presence of >30% of the tumour nuclei containing one 
mTOR  (FRAP1)  or  RPS6  signals  with  the  presence  of  two  signals  of  the 
correosponding chromosome enumeration probes.   103 
3.2.4 Correlation of mTOR positive chordomas with other markers 
Most of the chordomas (12/13) that showed immunoreactivity for 
p-mTOR were immunoreactive for total mTOR and showed two copies 
of mTOR locus by FISH, and all showed phosphorylation of 4E-BP1, 
and expressed eIF-4E. Activation of p70S6K was detected in 11 of the 
13 cases reactive for p-mTOR, and 7 of these showed immunoreactivity 
for p-RPS6. The two cases negative for p70S6K activation were also 
negative for p-RPS6 (Figure 3.6). 
3.2.5 Correlation of mTOR negative chordomas with other markers 
Thirty-five  of  48  chordomas  were  negative  for  p-mTOR;  30  of 
these could be analysed and 21 (70%) were immunoreactive for total 
mTOR.  Out  of  these  21  total  mTOR-immunoreactive  cases,  15  were 
analysable by FISH and most of these (11 of 15) showed two mTOR 
alleles while the remaining 4 revealed loss of one allele (Figure 3.6). 
Seven  of  the  9  cases  negative  for  total  mTOR  immunoreactivity  as 
assessed by immunohistochemistry were analysable by FISH and most 
of  these  5  of  7  showed  loss  of  one  allele.  The  remaining  two  cases 
showed 2 copies of the gene. 
Approximately fifty percent of the p-mTOR negative chordomas 
showed activation of neither p70S6K nor RPS6. The remaining p-mTOR 
negative chordomas were positive for p-p70S6K (Figure 3.6).   104 
3.2.6 Correlation of RPS6 negative chordomas with other markers 
Thirty-eight of 49 (78%) chordomas were negative for p-RPS6, 35 
of which were analysable for other markers. Twenty three of these 35 
analysable cases showed no expression of the total protein RPS6. Most 
of  these  cases  21  of  23  (91%)  showed  only  one  copy  of  the  gene 
(Figure 3.6). In total 21 cases of 49 (42%) showed loss of one copy by 
FISH. 
In view of RPS6 being located in the same chromosomal region 
as CDKN2A (p16
INK4), a common tumour suppressor gene that is lost 
frequently in chordomas (Hallor et al., 2008), it was suspected that the 
allelic loss of RPS6 correlated with the loss of CDKN2A and this was 
confirmed  by  showing  that  CDKN2A  was  detected  by 
immunohistochemistry in only 5 of 48 chordomas (Table 3.1), and that 
these  5  cases  showed  no  evidence  of  allelic  loss  for  RPS6  with 
immunoreactivity  for  total  RPS6  protein.  In  contrast,  ten  CDKN2A 
negative cases showed p-RPS6 immunoreactivity with no RPS6 allelic 
loss (no data for one case). 105 
 
Figure 3.6 A schematic diagram for non skull-based chordomas analysed by 
immunohistochemistry  (total  and  activated  forms)  and  FISH  for  mTOR  and 
p70S6K (A), and RPS6 (B). 
3.2.7 Methylation study of RPS6   
  To  address  the  issue  of  RPS6  loss  of  expression  in  the 
presence of two alleles of RPS6, the methylation status of the promoter 
of RPS6 was examined in cases negative for RPS6 protein which have 
two  RPS6  gene  alleles.  Paired  genomic  DNA  was  available  from  10 
cases, and the results showed that there was no hypermethylation of 
the  RPS6  promoter  region  in  tumour  samples  compared  to  matched 
normal DNA and to a positive control (Figure 3.7).  
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Figure  3.7  Pyro-sequencing  of  the  RPS6  promoter.  There  is  no 
hypermethylation  in  the  RPS6  promoter  region  in  any  of  the  examined  10 
chordoma cases. The experiment was performed two times, and each sample 
was  analysed  in  triplicates.  Error  bars  represent  standard  deviation  from  the 
mean. The positive control is bisulﬁte-treated mixed human DNA with more than 
90% methylation. 
3.2.8 Mutational analysis in PI3KCA and Rheb  
Direct  sequencing  for  commonly  reported  mutations  in  PI3KCA 
(exons 4, 5, 7, 9 and 20) (Samuels, 2004) and for predicted mutations in 
Rheb codons 15, 16 and 64 which are similar to KRAS codons 12,13 
and 61 respectively (Li et al, 2004; Yan et al, 2006), failed to reveal 
mutations in the examined chordomas. All the sequence data is on the 
attached compact disc.                                                                                                                                                                                                                                      107 
3.3 DISCUSSION 
In  this  part  of  the  project,  50  sacro-coccygeal,  50  skull-based 
chordomas  and  a  chordoma-derived  cell  line  U-CH1,  showed  strong 
evidence that the PI3K/AKT/TSC/mTOR pathway is activated in at least 
65%  of  the  tumours.  This  figure  is  based  on  the  numbers  of  the 
chordomas that exhibit p-mTOR and/or p-p70S6K.  
The phosphorylated form of p70S6K is generally considered as a 
biomarker for PI3K/AKT/TSC/mTOR pathway activation in preference to 
p-mTOR to assess the tumour response to mTOR antagonists and to 
predict which tumours may be responsive to such agents (Boulay et al., 
2004;  MacKenzie  and  von  Mehren,  2007;  Xu  et  al.,  2004).  Previous 
studies  found  p-mTOR  to  be  expressed  in  relatively  low  numbers  of 
tumours  such  as  renal  cell  carcinoma,  and  many  studies  make  no 
reference to tumour p-mTOR expression when assessing the effect of 
rapamycin and/or its analogues (El-Salem et al., 2007; Gao et al., 2003; 
Jaeschke  et  al.,  2002;  Scheper  et  al.,  2008;  Krishnan  et  al.,  2006). 
Technical difficulties involved in detecting large phosphorylated proteins 
(mTOR  289  kDa)  (Tkaczyk  et  al.,  2002),  in  addition  to  the  general 
transient expression of phosphorylated proteins may contribute to the 
difficulty  in  detecting  p-mTOR  (Riemenschneider  et  al.,  2006). 
Phosphorylation of mTOR may also occur on a variety of residues that 
have not been tested in this study (Cheng et al., 2004). The difficulties 
to  detect  the  phosphorylated  form  of  molecules  in  the 108 
PI3K/AKT/TSC/mTOR  by  either  Western  blot  analysis  or 
immunohistochemistry suggests that single test may not be enough to 
assess the activation status of the pathway and can not be used in the 
clinical settings.  
It is considered that the 9 (20%) sacro-coccygeal chordomas that 
do not express mTOR (total and phosphorylated) protein as assessed 
by immunohistochemistry (5 of these 9 revealed only one mTOR allele 
(2 cases with both alleles, 2 cases with no data) are unlikely to respond 
to mTOR inhibitors. Furthermore, it is also speculated that the 10 cases 
which express total mTOR but are negative for p-mTOR, p-S6K and p-
RPS6  would  also  be  at  high  risk  of  not  responding  to  mTOR 
antagonists. On the basis of this calculation 35% of the examined sacro-
coccygeal  chordomas  would  be  unlikely  to  be  responsive  to  mTOR 
antagonists.  
The  complete  absence  of  mTOR  expression  in  9  chordomas 
raises the question as to how cells survive in the absence of ribosomal 
biogenesis.  One  explanation  is  that  the  immunohistochemistry  for 
mTOR  is  not  sufficiently  sensitive  and/or  that  only  very  low  levels  of 
mTOR  are  required  for  assembling  the  protein  complex  mTORC1. 
Alternatively, an mTOR-independent pathway, capable of bringing about 
ribosomal biogenesis and initiation of translation, may be activated. The 
report  that  RAS/MEK/ERK  pathway  activates  RPS6  independently  of 
mTOR via p90S6K (RSK1) supports this postulate (Roux et al., 2004). 109 
In view of the importance of ribosomal synthesis in cell growth, 
the absence of RPS6 protein expression in 49% of chordomas is striking 
but  seems  to  be  robust  because  the  immunohistochemistry  data  is 
supported  by  the  finding  of  RPS6  allelic  loss  in  21  of  the  23  cases. 
Furthermore, the allelic loss of RPS6 located at 9p22.1 correlates with 
the reported loss of the adjacent gene CDKN2A located at 9p21.3 as 
detected by aCGH study (Hallor et al., 2008). The lack of RPS6 protein 
expression  in  some  cases,  suggests  that  its  role  in  protein  synthesis 
may be undertaken by other less studied substrates of p70S6K, such as 
splicing factor SCAR, translation initiation factor eIF-4B, EF-2B kinase 
and  pro-apoptotic  protein  Bad1  (Harada  et  al.,  2001;  Raught  et  al., 
2004; Richardson et al., 2004; Ruvinsky and Meyuhas, 2006). 
It  is  also  not  clear  how  loss  of  RPS6  contributes  to  the 
development  of  neoplasia  although  its  allelic  loss  also  has  been 
reported in chondrosarcomas, a tumour with similarities to chordomas 
(Rozeman  et  al.,  2006).  Interestingly,  a  causal  relationship  between 
RPS6  phosphorylation  and  protein  synthesis  has  revealed  conflicting 
results.  In  addition  to  reports  of  activation  of  this  protein  resulting  in 
elevated cell growth, there is also evidence of increased global protein 
synthesis in embryonic fibroblasts derived from RPS6-/- mice compared 
to  wild-type  cells  (Ruvinsky  et  al.,  2005).  Furthermore,  germline 
mutations in the ribosomal protein RPS19, which occur in patients with 
Blackfan  Diamond  syndrome,  a  cancer  susceptibility  syndrome 110 
associated with haematological malignancies, have already established 
a  role  for  the  loss  of  ribosomal  protein  in  cancer.  Mutations  in  this 
syndrome  are  directly  related  to  loss  of  ribosomal  proteins  such  as 
RPS19, RPL5 and RPL11 (Draptchinskaia et al., 1999). The possibility 
of  methylation  of  RPS6  promoter  has  been  largely  ruled  out  by  the 
pyrosequencing study of methylation in 10 matched samples of tumours 
and  normal  tissue,  suggesting  that  there  is  another  mechanism  for 
RPS6 loss of expression in these cases.  
The  results  of  this  study  shows  loss  of  expression  of  PTEN  in 
16%  of  chordomas  and  in  U-CH1,  the  chordoma-derived  cell  line  by 
immunohistochemistry which suggests that PTEN, a well known tumour 
suppressor gene, may play a role in the pathogenesis of chordomas and 
could be one of the mechanisms for activation of PI3K/AKT/TSC/mTOR 
signalling pathway in at least some chordomas. The results here are in 
agreement  with  the  recent  report  by  Han  et  al,  where  6  out  of  10 
examined  chordomas  revealed  no  expression  of  PTEN  by 
immunohistochemistry. The limited number of chordomas examined by 
Han et al., could be responsible for the relatively higher percentage of 
loss  of  PTEN  expression  (Han  et  al.,  2009a).  PTEN  mutations  are 
commonly reported in some carcinomas as prostatic, endometrial and 
hepatocellular  carcinomas  and  in  glioblastoms  (Li  and  Sun,  1998; 
Risinger et al., 1997).  111 
The previously reported loss of heterozygosity in chordomas from 
2 individuals with tuberous sclerosis complex syndrome (Lee-Jones et 
al., 2004) was one of the main reasons that triggered the performance 
of this study. However, the finding that AKT is activated in over 90% of 
chordomas argues that the tumour suppressor genes, TSC2 and TSC1, 
in sporadic chordoma are likely to be ‘inactivated’ not as a result of loss 
of heterozygosity but rather by phosphorylation of TSC2 by p-AKT (Inoki 
et al., 2002). Indeed, if the tumour suppressor genes were inactivated, 
absence of the TSC2 protein would be expected and this was not the 
case.  Furthermore,  the  FISH  results  confirmed  the  absence  of  allelic 
loss in TSC1 and TSC2 loci. For these reasons, it was decided not to 
sequence both genes for the mutations reported in individuals with the 
tuberous  sclerosis  complex  syndrome.  The  data  suggest  that 
inactivation of TSC1/2 complex in sporadic chordoma is most probably 
accounted for by phosphorylation of TSC2 by activated AKT and not as 
a consequence of a mutation or deletion of the TSC1 and TSC2 genes. 
The  failure  to  detect  Rheb  and  PI3KCA  mutations  in  23  chordomas 
provides evidence that these genetic events are unlikely to account for 
the  chordoma  tumourigenesis  in  most  cases.  Furthermore,  the 
published  aCGH  data  showing  that  neither  AKT  nor  PI3KCA  loci  are 
amplified  in  21  cases,  largely  excludes  activation  of  AKT  through 
genetic events (Hallor et al., 2008). 112 
The findings of this part of the project provide an evidence base 
for  treating  selected  chordomas  with  mTOR,  AKT  inhibitors,  and 
antisense molecules to the attractive cancer target, eIF-4E (Graff et al., 
2008)(Graff, 2008). A combination of agents rather than individual drugs 
is  more  likely  to  offer  therapeutic  success  particularly  as  there  is 
evidence  that  AKT  is  activated  at  Ser
473  by  mTORC2,  a  rapamycin-
insensitive molecule (Sarbassov et al., 2005). This view is supported by 
the recent report by Stacchiotti et al, where a response was seen using 
a  combination  of  an  inhibitor  of  mTOR  (sirolimus)  and  imatinib,  a 
receptor tyrosine kinase inhibitor in eight out of nine patients examined 
(Stacchiotti  et  al.,  2009).  The  development  of  a  new  generation  of 
mTOR blocking agents (TORKinibs) that interrupt the mTORC2 complex 
is under development and may provide therapeutic benefit over what is 
currently available (Feldman et al., 2009). 
This  part  of  the  project  provides  a  rationale  for  the  use  of 
PI3K/AKT/TSC/mTOR  pathway  inhibitors  in  the  treatment  of  selected 
chordomas. However, a detailed study of the effect of inhibitors, using in 
vitro and in vivo models is required before embarking clinical trials and 
introducing  these  inhibitors  as  therapeutic  options  for  chordoma 
management. 
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4. ANALYSIS OF THE FIBROBLASTIC GROWTH FACTOR 
RECEPTOR-RAS/RAF/MEK/ERK-ETS2/BRACHYURY 
SIGNALLING PATHWAY IN CHORDOMAS 
4.1 INTRODUCTION 
Chordomas  are  tumours  that  express  brachyury,  a  molecule 
involved  in  notochord  development.  This,  in  addition  to  their 
morphology, and the anatomical site in which they arise argues in favour 
of  them  showing  notochordal  differentiation  (Bjornsson  et  al.,  1993; 
Mirra  et  al.,  2002;  Vujovic  et  al.,  2006).  Little  is  known  about  the 
regulation of brachyury in mammals although in the ascidian, zebrafish 
and Xenopus embryos, it is well established that brachyury is regulated 
via  fibroblastic  growth  factor  receptors  (FGFRs)  through 
RAS/RAF/MEK/ERK/ETS2 pathway (Isaacs et al., 1994; Nakatani et al., 
1996; Schulte-Merker and Smith, 1995). The expression of brachyury in 
these  models  has  been  shown  to  require  signalling  through  basic 
fibroblastic  growth  factor  (bFGF),  embryonic  fibroblastic  growth  factor 
(eFGF) and FGFR1 (Ciruna et al., 1997; Isaacs et al., 1994). ETS2, a 
transcription  factor  also  has  been  found  to  be  required  for  brachyury 
expression in ascidian (Kawachi et al., 2003). 
4.1.1 FGFR-RAS/RAF/MEK/ERK pathway 
FGFR-RAS/RAF/MEK/ERK  pathway  is  a  signal  transduction 
pathway involved in embryonic development, cellular proliferation and 114 
differentiation and plays a crucial role in bone growth, chondrogenesis 
and osteogenesis (Liu et al., 2002; Peyssonnaux and Eychene, 2001). 
 Activation of this pathway is initiated by binding of members of 
the  fibroblastic  growth  factors  (FGFs)  to  fibroblastic  growth  factor 
receptors (FGFRs) with subsequent phosphorylation of a lipid-anchored 
adaptor protein known as fibroblast growth factor receptor substrate 2 
alpha (FRS2α) and binding of the growth factor receptor bound 2 (Grb2) 
and  a  guanine  nucleotide  exchange  factor  called  son  of  sevenless 
(SOS)  to  form  Grb2/SOS  complex  leading  to  the  activation  of  RAS 
which  in  turn  activates  RAF  kinase  (Avruch  et  al.,  2001).  RAF 
phosphorylates  and  activates  mitogen-activated  protein  kinase  kinase 
(MEK)  which  phosphorylates  and  activates  mitogen-activated  protein 
kinase (MAPK) (Kouhara et al., 1997; Meakin et al., 1999). A schematic 
diagram representating this pathway is shown in Figure 4.1. 115 
   
Figure  4.1  A  schematic  diagram  of  the  signalling  through  the  FGFR/ 
RAS/RAF/MEK/ERK-ETS2 pathway  
4.1.2 Fibroblastic growth factors (FGFs)  
Fibroblast  growth  factors  (FGFs)  are  a  family  of  structurally 
related  growth  factors  of  which  22  members  have  been  identified  in 
humans, 18 of which are associated with FGFRs activation (Ornitz and 116 
Marie,  2002).  Basic  fibroblastic  growth  factor  has  been  found  to  be 
expressed in chordoma using immunohistochemistry (Deniz et al, 2002). 
4.1.3 Fibroblast growth factor receptors (FGFRs)  
The  fibroblast  growth  factor  receptors  are  receptor  tyrosine 
kinases which bind to FGFs and include 4 members, FGFR1, FGFR2, 
FGFR3, and FGFR4. Alternative splicing of FGFR transcripts gives a 
diversity of FGFR isoforms. The FGFRs consist of three extracellular 
immunoglobulin-type  domains  (I,  II  and  III),  a  single  trans-membrane 
helix domain, and an intracellular tyrosine kinase domain (Figure 4.2).  
 
Figure 4.2 Diagrammatic representation of FGFR structure. I, II and III are D1, D2 
and  D3  immunoglobulin-like  domains,  AB,  Acid  box,  TM,  transmembrane  domain, 
and KD, kinase domain  
Several developmental bone diseases and syndromes are caused 
by gain of function germline mutations in various FGFR genes (Coutts 
and  Gallagher,  1995;  Ornitz  and  Marie,  2002).  Mutations  of  different 
FGFR  genes  are  also  implicated  in  many  types  of  cancers  such  as 
urothelial,  endometrial,  prostatic,  and  cervical  carinomas  (Dutt  et  al., 
2008; Hernandez et al., 2009; Rosty et al., 2005; van Rhijn et al., 2002), 
while  amplification  of  these  genes  has  been  reported  in  gastic 
carcinoma,  ovarian  carcinoma,  squamous  cell  carcinoma  and 117 
rhabdomyosarcoma (Freier et al., 2007; Gorringe et al., 2007; Kunii et 
al.,  2008;  Missiaglia  et  al.,  2009).  An  array  comparative  genomic 
hybridisation study of chordomas showed gain in the locus harbouring 
FGFR4 (Hallor et al., 2008).  
4.1.4 RAS, RAF, MEK and ERK  
RAS, the prototypical member of GTPases is activated in close to 
30% of all human cancers, most frequently in pancreatic cancer. The 
activation is caused mainly by point mutations in codons 12, 13 and 61 
which all form part of the GTP-binding domain (Bos, 1989)  
RAF is a serine/threonine kinase involved in signal transduction 
and in humans, there are three related genes; ARAF, BRAF and CRAF, 
of which BRAF is the key activator of mitogen activated protein kinase 
(MAPK) pathway in most tissues and cell types  
BRAF is activated mainly through point mutations in about 7% of 
all  human  cancers,  mainly  in  malignant  melanoma  (70%),  sporadic 
colorectal  tumours  (15%),  low  grade  ovarian  serous  carcinoma  and 
thyroid papillary carcinoma (Davies et al., 2002)(Davis et al, 2002). The 
most common activating mutation is the missense thymine to adenine 
transversion  at  nucleotide  1799  resulting  in  valine-to-glutamate 
substitution  at  residue  600  (V600E)  in  exon  15  while  the  rest  of 
mutations reside in the glycines of the G-loop in exon 11 (Davies et al., 
2002; Nucera et al., 2009). 118 
 Tandem duplication at the BRAF locus (7q34) has been found to 
produce  a  novel  oncogenic  fusion  gene  incorporating  a  constitutively 
active BRAF kinase domain and has been demonstrated in 29 of 44 
pilocytic astrocytomas (Jones et al., 2008). This is of interest because of 
the occurrence of pilocytic astrocytomas in two members of two different 
families with familial chordoma (Dalpra et al., 1999; Kelly et al., 2001; 
Miozzo et al., 2000). In pilocytic astrocytoma tandem duplication at 7q34 
leads to a fusion between KIAA1549 and BRAF (Jones et al., 2008).  
Mitogen  activated  protein  kinase  kinase/Extracellular  signal-
regulated kinase kinase (MAPKK/MEK) and mitogen activated protein 
kinase/Extracellular  signal-regulated  kinase  (MAPK/ERK)  are 
serine/threonine  protein  kinases  that  form  a  part  in  the  FGFR  signal 
transduction  pathway  (Ahn,  1993).  The  activation  of  ERK  results  in 
activation of ribosomal S6 kinase (RSK, p90
RSK) and many transcription 
factors including c-MYC, CREB (cAMP response element binding) and 
c-FOS (Jones et al., 1988; Zhao et al., 1995). 
4.1.5 ETS2 and brachyury 
ETS2 and brachyury are genes encoding for transcription factors. 
ETS2 provides a link between the FGFR/RAS/RAF/MEK/ERK pathway 
and  the  induction  of  brachyury  in  Xenopus  (Xbra)  and  thus  in  the 
development  of  the  posterior  mesoderm  during  early  embryonic 
development (Kawachi et al., 2003; Foulds et al., 2004; Kawachi et al., 
2003).  ETS2  is  known  to  be  translocated  in  leukaemia  and  prostatic 119 
cancer  (Sacchi  et  al.,  1986;  Yoshimura  et  al.,  1998).  Gibas  et  al, 
described a translocation at chromosome 21q22, involving either ERG 
or ETS2, in two sacral chordomas (Gibas et al., 1992).  
Brachyury plays an important role in notochord development, as 
well as specification of posterior mesodermal elements (Edwards et al., 
1996; Showell et al., 2004). Brachyury is expressed in chordomas and is 
largely specific for this disease (Vujovic et al., 2006; Tirabosco et al., 
2008). Recently, duplication of brachyury has been found to be a major 
susceptibility  factor  in  development  of  familial  chordomas.  The 
duplication has been found in four out of seven families studied (Yang et 
al., 2009b). 
4.1.6 Hypothesis and Aim  
The hypothesis of this work is that genetic alterations within the 
FGFR-RAS/RAF/MEK/ERK/ETS2-brachyury signalling pathway account 
for the development of chordoma. 
The aim of this part of the project was to investigate the FGFR- 
RAS/RAF/MEK/ERK/ETS2-brachyury  signalling  pathway  activation 
status  in  chordomas  and  to  look  for  genetic  abnormalities  in  this 
pathway  with  particular  focus  on  candidate  genes  chosen  on  the 
evidence provided in the introduction of this chapter.   120 
4.1.7 Objectives  
￿  Study  the  expression  of  the  four  FGFRs  in  chordomas  using 
immunohistochemistry on TMAs. 
￿  Determination of the activity of the FGFR pathway by assessing the 
phosphorylation  status  of  FRS2α  and  ERK1/2  by  Western  blot 
analysis of selected cases.  
￿  Screening  for  previously  reported  mutations  in  the  four  FGFR 
genes, KRAS, and BRAF by direct DNA sequencing or dHLPC. 
￿  Mutational  analysis  of  the  coding  exons  and  promoter  region  of 
brachyury by direct DNA sequencing. 
￿  Study  the  copy  number  variations  and  chromosomal 
rearrangements in ETS2, brachyury and FGFR4 loci using FISH. 
￿  Analysis  of  BRAF  locus  for  the  presence  of  tandem  duplication 
using RT-PCR. 121 
4.2 RESULTS 
4.2.1 Expression of the four FGFR proteins in chordoma 
Analysis of the expression of FGFRs on the non skull-based and 
skull-based chordomas in  a tissue  microarray revealed that  47 of  50 
(94%)  of  the  former  and  45  of  49  (91.8%)  of  the  latter  showed 
immunoreactivity for at least one of the FGFRs (Table 4.1, Figure 4.3). 
In 39 non skull-based chordomas and 31 skull-based chordomas, more 
than one receptor was detected by immunohistochemistry and in 17 non 
skull-based chordomas and 13 skull-based chordomas the tumour cells 
were immunoreactive for all 4 receptors. In the majority of cases, more 
than  50%  (+++)  of  the  tumour  cells  showed  immunoreactivity.  The 
details of immunohistochemistry results are shown in Table 4.1.  
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Table 4.1      FGFR 1, 2, 3 and 4 immunoreactivity in chordomas  
  Immunohistochemistry score  FGFR1  FGFR2  FGFR3  FGFR4 
3   +++  17  8  13  4 
     ++  0  0  0  1 
     +  0  1  0  0 
2   +++  8  9  10  11 
     ++  1  1  1  2 
      +  0  0  0  0 
1    +++  1  17  15  15 
      ++  0  1  0  2 
      +  1  3  0  0 
0  22  10  11  15 
Non skull based-
chordomas 
Total number of positive cases (%)  28/50 (56 %)  40/50 (80 %)  39/50 (78 %)  35/50 (70 %) 
3   +++  11  4  13  5 
     ++  2  3  3  3 
     +  0  1  1  0 
2   +++  7  3  7  9 
     ++  1  0  5  2 
      +  1  0  1  1 
1    +++  2  17  8  15 
      ++  0  2  0  3 
      +  0  1  2  0 
0  25  18  9  11 
Skull-based 
chordomas 
Total number of positive cases (%)  24/49 (49%)  31/49 (63%)  40/49 (82%)  38/49 (77%) 
 
 
 
The scoring system employed was as follows: Negative immunoreactivity (0). Positive immunoreactivity includes the following subgroups; (1) 'weak', the 
intensity of the staining is less than the positive control, (2) 'moderate' the intensity of the staining is as strong as the positive control, and (3) 'strong' the 
intensity of the staining is stronger than the positive control. In addition, +, ++ and +++ indicates that less than 5%, between 6% and 49%, and more than 50% 
respectively of the lesional cells were immunoreactive. 123 
 
Figure  4.3  Immunohistochemistry  results  of  FGFRs  on  chordoma  TMAs 
Representative  transmitted  light  photomicrographs  of  chordomas  on  TMA.  The 
photomicrographs on the left panel represent positive immunoreactivity and the right 
panel includes representative chordomas that were not immunoreactive for each of 
the four FGFRs. Magnification 200X.  124 
4.2.2  Western blot analysis for the active phosphorylated forms of 
FRS2a a a a and ERK  
To  test  whether  the  expressed  FGFRs,  detected  by 
immunohistochemistry,  were  involved  in  signalling  in  chordomas, 
Western  blotting  was  performed  using  antibodies  against  p-FRS2a 
(Tyr
196)  and  p-ERK1/2  (Thr
202/Tyr
204).  FRS2a  is  a  docking  adaptor 
signalling protein that links FGFRs to the RAS/RAF/MEK/ERK signalling 
pathway  and  ERK1/2  represents  a  critical  point  in  the  pathway 
activation. Western blot analysis showed phosphorylation of FRS2a and 
ERK1/2  in  6  chordomas  that  were  also  reactive  by 
immunohistochemistry for at least one of the FGFRs (Figure 4.4). Two 
chordomas  with no  reactivity by  immunohistochemistry for  any of the 
four FGFRs, were also negative by Western blot analysis for p-FRS2a, 
although these were positive for p-ERK1/2 (Figure 4.4). 125 
 
Figure  4.4  Western  blotting  analysis  for  p-FRS2a a a a  (Tyr
196)  and  p-ERK1/2 
(Thr
202/Tyr
204)  on  8  selected  chordomas  (CHD).    The  left  hand  panel  with  six 
chordomas were positive by immunohistochemistry for at least one of the FGFRs and 
showed a band corresponding to p-FRS2a and p-ERK1/2 by Western blotting. The 
middle  panel  of  two  chordomas,  found  to  be  negative  for  any  FGFR  by 
immunohistochemistry, did  not  display  a  band  for  p-FRS2a.  Nonetheless,  a  band 
was detected by Western blotting for p-ERK1/2 in these 2 cases. In the right hand 
panel, SKOV3 cell line, non stimulated and stimulated with basic FGF, was used as a 
positive control. The membranes were stripped and re-probed with total ERK1/2 and 
anti-GAPDH antibody to assure even loading of proteins in each lane. 
4.2.3  Mutational  analysis  of  the  four  FGFR  genes  by  direct 
sequencing for the previously reported mutations 
In view of FGFRs being known to be involved in the regulation of 
brachyury,  and  the  knowledge  of  mutations  in  these  genes  being 
implicated in tumourigenesis, direct sequencing of those exons in which 
activating  germline  and  somatic  mutations  have  been  reported 
previously was performed: these included FGFR1 (exons 3, 6, 11, 12, 126 
14), FGFR2 (exons 5, 7, 11, 12), FGFR3 (exons 2, 4, 5, 6, 8, 9, 15) and 
FGFR4 (exons 7, 9, 16). Sequencing failed to reveal any mutations in 
the  23  chordomas  analysed.  All  the  sequencing  data  are  on  the 
attached compact disc. 
4.2.4 FISH investigation for brachyury copy number gain 
FISH analysis of the brachyury locus in chordomas showed three 
patterns;  amplification  where  the  ratio  between  brachyury  specific 
signals  and  chromosome  6  chromosome  enumeration  probe  signals 
(CEP6) was more than 2, aneuploidy where there were more than two 
copies of both brachyury and CEP6 specific probes giving rise to a ratio 
of less than 2, and imbalance where two copies of CEP6 and more than 
two copies of brachyury locus were present (Table 4.2, Figure 4.5).   
Table 4.2 Brachyury FISH results for skull-based and non skull-based 
chordomas 
  Skull-based 
chordomas 
Non skull-based 
chordomas 
Total (%) 
Amplification  1/47  2/48  3/95 (3.2) 
Aneuploidy +6  23/47  17/48  40/95 (42) 
Imbalance (rearrangement)  5/47  4/48  9/95 (9.5) 
Disomic (normal pattern)  18/47  25/48  43/95 (45.3) 
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Figure  4.5  FISH  analysis  of  brachyury  gene  on  chordoma  TMAs. 
Photomicrographs of interphase FISH showing a metaphase spread to validate the 
probe localisation (A), chordoma with a normal disomic pattern (2 brachyury and 2 
CEP6  signals  (B),  aneuploidy  (equal  numbers  of  more  than  2  signals  for  both 
brachyury and  CEP6 (C), brachyury imbalance (more than 2 brachyury signals and 2 
CEP6 with a ratio less than 2 (D), examples of brachyury amplification (more than 2 
brachyury signals with a ration of brachury:CEP6 more than 2 (E and F). The red 
signals represent brachyury and the green signals represent CEP6 probes.  128 
4.2.5 FISH screening for ETS2 and FGFR4 amplification, and ETS2 
and ERG gene rearrangement 
The  FISH  analysis  for  ETS2  amplification  showed  a  normal 
pattern (disomy) with two green signals of chromosome 21 markers and 
two  ETS2  red  signals.  The  ‘in-house  generated’  break-apart  probe 
designed  to  detect  ETS2  and  ERG  rearrangement  showed  no 
rearrangement at the loci of these genes as assessed in 27 informative 
cases (Figure 4.6 A). FISH was performed on the non skull-based TMA 
which included 50 chordomas to determine if there was amplification of 
FGFR4  because  an  aCGH  report  previously  showed  that  the  locus 
harbouring FGFR4 was found to be gained in more than 5 out of 21 
cases  (Hallor  et  al,  2008).  However,  FISH  failed  to  reveal  any 
amplification of FGFR4 in the informative 43 cases (Figure 4.6 B).  
 
Figure  4.6  FISH  results  of  ETS2/ERG  rearrangement  and  FGFR4 
amplification.  (A) normal pattern 2 red and 2 green signals for ETS2/ERG 
breakapart  probes  (red  and  green).  (B)  normal  disomic  pattern  with  no 
amplification  using  FGFR4  probe  (red)  compared  to  chromosome  (5) 
enumeration probe (green).  129 
4.2.6 Mutational analysis of brachyury using direct sequencing of 
promoter region and coding exons  
Direct DNA sequencing of brachyury coding exons (2-9) and the 
promoter region showed that expression of brachyury is not accounted 
for by somatic mutations in 23 analysed chordomas. The sequencing 
data are on the attached compact disc. 
4.2.7  Screening  of  KRAS  and  BRAF  for  the  commonly  reported 
mutations  using  denaturing  high-performance  liquid 
chromatography (dHLP)  
As  KRAS  and  BRAF  are  upstream  molecules  in  the  signalling 
pathway  of  ETS2  and  brachyury.  Denaturing  high-performance  liquid 
chromatography  (dHPLC)  for  detection  of  the  common  mutations  in 
KRAS (exons 2 and 3; codons 12, 13, and 61) and BRAF (exons 11 and 
15) in 23 chordomas failed to reveal any abnormalities.  
4.2.8 Screening for tandem duplication at BRAF locus 
A reverse transcription polymerase chain reaction (RT-PCR) 
with specific primers to detect the oncogenic fusion gene formed by 
tandem  duplication  at  the  locus  of  BRAF  between  BRAF  and 
KIAA1549  failed  to  detect  the  tandem  duplication  in  any  of  the 
examined 23 cases (Figure 4.7).  130 
 
Figure 4.7 RT-PCR analysis for tandem duplication at BRAF locus 
and the resulting transcripts of the oncogenic fusion gene. The left hand 
panel shows negative control (no template control) and positive controls for 
the three possible fusion transcripts between KIAA1549 exon 15 and BRAF 
exon 9 (15_9, 159 bp), KIAA1549 exon 16 and BRAF exon 9 (16_9, 124 bp) 
and KIAA1549 exon 16 and BRAF exon 11 (16_11, 182 bp). The right hand 
panel  shows  examples  of  chordoma  cases  lacking  the  presence  of  the 
oncogenic gene transcripts. The primer pairs used were described in chapter 
2. Positive controls were cDNA with known fusion transcripts and negative 
control was formed of the PCR reaction mix without DNA template. The RT-
PCR products were electrophoresed on 8% acrylamide gels. 
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4.3 DISCUSSION 
The  effects  of  FGFR  signalling  on  tumours  are  numerous  and 
include  increased  proliferation,  resistance  to  apoptosis,  enhanced 
motility  and  invasiveness,  increased  angiogenesis,  metastasis,  and 
resistance to chemotherapy and radiotherapy, all of which can result in 
tumour progression. As brachyury is known to be regulated by FGFR1 
and FGFR3 in development (Hoffmann et al., 2002; Yamaguchi et al., 
2004b),  it  was  hypothesized  that  the  FGFR  signalling  pathway  is 
involved in the development of this tumour. Therefore interruption of the 
FGF signalling system is an attractive therapy, particularly since such 
therapies  can  affect  tumour  cells  directly  in  addition  to  tumour 
angiogenesis (Reis-Filho et al., 2006; Dutt et al., 2008; Knowles, 2008). 
Of importance is that some agents are currently already in clinical trials 
(Trudel et al., 2006). 
The results of this study demonstrate for the first time that FGFR1 
and  FGFR3  are  expressed  in  52.5%  and  80%  of  chordomas 
respectively. It is also of particular interest that over 90% of chordomas 
express at least one of the four FGFRs. The study also shows that the 
expression of FGFRs is accompanied by activation of the downstream 
pathway  as  evidenced  by Western  blot  analysis  for  p-FRS2α  (Tyr
196) 
and  p-ERK1/2  (Thr
202/Tyr
204).  All  6  chordomas,  which  are 
immunoreactive for at least one of the FGFRs, were also reactive for the 
phosphorylated  forms  of  both  FRS2α  and  ERK1/2  by  Western  blot 132 
analysis  while  2  chordomas  that  were  negative  for  all  FGFRs  by 
immunohistochemistry, were also negative for p-FRS2α although they 
showed p-ERK1/2 by Western blot analysis. This suggests that in the 
minority  of  cases,  activation  of  the  RAS/RAF/MEK/ERK  signalling 
pathway in chordomas is not dependent only on FGFR signalling and 
therefore can be mediated by alternative receptors. As it is known that 
chordomas  also  express  several  other  tyrosine  kinase  receptors 
including c-MET, PDGFR β, and KIT, EGFR, HER2, and TrKA which 
also  activate  the RAS/RAF/MEK/ERK pathway,  these  should  be 
considered  candidates  for  the  regulation  of  brachyury  (Weinberger  et 
al., 2005; Tamborini et al., 2006; Park et al., 2007; Fasig et al., 2008; 
Naka et al., 2008).  
Signalling  through  FGFRs  can  activate  multiple  signal 
transduction  pathways  that  are  known  to  be  implicated  in 
tumourigenesis,  and  include  RAS/RAF/MEK/ERK,  phospholipase  C 
gamma  (PLCγ),  phosphatidyl  inositol  3  kinase  (PI3K),  and  signal 
transducers and activators of transcription (STAT) pathways (Chen et 
al., 2001; Chen et al., 2005; Hart et al., 2000). However, this part of the 
project focused on the RAS/RAF/MEK/ERK pathway as it represents the 
main downstream pathway in FGFR downstream signalling and analysis 
of the pathways was considered beyond the scope of this study.   
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 The  occurrence  of  FGFR  mutations  is  well  documented  in  the 
literature, and these are associated with both developmental syndromes 
and neoplasia. Gain of function germline mutations in FGFR2 results in 
craniosynostosis  syndromes,  mutations  in  FGFR1  are  a  cause  of 
Pfeiffer  syndrome,  a  rare  craniosynostosis  syndrome  and  FGFR3 
mutations are the cause of chondrodysplasia syndromes (Muenke et al., 
1994; Muenke et al., 1997; Hart et al., 2000; Chen et al., 2001; Chen et 
al.,  2005;  Ornitz  and  Marie,  2002).  The  mutations  implicated  in 
neoplasia occur in urothelial, endometrial, gastric and prostatic cancers 
(Mehta et al., 2000; Shin et al., 2000; Kwabi-Addo et al., 2004; Forbes 
et al., 2006; Elbauomy et al., 2007; Pollock et al., 2007; Tomlinson et 
al., 2007; Kunii et al., 2008) and many of these mutations reported in 
neoplasia  are  identical  to  germ-line  mutations  known  to  cause 
developmental syndromes.  
Apart  from  FGFR1  being  known  to  be  involved  in  brachyury 
expression, FGFR genes were therefore considered strong candidates 
for the role of mutation-bearing genes that would be causative in the 
development/progression  of  chordomas.  Nevertheless,  despite  the 
immunoreactivity of the majority of chordomas for FGFRs the results in 
this section showed absence of the previously reported mutations in the 
23 analysed chordomas by direct sequencing. Based on the previously 
reported amplification of some FGFR genes in cancer like gastric cancer 
and rhabdomyosarcoma (Freier et al., 2007; Gorringe et al., 2007; Kunii 134 
et al., 2008; Missiaglia et al., 2009) and on the reported allelic gain at 
the  chromosomal    area  5q35.2  which  harbours  FGFR4  using  array 
comparative  genomic  hybridisation  (Hallor  et  al.,  2008),  it  was  worth 
investigating  whether  FGFR4  is  amplified  that  there  is  gain  in 
chordomas  but  FISH  failed  to  detect  increased  copy  number  of  this 
gene in 43 chordomas. Amplification of the other FGFR genes was not 
studied because there is no evidence in the literature of allelic gain in 
the loci of these genes in chordomas.  
The absence of activating mutations in KRAS and BRAF together 
with the absence of tandem duplication at the BRAF locus in 23 cases 
examined suggests that genetic abnormalities involving these genes are 
unlikely  to  be  the  direct  cause  of  FGFR  pathway  activation  in 
chordomas. However, some of the less common BRAF mutations not 
screened in this study may explain activation of this signalling pathway.   
ETS2  has  previously  been  implicated  in  pathogenesis  of 
chordoma  by  karyotyping  (Gibas  et  al.,  1992)  and  it  is  a  particularly 
interesting candidate because this gene lies upstream of brachyury and 
is known to be involved in its regulation and it is also phosphorylated 
through activation of the RAS/RAF/MEK/ERK pathway (Kawachi et al., 
2003; Matsumoto et al., 2007). Furthermore, rearrangements involving 
ETS2  have  been  detected  in  other  neoplasms  including  acute 
megakaryocytic  leukaemia,  acute  non-lymphoblastic  leukaemia  and 
prostatic  cancer  (Sacchi  et  al.,  1986;  Hsu  et  al.,  2004;  Mehra  et  al., 135 
2007). However, the ‘in-house’ breakapart BAC probe failed to reveal a 
rearrangement in this gene in 23 chordomas. Furthermore, ETS2 was 
not  amplified  as  assessed  by  FISH.  Therefore  it  appears  that  re-
arrangement and amplification in this gene are unlikely to represent a 
common tumourigenic event in chordomas. 
A  recent  report  has  shown  that  duplication  of  brachyury  gene 
increased the susceptibility to development of familial chordoma in four 
out of 7 studied families with familial chordomas (Yang et al., 2009b). 
The failure to detect point mutations in any of the coding regions, splice 
junctions and promoter region of this gene in 23 chordomas implies that 
the expression of brachyury mRNA and protein is likely to be driven by 
other  mechanisms  or  by  events  in  upstream  molecules.  Looking  for 
mutations in brachyury was considered a reasonable approach despite 
no  brachyury  mutations  being  reported  in  tumours  to  date  because 
tumourigenic mutations have been found in related T-box genes, TBX2 
and TBX3 which has been reported to occur in pancreatic and breast 
cancers (Sinclair et al., 2002; Fan et al., 2004). Furthermore, although 
brachyury amplification was detected only in 3 cases, a finding which 
corresponds  to  the  results  of  the  array  comparative  genomic 
hybridisation  data  previously  published  which  showed  gain  of  the 
brachyury locus in 6 out of 21 cases (Hallor et al., 2008), it is considered 
that amplification of this gene is also unlikely to account for the driving 
force in the growth and development of this tumour in view of the small 136 
percentage of identified cases. However, the possibility remains that the 
aneuploidy and chromosomal imbalance affecting brachyury in 40% of 
chordomas examined could be a mechanism implicating brachyury in 
chordoma pathogenesis.  
Recently, Santarius et al., have developed a weight-of-evidence 
based  classification  to  facilitate  the  identification  of  the  key  cancer 
genes. They classified the genes implicated in cancer into 4 classes (I-
IV)  based  on  the  type  of  supportive  data.  According  to  their  criteria, 
brachyury can be categorised as a class II gene with 3 points providing 
supporting  evidence  for  its  involvement  in  development  of  cancer 
(Santarius et al., 2010). The criteria implicating brachyury in chordoma 
development include (1) the reported duplication of brachyury gene in 
familial  chordomas  (Yang  et  al.,  2009b);  (2)  the  expression  and 
activation  of  other  genes  in  the  same  pathway  such  as  FGFRs  and 
FRS2α as detailed in the previous chapter; and (3) the biological effect 
resulting from targeting brachyury with shRNA in the chordoma cell line 
U-CH1 (see chapter 5).   
This part of the project has provided evidence for the activity of 
FGFR-RAS/RAF/MEK/ERK  signalling  in  chordomas  and  has 
demonstrated that oncogenic events involving FGFRS, KRAS, BRAF, 
and  ETS2  are  rare  events  in  these  neoplasms.  Although  brachyury 
amplification  was  detected  in  a  small  percentage  of  chordomas,  the 
detected aneuoploidy of chromosome 6 and the genetic imbalance at 137 
brachyury  locus  6q27  may  be  a  possible  mechanism  by  which 
brachyury  is  involved  in  the  progression  and  pathogenesis  of  the 
sporadic  form  of  this  disease.  Further  investigations  using  a  greater 
number  of  chordoma  cases,  and  other  genome-wide  platforms  are 
required to validate these findings.  138 
5. KNOCKDOWN OF BRACHYURY GENE IN CHORDOMA-DERIVED 
CELL LINE U-CH1 USING LENTIVIRUS-DELIVERED SHORT 
HAIRPIN RNA (shRNA)  
5.1 INTRODUCTION 
The  century  old  concept  that  chordomas  show  notochordal 
differentiation  was  firmly  established  after  the  gene  expression 
microarray  finding  that  brachyury,  a  gene  essential  for  notochordal 
development, is specifically highly expressed in chordomas (Henderson 
et  al.,  2005).  Brachyury  expression  has  proved  to  be  a  specific  and 
sensitive marker for chordomas whereas a wide range of other tumours 
and normal tissues failed to express brachyury (Tirabosco et al., 2008; 
Vujovic  et  al.,  2006).  The  exceptions  include  hemangioblastomas 
(Glasker et al., 2006) and normal spermatogenic tissue (Tirabosco et 
al.,  2008).  In  a  very  recent  report,  brachyury  duplication  has  been 
detected  in  members  from  four  out  of  seven  families  with  familial 
chordoma and it was concluded that brachyury duplication increased the 
susceptibility  to  develop  chordoma  (Yang  et  al.,  2009b).  Brachyury 
expression by all chordomas and the duplication of brachyury in familial 
chordomas  strongly  suggest  a  pathogenic  role  for  brachyury  in  this 
tumour  type.  One  of  the  most  effective  experimental  approaches  to 
elucidate the function of a gene is to knockdown its transcripts using 
short hairpin RNA (shRNA) in vitro or in vivo models and look for the 
consequences (Abbas-Terki et al., 2002). The models available to study 
chordomas are very sparse and the only in vitro model currently is the 139 
U-CH1 cell line developed in Ulm University, Germany from a recurrent 
sacral chordoma (Scheil et al., 2001).  
5.1.1 Brachyury 
Brachyury or T gene is the prototypic member of the T-box family 
of  transcription  factors  and  these  are  characterized  by  a  conserved, 
sequence-speciﬁc  DNA-binding  domain  known  as  T  box  (Muller  and 
Herrmann, 1997; Scheil et al., 2001). Brachyury was originally identiﬁed 
in 1927 as a tail length mutation in mouse. Hermann et al., cloned the 
mouse brachyury gene in 1990, while Edwards et al, (1996) cloned the 
human  T  (brachyury)  and  described  gene  structure  and  the  mRNA 
sequence (Edwards et al., 1996; Herrmann et al., 1990). The function of 
brachyury is conserved in all vertebrates and it is crucial for notochord 
development and differentiation and to direct the differentiation of the 
posterior  mesoderm  (Cunliffe  and  Smith,  1992).  The  open    reading  
frame of human brachyury encodes  a protein of 435  amino  acids  that  
shares 91%  identity  overall  with mouse  brachyury. In humans, the 
brachyury gene has been mapped to the region 6q27 (Edwards et al., 
1996).  
5.1.2 Short hairpin RNA (shRNA)  
RNA  interference  (RNAi)  is  a  phenomenon  in  which  double-
stranded RNA (dsRNA) suppresses expression of a target protein by 
stimulating the specific degradation of the target mRNA (Hannon et al, 
2002). Short hairpin RNA (shRNA) is one of the methods of RNAi, and 140 
is composed of a sequence of RNA that makes a tight hairpin turn and 
can be used to silence gene expression. shRNA uses a vector to be 
introduced into cells and this ensures its continuous stable expression 
so that it can be cleaved by the cellular machinery into small interfering 
RNA (siRNA). The resulting siRNA is then bound to the RNA-inducing 
silencing  complex  (RISC)  and  targets  mRNA  which  leads  to  its 
degradation and silencing of the expression of the gene of choice (Paul 
et al.,  2002; Sui  et  al., 2002; Cao et al, 2005). Lentivirus delivery  of 
shRNA has been shown to be an efficient tool for delivery of shRNA into 
the cells (Abbas-Terki et al., 2002a).  
5.1.3 Hypothesis and Aims  
This  part  of  the  project  was  based  on  the  hypothesis  that 
brachyury, being highly expressed in all chordomas and showing copy 
number gain in a subset of familial chordomas, plays a central role in 
the formation of chordomas. It was also hypothesized that targeting the 
expression  of  this  gene  would  affect  the  development  and/or 
progression of the tumour. If this were the case, the genes which are 
transcriptionally  regulated  by  brachyury  could  be  identified  and  this 
would  be a means  of identifying therapeutic targets. The aim  was to 
establish knockdown of the brachyury gene in the chordoma-derived cell 
line U-CH1 and to study the cellular and morphological changes induced 
by this knockdown. 141 
5.1.4 Objectives 
￿  Preparation  of  the  lentivirus  (pGIPZ)  containing  short  hairpins 
targeting  brachyury  mRNA  along  with  the  use  of  appropriate 
controls including an empty vector and non-silencing scrambled 
shRNA. 
￿  Infection of the U-CH1 cells with lentivirus particles containing the 
shRNA constructs. 
￿  Confirm  the  knockdown  of  brachyury  at  the  mRNA  level  using 
qRT-PCR and at the protein level by Western blot analysis.  
￿  Study  the  morphologic  changes  induced  in  the  U-CH1  cells 
resulting from brachyury knockdown. 142 
5.2. RESULTS 
5.2.1 Silencing of brachyury gene in U-CH1 cell line 
The silencing of brachyury gene in U-CH1 cell line was achieved 
using two different clones directed against two different regions of the 
gene. The first clone, V2LHS_153725, was directed against the region 
encompassing  the  junction  between  exons  4  and  5,  and  the  second 
clone, V2LHS_153729, was directed against the region located at exon 
9, at the 3’UTR, of the gene (Figure 5.1).  
 
Figure  5.1  Structure  of  brachyury  gene  with  mapping  of  the  two  shRNA 
constructs  used  for  its  silencing.  The  boxes  represent  exons  and  the  lines 
represent introns. V2LHS_153725 is directed at the end of exon 4 and the start of 
exon 5. V2LHS_153729 targets 3’UTR of exon 9. 
5.2.1.1 RT-PCR for brachyury expression  
qRT-PCR was performed on mRNA obtained from the U-CH1 cell 
line and this revealed 97% silencing with construct V2LHS_153725 and 
98.4% silencing with construct V2LHS_153729 (Figure 5.2).  
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Figure 5.2 Results of RT-qPCR for brachyury knockdown in the U-CH1 cell line. 
The  knockdown  was  performed  using  two  different  constructs  (V2LHS_153725, 
V2LHS_153729)  and  an  empty  vector  and  non-silencing  construct  as  controls. 
Brachyury expression is corrected to the PGK expression as a reference gene and 
normalised  to  the  empty  vector. The figure  represents  results from  three  different 
experiments, each performed in triplicate. Error bars represent standard deviation. 
 * p < 0.05 in comparison to non silencing vector control. 
5.2.1.2 Western blot analysis of protein expression 
Western blotting showed almost complete absence of brachyury 
protein in U-CH1-derived lysates, the cells of which had been targeted 
by the two shRNAs (V2LHS_153725, V2LHS_153729).  Empty vector and 
non-sliencing constructs were used as controls (Figure 5.3 A&B). 
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Figure 5.3 Western blot analysis of protein lysates from U-CH1 cells infected 
with  lentiviral  shRNA  targeting  brachyury.  (A)  represents  the  Western  blot 
images  and  (B)  represents  densitometric  measurement  of  relative  brachyury 
expression corrected to GAPDH as a loading control and to the expression of the 
cells infected with empty vector construct. * p<0.05  
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5.2.2 Cellular changes in U-CH1 cells resulting from brachyury 
knockdown 
5.2.2.1 Morphological changes 
The U-CH1 cells with brachyury knocked down showed striking 
cellular  morphological  changes  in  the  form  of  abnormal  shapes, 
spindling,  flattening  and  extensive  branching  (Figure  5.4).  These 
changes  started  to  appear  on  the  fourth  day  after  infection,  were 
progressive in nature, and were associated with growth arrest as shown 
by the very low cell density in the ‘knockdown’ cells compared to the two 
controls after two weeks from the onset of infection. These changes are 
reminiscent of replicative senescence noticed in human tissue cultures 
after  a  large  number  of  passages  (Hayflick  and  Moorhead,  1961). 
Staining for detection of SA-β Gal. confirmed the presence of premature 
senescence;  65%  of  the  cells  in  which  brachyury  had  been  knocked 
down stained for senescence-associated beta galactosidase while less 
than  2%  of  the  cells  in  the  control  cultures  showed  positive  staining 
(Figure 5.5). 146 
 
Figure 5.4 Morphological changes in U-CH1 cells as a result of brachyury 
silencing.  Representative  microscopic  photomicrographs  (phase  contrast  and 
fluorescent with GFP) of U-CH1 cells infected with lentivirus-delivered  shRNA 
targeting brachyury showing various morphologic abnormalities ofcells in which 
brachyury  was  knocked  down  (A-H)  compared  to  the  control  cultures  (empty 
vector (I and J) and non-silencing/scrambled shRNA (K and L). The magnification 
in all images is 100X. 
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Figure 5.5 Senescence-associated beta galactosidase staining of U-CH1 cells 
with silencing of brachyury. Transmitted light microscopic images showing positive 
staining  of  a  large  proportion  (65%)  of the  cells  in  which  brachyury  was  silenced 
(A&B)  compared  to  (2%)  of  the  cells  with  empty  vector  (C)  and  a  non-silencing 
construct  (D).  Hundred  cells  from  different  fields  were  counted  per  slide. 
Magnification: 100X. 
5.2.3 Silencing of brachyury gene in 293T cells and HeLa cells 
In  order  to  exclude  the  possibility  that  the  introduction  of  the 
lentivirus  shRNA  targeting  brachyury  was  toxic  to  the  cells,  a 
knockdown of brachyury gene was performed in two different cell lines, 
293T and HeLa. In both these cell lines no change in the morphology or 
proliferative  capacity  was  induced  when  compared  to  the  controls 
(Figure 5.6).  148 
 
 
Figure 5.6 Morphology of 293T cells with brachyury knocked down. 293T cells 
were  infected  with  lentivirus-delivered  shRNA  targeting  brachyury.  These  cells 
showed  no  morphologic  abnormalities  when  brachyury  was  silenced  (A  &  B) 
compared to empty vector (C and D) and non-silencing scramble shRNA (E and F). 
For  each  construct,  a  transmitted  light  microscopic  and  a  fluorescent  microscopic 
images with GFP are shown. Magnififcation: 100X  
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5.3 DISCUSSION  
The work presented in this chapter has proved that brachyury can 
be  efficiently  silenced  using  lentiviral-delivered  shRNA  which  targets 
brachyury  mRNA.  Gene  knockdown  is  a  very  useful  tool  to  study 
brachyury  function;  however,  the  major  concern  in  a  knockdown 
experiment is the specificity of the shRNA to the gene of interest. There 
are several ways to show this specificity as proposed by Cullen, (2006). 
The work presented here has shown multiple ways to prove the shRNA 
specificity  towards  brachyury.  First,  the  knockdown  was  successful 
using two different silencing constructs; second, the knockdown using 
both  constructs  was  confirmed  on  both  mRNA  and  protein  levels  by 
qRT-PCR and Western blot analysis respectively; third, the use of non-
silencing  scrambled  shRNA  and  an  empty  vector  did  not  induce 
alteration in the level of brachyury expression (mRNA or protein); fourth, 
the same constructs had no effect on two different cell lines 293T and 
HeLa  that  did  not  express  brachyury.  Another  means  of  proving  the 
specificity of shRNA knockdown is to perform a rescue experiment. This 
involves introducing brachyury cDNA into the cells in which brachyury 
has  been  knocked  down  and  inducing  a  reversal  of  the  cellular  and 
functional changes caused by knocking down brachyury. However, this 
has not been done due to limitation of time and is planned for future 
work. This knockdown model can now be used in a variety of ways to 
study the role of brachyury in the pathogenesis of chordoma.    150 
The  cellular  effects  of  knocking  down  brachyury  can  lead  to  a 
better understanding of its biological functions. Very little is known about 
the effect of brachyury over-expression in cells and tissues. However, 
two members of the T-box family, TBX2 and TBX3, have been shown to 
affect  cellular  proliferation  and  to  be  involved  in  the  development  of 
cancer  (Jacobs  et  al.,  2000).  The  evidence  includes  their  ability  to 
repress  the  promoter  of  p14
ARF,  which  affects  the  TP53  tumour 
suppressor pathway (Jacobs et al., 2000; Brummelkamp et al., 2002; 
Yarosh et al., 2008) In addition, TBX2 maps to 17q23 locus, which is 
frequently altered in ovarian and breast carcinomas (Campbell et  al., 
1995; Barlund et al., 2000). TBX2 has been also found to be amplified in 
some breast-cancer cell lines,  and in  a subset of  breast carcinomas, 
and  melanomas,  and  to  be  highly  expressed  in  more  than  60%  of 
pancreatic carcinomas (Sinclair et al., 2002; Sinclair et al., 2003; Chen 
et al., 2008).  
p19
ARF in mice or p14
ARF in humans is the alternative transcript 
encoded by the INK4a
ARF locus which also encodes p16
INK4a. Jacobs et 
al, showed that TBX2 represses CDKN2A and that affected cells were 
able  to  bypass  the  senescence-like  growth  arrest  induced  by  p14
ARF 
(Hallor et al., 2008; Naka et al., 2005). Generally, the T box genes are 
transcriptional activators. However, TBX2 and TBX3 are exceptions as 
they repress the promoter of p14
ARF and it is interesting to postulate that 
brachyury behaves in a similar way, and thereby regulates the cell cycle 151 
or  senescence  checkpoint.  The  argument  for  this  is  that  the 
morphological  changes  in  the  U-CH1  cells  resulting  from  brachyury 
knockdown are very similar to the premature senescence noticed when 
TBX2  is  knocked  down  in  breast  carcinoma  cell  lines  (Jacobs  et  al., 
2000).  This  raises  the  possibility  that  brachyury  may  account  for  the 
proliferation  of  chordoma  cells  in  a  mechanism  similar  to  TBX2 
regulation of the promoter area of CDK2NA. The positive staining for SA 
β-gal.  supports  this  concept.  It  is  also  noteworthy  that  p16
INK4,  a 
CDKN2A protein product, is down-regulated in chordomas and that the 
locus  of  CDK2NA  is  lost  in  more  than  70%  of  cases  in  an  array 
comparative genomic hybridisation study performed on 21 chordomas 
(Naka et al., 2005; Hallor et al., 2008).  152 
6. ANALYSIS OF EPIDERMAL GROWTH FACTOR 
RECEPTOR IN CHORDOMAS 
6.1 INTRODUCTION  
The main treatment option of chordomas is surgical removal with 
or  without  post-operative  radiotherapy.  Radical  excision  is  rarely 
achieved due to the infiltrative nature of the tumour and the presence of 
vital structures in the tumour vicinity of both the skull base and in the 
sacro-coccygeal area (Agrawal et al., 2006; Smolders et al., 2003).  
Radiotherapy alone is the second line of treatment if surgery is 
not feasible in which is usually the case for the skull-based chordomas. 
Proton  beam  radiotherapy  and  the  new  modalities  of  photon 
radiotherapy  such  as  intensity  modulated  radiation  therapy  (IMRT), 
stereotactic  radiosurgery  and  carbon-ion  radiotherapy  offer  a  better 
control of the disease (Gabriele et al., 2003; Muthukumar et al., 1998; 
Schulz-Ertner et al., 2003a; Schulz-Ertner et al., 2003b). Chordomas are 
regarded as chemo-resistant and so there is no role for chemotherapy 
(Fleming et al., 1993) 
Hence, molecular therapeutic strategies have become relevant for 
the  management  of  chordomas.  Some  agents  are  already  in  clinical 
trials,  such  as  imatinib  mesylate,  targeting  the  patelet-derived  growth 
factor  receptor  β  (PDGFR-β).  In  a  preliminary  study,  Casali  et  al., 
treated  six  patients  with  imatinib  mesylate  (Casali  et  al.,  2004). 
Subsequently a more organized phase II clinical trial has been started 153 
using this drug in 55 patients with advanced chordomas and showed a 
clinical benefit rate (complete response plus partial response plus stable 
disease for at least 6 months) of 73% and 38% of patients were free 
from  progression  at  1  year  (Stacchiotti  et  al.,  2007;  Ferraresi  et  al., 
2010).  Epidermal  growth  factor  receptor  (EGFR)  represents  another 
possible target as EGFR inhibitors are already in clinical use for some 
tumours such as non small cell lung cancer (NSCLC), colorectal and 
head and neck cancers (Dassonville et al., 2007; Roberts et al., 2002).  
There  are  a  few  reports  showing  expression  of  EGFR  in 
chordomas  by  immunohistochemistry  (Tamayama  et  al.,  1990; 
Weinberger et al., 2005; Fasig et al., 2008; Ptaszynski et al., 2009) and 
one  study  showed  over  expression  of  the  EGFR  ligand  transforming 
growth factor-alpha (TGF-α) in 10 out of 14 chordomas (Deniz et al., 
2002).  Three  reports  showed  chordoma  response  to  the  inhibitors  of 
epidermal  growth  factor  receptor  (EGFR)  in  three  patients  with 
advanced chordoma, suggesting EGFR as a possible therapeutic target 
(Hof et al., 2006; Linden et al., 2009; Singhal et al., 2009). 
6.1.1 Epidermal Growth Factor Receptor (EGFR) 
Epidermal growth factor receptor is a member of HER (Human 
Epidermal Growth Factor Receptor) family of tyrosine kinase receptors. 
The family is composed of four closely related receptors including EGFR 
(HER1, ErbB1), HER2/neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4) 
(Ullrich et al., 1984; Ullrich and Schlessinger, 1990). 154 
EGFR is a large (170kDa) trans-membrane glycoprotein with an 
extra-cellular  ligand-binding  domain  and  a  cytoplasmic  domain  with 
intrinsic tyrosine kinase activity and multiple autophosphorylation sites 
(Yarden and Ullrich, 1988). Five autophosphorylation sites have been 
identified: three major (Tyr
1068, Tyr
1148, and Tyr
1173) and two minor (Tyr
992 
and Tyr
1086) sites (Biscardi et al, 1999). The Tyr
1173 site represents the 
most  important  phosphorylation  site  in  vivo  (Lombardo  et  al.,  1995;  
Chattopadhyay  et  al.,  1999).  In  addition,  EGFR  activation  results  in 
phosphorylation of Tyr
845 required for mitogenic responses and Tyr
1101 
that  represents  a  binding  site  for  SH2  domain-containing  proteins 
including the adaptor protein Grb-2 (Mass, 2004). 
Epidermal  growth  factor  (EGF)  and  TGF-α  represent  the  two 
major  ligands  of  EGFR  and  their  binding  leads  to  receptor 
autophosphorylation  and  subsequent  activation  of  downstream  signal 
transduction  pathways,  mainly  the  RAS/RAF/MEK/ERK  and  the 
PI3K/AKT  pathways  (Figure  6.1).  This  activation  leads  to  cell 
proliferation, tumour growth, metastasis, angiogenesis and inhibition of 
apoptosis (Schlessinger, 2000; Yarden and Sliwkowski, 2001; Buettner 
et al., 2002; Song et al., 2002) 
The  mechanisms  of  increased  EGFR  signalling  include  high 
expression  levels  as  a  consequence  of  mutations  (point  mutations, 
increased gene dosage), heterodimerization with other members of the 155 
HER family such as HER2, and increased ligand expression (Arteaga, 
2002) .  
 
Figure 6.1 Schematic diagram of the EGFR signalling pathway 
6.1.2 EGFR Inhibitors 
The inhibitors of EGFR in clinical trials are classified mainly into 
two classes, anti-EGFR monoclonal antibodies such as mAb 528 and 
C225 (cetuximab) and small-molecule tyrosine kinase inhibitors (TKIs) 
as gefitinib (ZD1839), erlotinib (OSI-774) and tyrphostin (AG1478) (Ellis 156 
et al, 2006). The tyrphostin (AG1478) is a reversible, highly potent and 
selective  inhibitor  of  EGFR  tyrosine  kinase  activity  (Ellis  et  al.,  2006; 
Zhang and Chang, 2008; Zhu et al., 2001).   
Monoclonal antibodies against EGFR competitively inhibit ligand 
binding and thereby prevent receptor activation while TKIs competitively 
bind to the ATP binding domain of EGFR to inhibit autophosphorylation 
and activity (El-Rayes and LoRusso, 2004; Marshall, 2006). Food and 
Drug Administration (FDA) have approved only five EGFR inhibitors for 
clinical use. These include two monoclonal antibodies (cetuximab and 
panitumumab), two small-molecule TKI (erlotinib and gefitinib) and one 
that binds to both EGFR and HER2 (lapatinib). However, gefitinib was 
withdrawn in 2005 because of the results of phase 3 clinical trial that 
showed no survival benefit in patients with non-small cell lung cancer 
(NSCLC) (Raponi et al., 2008; Rocha-Lima et al., 2007; Thatcher et al., 
2005). 
Monoclonal  antibodies  exhibit  greater  speciﬁcity  for  the  EGFR 
compared with some of the small-molecule compounds (Mendelsohn, 
2001). In addition, receptor inhibition with monoclonal antibodies can be 
achieved  with  lower  concentrations  than  those  required  for  small-
molecule inhibitors. However, monoclonal antibodies are administered 
intravenously, whereas the small-molecule tyrosine kinase inhibitors are 
orally active (Mendelsohn and Baselga, 2003). 157 
6.1.3 Hypothesis and Aims 
In  this  part  of  the  project,  it  was  hypothesised  that  EGFR 
activation as a consequence of over-expression due to increased gene 
dosage or activating mutations may result in chordoma progression. The 
main  aim  of  this  part  of  the  project  was  to  investigate  if  there  were 
molecular evidence for offering EGFR inhibitors as a systemic treatment 
for a selective group of chordoma patients. To achieve this, a cohort of 
chordomas was screened for EGFR expression and for genetic changes 
(mutations and copy number variation).  If evidence was found for either 
or  both  of  these  abnormalities  in  chordomas,  the  effect  of  an  EGFR 
inhibitor,  tyrphostin  (AG1478)  was  to  be  tested  on  the  only  available 
chordoma-derived cell line, U-CH1.  
6.1.4 Objectives 
￿  Analysis  of  total  and  phosphorylated  EGFR  expression  in 
chordomas using immunohistochemical technique on TMAs. 
￿  Assessment  of  the  p-EGFR  status  and  other  phospho- 
receptor tyrosine kinases (RTK) in the chordoma cell line and 
chordoma  cases  using  a  phospho-RTK  antibody  array 
membrane.  
￿  Determination of EGFR gene dosage in chordomas and the U-
CH1 cell line using interphase FISH on chordoma TMAs.  
￿  Mutational  analysis  of  (exons  18-21)  encoding  the  tyrosine 
kinase domain of EGFR using direct sequencing of genomic 158 
DNA,  including  the  coding  sequence  and  flanking  intronic 
regions. 
￿  Application  of  EGFR  inhibitor  tyrphostin  (AG1478)  to  the 
chordoma-derived cell line U-CH1 in vitro and analysis of its 
cellular effects. 159 
6.2 RESULTS 
6.2.1  Immunohistochemical  analysis  of  EGFR  and  p-EGFR 
expression in chordomas using TMAs 
Thirty-two of 49 (65%) of the non skull-based chordomas and 30 
of 48 (62.5%) of the skull-based chordomas expressed total EGFR as 
assessed  by  immunohistochemistry,  whereas  24  of  49  (49%)  of  non 
skull-based  chordomas  and  22  of  48  (46%)  of  the  skull-based 
chordomas  showed  p-EGFR  immunoreactivity  (Figure  6.2).  The 
immunoreactivity was membranous and or cytoplasmic. A cut-off point 
of  10%  of  immunoreactive  cells  was  required  to  classify  the  case 
positive for either EGFR or p-EGFR expression. In most cases, more 
than 90% of the neoplastic cells were immunoreactive (Table 6.1).  
The  non-neoplastic  cells  (macrophages,  lymphocytes  and 
fibroblasts)  in  the  cores  were  used  as  internal  negative  controls. 160 
Table 6.1 EGFR and pEGFR expression in chordomas by immunohistochemistry  
TMA  Immunohistochemistry score  EGFR  p-EGFR 
3   +++  5  0 
     ++  1  0 
     +  0  0 
2   +++  2  3 
     ++  1  0 
     +  0  0 
1   +++  19  17 
     ++  3  4 
     +  1  0 
0  17  25 
Non skull-based 
chordomas 
Total number of positive cases (%) 
 
32/49 (65) 
 
24/49 (49) 
 
3   +++  3  1 
     ++  1  0 
     +  0  0 
2   +++  7  3 
     ++  1  1 
     +  1  0 
1   +++  11  13 
     ++  0  4 
     +  6  0 
0  18  26 
Skull-based 
chordomas 
Total number of positive cases (%) 
 
30/48 (62.5) 
 
22/48 (46) 
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 Figure  6.2  EGFR  and  p-EGFR  immunohistchemistry.  positive  control  for  EGFR 
antibody (epidermal squamous cells) (A), positive control for p-EGFR antibody (formalin-
fixed squamous cell carcinoma cell line, A431) (B), chordoma immunoreactive for EGFR 
(C), chordoma immunoreactive for p-EGFR (D), chordomas showing no immunoreactivity 
for EGFR (E) and  p-EGFR (F).  
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6.2.2 Profiling of the receptor tyrosine kinases using receptor tyrosine 
kinase antibody array membranes 
Protein lysates of the U-CH1 chordoma cell line and three primary 
tumours revealed high level expression of the active phosphorylated form 
of EGFR using the R&D p-RTK Antibody Proteome Profiler Array on which 
there were 42 different receptor tyrosine kinases in duplicates (Figure 6.3, 
6.4).  The  membranes  also  showed  high  level  expression  of  some  other 
RTKs  in  the  cell  line  and  the  three  chordomas  including  macrophage-
stimulating protein receptor (MSPR) and ephrin B2 (EphB2) (Figure 6.3). 
 
Figure 6.3 Human phopho-RTK antibody array membranes for U-CH1 cell line and 
3 chordomas. The membranes show high expression level of p-EGFR (red arrows). The 
duplicate spots at the 4 corners of each membrane represent positive controls. 163 
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Figure 6.4 Densitometric analysis of p-EGFR expression in the U-CH1 cell line and 
three  chordomas  using  RTK  antibody  array  membranes.  The  cell  line  showed 
expression higher than the positive control, and the three chordoma cases showed high 
expression  but  slightly  lower  than  the  positive  control.  The  background  effect  was 
substracted  from  each  variable.  The  relative  expression  levels  were  adjusted  to  the 
background signals. The RTK antibodies included in the array membranes were spotted 
in  duplicates.  The  mean  densitometric  values  for  these  dfuplicates  were  used  in  this 
figure.   
6.2.3  Fluorescent  in  situ  hybridisation  of  EGFR  probe  and 
chromosome 7 chromosome enumeration probe (CEP7)  
The results of the FISH assay for EGFR in 96 chordomas are shown 
in Table 6.3. The results were divided into FISH positive and FISH negative 
groups  according  to  the  Colorado  criteria  developed  for  lung  carcinoma 
(Cappuzzo et al., 2005; Cappuzzo et al., 2008; Martin et al., 2009; Varella-
Garcia  et  al.,  2009).  The  former  comprises  two  categories;  high  level 
polysomy (≥ 4 copies/cell in ≥ 40% of cells) and amplification, defined by 164 
the presence of tight gene clusters, a ratio of EGFR gene signals:CEP7 
signals ≥ 2, or ≥ 15 copies of the gene per cell in ≥ 10% of analysed cells. 
The second comprises low level polysomy, defined as > 2 copies/cell in ≤ 
40% of cells or 3 copies/cell in ≥ 40% of cells, and diosomy (≤ 2 copies in > 
90% of the cells) (Martin et al, 2009; Cappuzzo et al, 2005). Figure 3 shows 
examples of EGFR FISH. 
Table 6.2. Results of EGFR FISH assay 
  EGFR gene status  Non base of 
skull chordomas 
Skull-based 
chordomas 
Total  
Amplification  5/50 (10%)  1/46 (2%)  FISH 
positive  High level polysomy  16/50 (32%)  21/46 (46%) 
43/96 
(45%) 
Low level polysomy  10/50 (20%)  7/46 (15%)  FISH 
negative  Diosomy  19/50 (38%)  17/46 (37%) 
53/96 
(55%) 
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Figure 6.5 Representative images of FISH of EGFR on chordoma TMAs. metaphase 
spread showing mapping of the probes EGFR (red) and CEP7 (green) to the correct 
chromosomal regions (A),  diosomy  with  2  EGFR  and  2  CEP7 signals  in  most of the 166 
nuclei (B), low level polysomy (C), high level polysomy (D&E) and amplification (F). Fifty 
intact and non overlapping nuclei were counted for each case.  
 
6.2.4  Mutational  analysis  of  exons  (18-21)  of  EGFR  encoding  the 
tyrosine kinase domain 
Mutational  analysis  of  the  exons  encoding  the  tyrosine  kinase 
domain of EGFR by direct sequencing of genomic DNA failed to reveal any 
mutations in the 23 analysed cases. However, a recently reported single 
nucleotide  polymorphism  (SNP)  (I.D  rs1050171  and  submission  number 
ss52067157) in exon 20 was identified in 15 of 23 (65.2%) tumours. The 
SNP  represents  replacement  of  G  to  A  in  glutamine  (number  787  and 
cDNA position 2607). To date there is no disease-association reported, and 
its prevalence in European population was found to be 58% whereas it was 
rare  in  the  Asian  and  Sub-Saharan  African  populations 
(http://www.ncbi.nlm.nih.gov/snp). This SNP is synonymous and so has no 
functional effect. 
EGFR cDNA sequence: 
 
 
  2521 ATCCTCGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTG 
   759 -I--L--D--E--A--Y--V--M--A--S--V--D--N--P--H--V--C--R--L--L- 
                                 R                                  
  2581 GGCATCTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTC 
   779 -G--I--C--L--T--S--T--V--Q--L--I--T--Q--L--M--P--F--G--C--L- 
 
Figure 6.6 Mapping of the SNP reported in exon 20 of EGFR. The SNP represents 
replacement of G to A in glutamine (number 787 and cDNA position 2607). The normal 
pattern is CAG, which changed to CAA in the SNP pattern. This does not change the 
amino acid. 
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6.2.5 Effects of the selective EGFR inhibitor tyrphostin (AG1478) on 
the U-CH1 chordoma-derived cell line 
6.2.5.1  Morphological  changes  of  U-CH1  cells  in  response  to  tyrphostin 
(AG1478) treatment 
The  EGFR  TKI  tyrphostin  (AG1478)  was  applied  to  the  cells  at 
various  concentrations  diluted  in  DMSO  (0,  5,  10,  20,  50,  100  and  200 
nmol/L). The cells showed morphological changes in response to the drug 
in the form of spindling and reduction in size together with decreased cell 
densities (Figure 6.7).  168 
 
Figure  6.7  Morphological  changes  of  U-CH1  cells  in  response  to  tyrphostin 
(AG1478).  Phase  contrast  photomicrographs  of  the  U-CH1  chordoma  cell  line  in 
response to various drug concentrations. The drug was applied to the cells for 4 days in 
complete  medium.  The  experiment  was  performed  three  separate  times.  Pictures 
represent examples of one experiment. Magnification is 100X. 
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6.2.5.2 Effect of tyrphostin (AG1478) on proliferation of U-CH1 cells as 
assessed indirectly by MTS assay 
The  MTS  indirect  proliferation  assay  (CellTiter  96®  AQueous  Non-
Radioactive Cell Proliferation Assay (Promega) demonstrated that tyrphostin 
(AG1478) inhibited the growth of U-CH1 cells in a dose-responsive manner 
and resulted in a significant reduction in cell number being detected at a 
concentration as low as 20 nmol/L (Figure 6.8). The reduction in cell number 
was  progressive  with  time  over  7  days.  Removal  of  tyrphostin  (AG1478) 
from  the  cultures  after  4  days  revealed  that  the  cell  number  recovered 
significantly apart from the cultures exposed to 100-200 nmol/L (Figures 6.9, 
6.10). The experiments showed that there was more than 85% cell number 
recovery  after  4  days  growth  following  removal  of  the  treatment  in 
concentrations equal to or less than 50 nmol/L. At concentrations of 100 and 
200  nmol/L,  the  cells  showed  only  partial  recovery  of  the  cell  number. 170 
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Figure 6.8 MTS assay of U-CH1 cells treated with tyrphostin (AG1478).  The figure 
represents results from three separate experiments, with each variable being performed 
in triplicates.  Error bars represent standard deviation of the calculated mean, * p<0.05 
compared to vehicle (DMSO).  
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Figure  6.9  Effect  of  tyrphostin  (AG1478)  withdrawal  from  U-CH1  cells.  The  cells 
were  grown  in  complete  medium  containing  a  range  of  concentrations  of  tyrphostin 
(AG1478), for 4 days, after which the drug was removed and the cells were grown in 
complete medium for another 4 days. Removal of the drug at concentrations of 50 nmol/L 
or less resulted in the morphology of the cells and the cell density returning to that of the 
control cultures (B, C, D). Cells treated with 100 nmol/L showed partial restoration of 
morphology  and  cell  density  (E),  and  cells  treated  with  200  nmol/L  showed  little 
reversibility  of  the  drug  effects  (F).  The  experiment  was  performed  three  times  in 
triplicates. Images are from one representative experiment. Magnification is 100X.  
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Figure  6.10  MTS  assay  of  U-CH1  cells  after  withdrawal  of  tyrphostin  (AG1478) 
cells. The cells were treated with the drug for 4 days after which the drug was withdrawn 
and cells were grown for another 4 days. There is restoration of up to 85% of the activity 
of cells treated with concentrations equal to or less than 50 nmol/L compared to the 
vehicle (DMSO) control. The concentrations of 100 and 200 nmol/L showed only partial 
restoration of the MTS processing activity. 
6.2.5.3 The effect of tyrphostin (AG1478) on tyrosine phosphorylation 
of EGFR 
The effect of tyrphostin (AG1478) on the expression of p-EGFR in U-
CH1 cells was investigated using pEGFR-specific membranes. When the 
cells  were  exposed  to  vehicle  (DMSO)  alone  the  membranes  showed 
phosphorylation of EGFR at three sites Tyr
845, Tyr
1086 and Tyr
1173, whereas 
phosphorylation  of  these  sites  was  clearly  diminished  when  the 
membranes were exposed to tyrphostin (AG1478) in drug concentration as 
low as 20 nmol/L (Figure 6.11). The results of the EGFR phosphorylation 173 
antibody  array  membranes  were  confirmed  by  Western  blot  analyses 
which also showed a dose-dependent response (Figure 6.12).  
 
Figure 6.11 EGFR phosphorylation of U-CH1 cells in the presence and absence of 
tyrphostin (AG1478)  using  p-EGFR  antibody  array  membranes. The  cells  treated 
with vehicle (DMSO) on the right side showed EGFR phosphorylation at the sites Tyr
845, 
Tyr
1086, Tyr
1173 while cells treated with 20 nmol/L of tyrphostin (AG1478) showed marked 
reduction of these phosphorylation sites.  
6.2.5.4 Effect of tyrphostin (AG1478) on activation of MAPK and AKT 
downstream targets of EGFR signalling   
Activation of EGFR leads to proliferation of cells mainly by inducing 
downstream  signalling  through  RAS/RAF/MEK/ERK  and  PI3K/AKT 
pathways.  To  test  whether  AG1478  could  inhibit  activation  of  these 
downstream  pathways,  U-CH1  cells  were  treated  with  a  range  of 
concentrations of AG1478 and the expression of p-AKT and p-ERK1/2 was 
determined  by  Western  blot  analysis  using  phospho-specific  antibodies 174 
directed against p-AKT (Ser
473) and p-ERK 1/2 (Thr
202/Tyr
204) respectively. 
The results showed that p-AKT and p-ERK decreased significantly after 
treatment with AG1478 with 200 nmol/L (Figure 6.12).  
 
Figure  6.12  Western  blot  analysis  of  the  effect  of  various  concentrations  of 
tyrphostin (AG1478) on U-CH1 cells. The upper panel shows a gradual reduction of the 
expression  of  p-EGFR  in  response  to  increasing  concentrations  of  the  drug.  The 
expression of p-AKT and p-ERK1/2 shows a marked decrease at the concentration of 
200 nmol/L while being nearly constant at the lower concentrations. The membrane was 
probed with anti-GAPDH antibody as a loading control. 
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Figure 6.13 Densitometric measurements of Western blot analysis of the effect of 
various  concentrations  of  tyrphostin  (AG1478)  on  U-CH1  cells.  The  total  EGFR 
expression  is  not  significantly  affected  by  addition  of  the  drug.  The  p-EGFR  showed 
marked reduction with nearly with almost absent expression at concentrations of 100 and 
200 nmol/L. p-ERK and p-AKT were significantly reduced with the concentration of 200 
nmol/L. The expression was adjusted to GAPDH expression as a loading control. The 
experiment  was  performed  three  separate  times  and  each  variable  was  analysed  in 
triplicates. Error bars represent standard deviation. * p< 0.05.  
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6.3 DISCUSSION 
EGFR  represents  an  important  candidate  for  molecular  targeted 
therapy as it plays an essential role in the growth of many types of solid 
tumours  especially  non-small  cell  lung  cancer,  colon  cancer,  head  and 
neck and pancreatic cancers (Roberts et al., 2002). Some EGFR inhibitors 
are  already  in  clinical  use  for  management  of  some  of  these  tumours 
(Rocha-Lima et al., 2007).  
The few reports which have described the expression of EGFR in 
chordomas using immunohistochemical techniques show a wide range of 
immunoreactivity from 61% to 100% (Tamayama et al., 1990; Weinberger 
et al., 2005; Fasig et al., 2008; Ptaszynski et al., 2009). In comparison, the 
results presented here revealed EGFR expression in 64% of the examined 
cases. The difference in the expression levels reported can be attributed to 
different  immunohistochemical  techniques  employed  including  different 
antibodies, and the use of TMAs compared to whole tissue sections, the 
differences  in  scoring  systems  adopted  and  the  size  of  the  examined 
cohort. The results presented in this part of the project are closest to the 
67% reported by Fasig et al., (2008) who also used TMA and adopted a 
similar scoring system and only included a positive result when a minimum 
of 10% of the lesional cells were immunoreactive (Karamouzis et al., 2007; 
Fasig  et  al.,  2008).  The  expression  of  EGFR,  as  determined  by 
immunohistochemistry,  is  associated  with  a  poor  prognosis  in  many 
cancers including gastric, esophageal and breast carcinomas compared to 177 
EGFR negative tumours, although this is not the case for lung carcinoma 
(Kris  and  Tonato,  2002;  DiGiovanna  et  al.,  2005;  Gibault  et  al.,  2005). 
However, most of the studies and clinical trials found that expression of 
EGFR  alone  is  not  a  robust  predictor  of  response  to  therapeutic 
intervention with EGFR inhibitors (Bishop et al., 2002; Chung et al., 2005; 
Dei Tos and Ellis, 2005; Sartore-Bianchi et al., 2007). The assessment of 
the phospho-EGFR status in tumours in other studies has failed to show 
that this is a good predictor of response to anti-EGFR therapy (Rego et al., 
2010). 
The  best  evidence  for  predicting  the  response  to  EGFR  inhibitors 
include EGFR gene dosage, somatic mutations in EGFR, mutations in the 
downstream molecules in the EGFR signalling pathway especially KRAS 
and the absence of PTEN expression (Frattini et al., 2007) 
High level EGFR gene dosage detected by FISH either in the form of 
amplification or balanced polysomy has been reported to be a predictive of 
good response to anti-EGFR therapy (Cappuzzo et al., 2005; Moroni et al., 
2005; van Krieken et al., 2008).  Hence the finding that 45% (43 of 96)  
chordomas showed high level EGFR gene dosage either by amplification 
(6%) or by high level polysomy (39%) suggest that a substantial number of 
these tumours may respond well to anti-EGFR therapy.  
Failure to detect any mutations in the exons (18-21) coding for the 
EGFR tyrosine kinase domain, suggests that EGFR mutation is not a major 
mechanism for EGFR activation in chordomas. However, the presence of 178 
unreported  mutations,  outside  the  examined  exons  or  in  the  introns 
remains a possibility. Single nucleotide polymorphisms (SNPs) represent 
the most common genetic variation in the human genome and they may 
contribute  to  the  susceptibility  to  cancers.  A  recently  reported  SNP  was 
found in 65% of the chordomas examined in this study and although little is 
known  about  the  contribution  of  this  SNP  to  the  disease  process,  the 
possibility  remains  that  it  may  have  an  effect  on  EGFR  expression  or 
activity  (Choi  et  al.,  2007).  Another  predictor  of  sensitivity  to  anti-EGFR 
drugs is the mutation status of the EGFR downstream molecules especially 
those in the RAS/RAF/MEK/ERK pathway including KRAS, NRAS, HRAS, 
BRAF  and  MEK1/2.  This  necessitates  conducting  mutational  analysis  of 
these genes in chordomas (Raponi et al., 2008), although no mutations in 
KRAS, BRAF were identified in 23 chordomas in this study as described in 
chapter 4.  
The  in  vitro  response  of  the  U-CH1  chordoma-derived  cell  line 
presented in this work provides an evidence base that chordomas may be 
responsive  for  the  anti-EGFR  therapy.  The  dose-dependent  inhibition  of 
phosphorylation of EGFR as shown by the Western blot analysis and the 
reversibility of the morphologic changes of the cells after drug withdrawal 
proves that the effects seen are specific and caused mainly by inhibition of 
EGFR  signalling.  The  application  tyrphostin  (AG1478)  to  a  cell  line  that 
does not overexpress EGFR would be usefull as a control to exclude the 
possibility of the drug toxic effect, although the dose dependent effect seen 179 
on  U-CH1  cells  can  provide  evidence  that  the  drug  is  not  mediating  its 
effect through a direct toxicity. The  diminished expression  of p-ERK 1/2 
(Thr
202/Tyr
204)  and  p-AKT  (Ser
473)  provides  further  evidence  to  the 
specificity of the drug. However, the effect on these downstream molecules 
is only evident with higher doses (200 nmol/L) and this suggests that the 
range of doses which may be required to cause the cellular effect is higher 
that that is required to inhibit the EGFR phosphorylation..  
The detection of HER2 phosphorylation at (Tyr
1112) in U-CH1 cells as 
detected by the p-EGFR antibody array membranes and the detection of p-
HER2  by  the  RTK  antibody  array  membranes  may  be  an  indication  of 
ERBB2 activation in chordomas, however, the chordomas examined in this 
study failed to show HER2 expression by immunohistochemistry. Further 
investigation  of  HER2  status  using  FISH  in  this  tumour  is  required; 
however, it is beyond the scope of this project. 
The findings of this study including the high copy number of EGFR 
and the response of the chordoma cell line to the EGFR inhibitor tyrphostin 
(AG1478) provides an evidence base for the first time for a clinical trial to 
be carried to test the effect of treating chordomas with EGFR inhibitors. 
However,  as  in  the  treatment  of  other  tumour  knowledge  of  the  EGFR 
mutation status, the copy number and the mutations in genes involved in 
the downstream pathways especially RAS and PTEN genes is required if 
useful information is to be acquired from such a trial.  180 
7. CONCLUSIONS AND FUTURE WORK 
7.1 Conclusions 
The  work  presented  in  this  thesis  was  started  with  the  aim  of 
identifying  the  molecules  and  mechanisms  involved  in  chordoma 
pathogenesis,  and  to  find  an  evidence  base  on  which  to  offer  new 
treatments for the management of chordomas. 
In the first chapter of the results, the previous reports of chordomas 
arising in the context of tuberous sclerosis complex syndrome stimulated 
investigations into whether there was activation of PI3K/AKT/TSC/mTOR 
pathway  in  chordomas  and  to  discover  if  there  were  underlying  genetic 
changes in TSC1 and or TSC2 genes. The expression of TSC proteins by 
most  of  the  chordomas  investigated  suggested  that  activation  of  this 
pathway is unlikely to be due to genetic events in these two genes and 
directed the work towards looking for other mechanisms of activation of this 
pathway.  The activity of PI3K/AKT/TSC/mTOR pathway was investigated 
using  multiple  techniques  including  immunohistochemistry  with  phospho-
specific antibodies directed towards the active forms of molecules involved 
in  this  pathway.  The  results  of  immunohistochemistry  were  validated  by 
Western blot analysis on selected cases. Mutations affecting PI3KCA and 
RHEB genes were not detected by direct DNA sequencing of the regions of 
the  genes  where  mutations  have  been  previously  reported.  The  genetic 
status of mTOR (FRAP1), RPS6, TSC1, TSC2 has been investigated using 
FISH and the allelic loss of mTOR and RPS6 in some cases provided an 181 
explanation  for  the  loss  of  expression  of  these  molecules  by 
immunohistochemistry. The absence of allelic loss of TSC1 and TSC2 in all 
the examined cases supported the notion that abnormal genetic events in 
these genes are not essential for chordoma development. In conclusion, 
the first chapter, showed that a subset of chordomas showed activation of 
PI3K/AKT/TSC/mTOR  pathway  and  therefore  these  would  be  potentially 
responsive to inhibition of this pathway using rapamycin and its derivatives, 
PI3K inhibitors, AKT inhibitors or a combination of these agents.  
In  the  second  chapter,  the  role  of  FGFR/RAS/RAF/MEK/ERK-
ETS2/Brachyury  signalling  pathway  in  chordoma  development  was 
investigated.  This work was based on the evidence accumulated in the 
literature from studies performed in the lower vertebrates and amphibians 
which  showed  that  brachyury  is  regulated  by  FGFR  signalling.  Using 
immunohistochemistry,  FGFR  expression  was  found  in  most  of  the 
chordomas  (>  90%)  and  activity  of  this  pathway  was  proved  by  the 
detection  of  phosphorylated  FRS2α  by  Western  blot  analysis.  To 
investigate  the  mechanisms  underlying  FGFR  pathway  activation  in 
chordomas, direct sequencing of genomic DNA was performed to look for 
the  commonly  reported  mutations  in  the  four  FGFR  genes.  dHLPC 
screening  was  employed  to  look  for  the  common  mutations  previously 
reported in KRAS and BRAF.  
The failure to detect mutations in all of these genes suggests that 
genetic events in these genes are not a common mechanism for chordoma 182 
development.  The  activation  of  this  pathway  in  chordomas  offers  some 
potential  therapeutic  targets  because  FGFR  and  RAS  are  emerging  as 
therapeutic  targets  for  some  cancers  including  endometrial  carcinoma, 
urothelial carcinoma and multiple myeloma. Although direct sequencing of 
the  brachyury  coding  exons  and  promoter  region  failed  to  detect  any 
mutation, the presence of genetic changes detected by FISH in this gene 
provided  for  the  first  time,  evidence  for  involvement  of  brachyury  in  the 
pathogenesis  of  sporadic  chordomas  and  is  concordant  with  the  recent 
report  implicating  duplication  of  brachyury  in  susceptibility  to  the 
development of familial chordoma.  
In  the  third  chapter  of  results,  further  evidence  for  the  role  of 
brachyury  in  chordoma  pathogenesis  was  provided  by  using  shRNA 
technique to knockdown brachyury gene in the only available chordoma-
derived  cell  line,  U-CH1.  The  striking  cellular  changes  resulted  from 
knocking  down  brachyury  in  these  cells  provided  in  vitro  evidence  for  a 
pathogenic role for brachyury in chordoma development and proves that it 
is not only expressed in chordoma cells but it also plays an essential role in 
the biology of these cells. The resulting effect of brachyury knockdown on 
the U-CH1 chordoma cells opens the door for the possibility of the future 
targeting  of  this  gene  or  its  downstream  targets  in  the  management  of 
chordomas.  
In the last chapter, the role of EGFR was investigated. The reason 
for investigating this gene was based on the fact that EGFR acts upstream 183 
of the PI3K/TSC/mTOR and RAS/RAF/MEK/MAPK pathways which were 
shown to be activated in a subset of chordomas as proved in the first two 
chapters of the results. 
Furthermore,  there  is  accumulating  evidence  in  the  literature 
providing evidence for activation of receptor tyrosine kinases in chordomas. 
EGFR is an attractive molecule in the therapeutic context as inhibitors of 
this molecule are already in clinical use for treatment of certain cancers 
such as non-small cell lung carcinoma and colon carcinoma. The results in 
this  chapter  provided  evidence  for  expression  of  EGFR  and  its 
phosphorylated  form  in  more  than  50%  of  chordomas  examined  by 
immunohistochemistry.  Although,  direct  DNA  sequencing  failed  to  detect 
any mutations in  the exons coding for  the kinase  domain  of EGFR, the 
presence  of  gene  copy  number  gain  detected  by  FISH  provides  good 
evidence for the involvement of EGFR in the growth of chordoma cells. The 
presence of copy number gain also suggests that at least some chordomas 
are potentially responsive to anti-EGFR  therapy. This concept has been 
also supported by the in vitro work performed on U-CH1 where the EGFR 
inhibitor  tyrphostin  (AG1478)  induced  a  marked  decrease  in  the  cell 
numbers and cell morphology.  184 
7.2 Future work 
The data presented here provides a basis for several new projects. 
An area that needs more investigation is the preclinical evidence for the 
benefit of therapeutic agents in the management of chordoma, although, 
this is difficult to perform in vivo as there is only one cell line available for 
testing. However, as there is no effective treatment for this disease there is 
an  argument  that  clinical  trial  could  be  undertaken  using  inhibitors  to 
EGFR, mTOR and other molecules which we have found to be activated in 
chordomas.  
Another  appealing  project  to  undertake  is  to  investigate  the 
downstream  targets  of  brachyury  which  are  still  unknown  in  mammalian 
cells.  The  cells  in  which  brachyury  has  been  knocked  down  could  be 
exploited  for  this  purpose;  this  could  be  achieved  by  rescuing  the 
knockdown model and looking for the expression of downstream targets by 
performing a gene expression microarray (GEM). 
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